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Summary 
The overall goal of this project was to investigate the molecular link between nucleotide 
metabolism and biofilm formation, with a particular focus on pyrimidine starvation. The 
potential of using nucleoside based drugs as antibacterial compounds was also explored. 
In order to determine which intermediates in the de novo pyrimidine biosynthesis pathways 
are required for biofilm formation, a set of single gene knockout mutants was evaluated for its 
ability to form biofilms. The molecular links between nucleotide biosynthesis and biofilm 
formation were probed by assessing the effect of disruption of nucleotide biosynthesis 
pathways on the expression of a diverse set of genes. Gene expression levels were measured 
with RNA sequencing, GFP-promoter fusions and RT-qPCR. Transcriptome profiles were 
analysed using a network based approach that integrates a variety of “omics” data. 
Furthermore metabolite analysis and mutant phenotyping were also used. 
Our results indicate that pyrimidine starvation is a limiting factor for biofilm formation and 
that biofilm inhibition is associated with a repression of the transcription of csgD. Interestingly 
csgD down-regulation occurs despite an increase in c-di-GMP, which is known to stimulate 
biofilm formation. We explored the possible causes behind the increased c-di-GMP level and 
concluded that it is propelled by an increase of the precursor GTP. In fact, not only GTP but 
also other purine pathway intermediates showed an increased intracellular concentration. We 
propose that this increase is driven by an unknown factor that prevents repression of purine 
and PRPP biosynthesis genes by PurR. 
We also explored possible mechanisms behind the down-regulation of csgD despite high c-di-
GMP levels. Based on transcriptome data analyzed with a network-based approach, we 
hypothesize that the global regulator Fis is involved. Fis negatively regulates rpoS expression 
and RpoS is known to activate csgD transcription. Transcription of fis is sensitive to nucleotide 
availability, providing a link between pyrimidine starvation, csgD down regulation and 
biofilm inhibition.  
Our results indicate that interfering with nucleotide biosynthesis and signalling is a feasible 
way to combat biofilms, as demonstrated with 5-FU. 
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Samenvatting 
Het algemene doel van dit project was het onderzoeken van de moleculaire koppeling tussen 
nucleotide metabolisme en biofilmvorming, met bijzondere aandacht voor pyrimidine-
limitatie. Het potentieel van het gebruik van nucleoside-gebaseerde geneesmiddelen als 
antibacteriële verbindingen werd tevens onderzocht. 
Om te bepalen welke tussenproducten in de de novo pyrimidine biosynthese pathways nodig 
zijn voor biofilmvorming, werden een reeks ‘single-gene knock-out’ mutanten geëvalueerd 
voor hun biofilm-vormend vermogen. De moleculaire schakels tussen nucleotidebiosynthese 
en biofilmvorming werden onderzocht door het effect van een verstoring in de 
nucleotidebiosynthese pathway te beoordelen op de expressie van een brede set van genen. 
Genexpressieniveaus werden gemeten met RNA-sequencing, GFP-promoter fusies en RT-
qPCR. De transcriptieprofielen werden geanalyseerd met behulp van een netwerk-gebaseerde 
aanpak die een verscheidenheid van “omics-data” integreert. Bovendien werden 
metabolietanalyse en mutanten fenotypen gebruikt. 
Onze resultaten geven aan dat pyrimidine-limitatie een beperkende factor is voor 
biofilmvorming en dat de biofilm inhibitie gerelateerd is met een down-regulatie van de 
transcriptie van csgD. Een interessante bevinding is dat csgD down-regulatie plaatsvindt 
ondanks een toename in het signaalmolecule c-di-GMP, dat bekend staat om bioflmvorming 
te stimuleren. We hebben de mogelijke oorzaken van de verhoogde c-di-GMP concentratie 
onderzocht en vonden dat deze gelinkt is aan een toename van de precursor GTP. In feite, 
werd niet enkel voor GTP, maar ook voor andere purines een verhoogde intracellulaire 
concentratie aangetoond. We veronderstellen dat deze stijging wordt gedreven door een 
onbekende factor die de repressie van purine- en PRPP-biosynthese-genen door PurR 
voorkomt. 
We hebben ook de mogelijke mechanismen onderzocht die de down-regulatie van csgD 
kunnen verklaren, ondanks de hoge c-di-GMP concentraties. Op grond van transcriptome data 
geanalyseerd met een netwerk-gebaseerde benadering, veronderstellen we dat de “globale 
regulator” Fis betrokken is. Fis oefent een negatieve regulatie uit op de rpoS expressie en RpoS 
staat bekend om csgD transcriptie te activeren. Transcriptie van fis is gevoelig voor nucleotide 
beschikbaarheid, wat een link voorziet tussen pyrimidine-limitatie,, csgD-regulatie  en 
inhibitie van biofilmvorming.  
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Onze resultaten wijzen erop dat interferentie met nucleotide biosinthese en “signalling” een 
haalbare manier is om biofilmen te bestrijden, zoals aangetoond met 5-FU. 
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Chapter 1  
1 A general introduction to Salmonella and biofilm 
formation and outline of the thesis 
1.1 Abstract 
Members of the Salmonella genus are important food borne pathogens causing gastro-
intestinal infections in humans and animals. Members of this genus have the ability to switch 
between free-living planktonic growth and multicellular biofilm-based growth. Because 
biofilms provide protection against various stresses, the ability to form biofilms contributes to 
survival inside the host as well as in the environment. In the food processing and agricultural 
industries, S. Typhimurium biofilm formation is particularly relevant with regard to food-
safety. A better understanding of the processes involved in regulating S. Typhimurium biofilm 
formation facilitates the development of improved prevention methods. The process of biofilm 
formation is complex, and regulation involves many different components. 
1.2 Aim and scope of thesis 
This thesis explores the role that pyrimidine metabolism plays in the transitioning from free-
living to biofilm growth. These new insights might facilitate the development of new drugs, 
so called anti-biofilm agents, which work by targeting the nucleotide biosynthesis pathways. 
Also evaluated is the potential of using nucleoside and nucleotide analog drugs as antibacterial 
and antibiofilm agents. 
Understanding the molecular basis of phenotypes is a central problem in biology. However, 
revealing the underlying mechanisms has proven to be non-trivial, as changes in a specific 
phenotype may result from perturbations of many pathways, any of which may contribute very 
little to the observed phenotype on its own. Network based approaches have proven to be very 
useful when searching for mechanistic insights (Janga & Contreras-Moreira, 2010; Ruan et 
al., 2010; DeMaeyer et al., 2013; Mulas et al., 2017). Here we have used PheNetic (available 
at http://bioinformatics.intec.ugent.be/phenetic2), a sub network inference algorithm to 
reconstruct the mechanistic interactions at play in inducing pyrimidine-dependent biofilm 
formation.  
Chapter 1 introduces the importance of Salmonella and our current understanding of 
Salmonella taxonomy. The impact of biofilms in the clinical and industrial environments, and 
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the state of the-art techniques used for studying biofilms are discussed. Factors involved in 
regulating the switch from free-living to biofilm-based growth are also introduced. Chapter 2 
introduces the role of nucleotides and nucleotide derived signalling molecules in biofilm 
formation and other physiological processes. In Chapter 3 the prospect of using nucleoside- 
and nucleotide analogues to combat biofilm formation are discussed in the form of a review 
article (Yssel et al., 2017). Chapter 4 to 5 summarizes the results obtained during the course 
of the author’s doctoral studies. In Chapter 4 the phenotypic effects of pyrimidine starvation 
on the biofilm phenotype is discussed, while Chapter 5 explores the regulatory mechanisms 
behind the observed effects. In Chapter 6 the potential of using 5-FU (known to disrupt 
nucleotide pool sizes) against Salmonella biofilm formation is investigated. Future 
perspectives, shortcomings and conclusions appear in Chapter 7. 
1.3 Introduction 
 Salmonella taxonomy 
Members of the Salmonella genus are characterized by their motility, rod-shape, inability to 
form spores and Gram-negative cell walls, furthermore they are chemotrophs and facultative 
anaerobes. Members of the Salmonella genus are often pathogenic to humans and/ or animals 
and can cause intestinal or systemic infections. Salmonellae are part of the family 
Enterobacteriaceae, the phylum Proteobacteria and the class γ-proteobacteria and are closely 
related to Escherichia. One of the most important differences between Salmonella and 
Escheirchia is that the typical Salmonella genome contains a large number of additional 
virulence genes located on pathogenicity islands. This bestows Salmonella with the ability to 
invade epithelial cells and to survive within phagocytic cells (Hensel et al., 1997; Folkesson 
et al., 1999; Ochman et al., 2000; Folkesson et al., 2002; Winfield & Groisman, 2004; Haneda 
et al., 2009). The Salmonella genus can be divided into two species, S. bongori and S. enterica. 
The S. enterica species is further subdivided into six subspecies: (I) enterica, (II) salamae, 
(IIIa) arizonae, (IIIb) diarizonae, (IV) houtenae and (V) indica (Brenner et al., 2000; Jenkins 
& Gillespie, 2006). Before the advent of PCR and DNA sequencing the subspecies were 
further subdivided into serovars based on the Kauffmann-White-Le Minor scheme which 
evaluates the presence or absence of O-, H-, and surface-antigens. More recently, genetic 
methods have been used to give a more accurate determination of the evolutionary 
relationships between serovars (Boyd et al., 1996; Cai et al., 2005; Dilmaghani et al., 2010; 
Soler-Garcia et al., 2014; Zhao et al., 2015). Nearly all Salmonella isolates from 
homoeothermic hosts are members of the enterica subspecies. Only serovars of the enterica 
  Chapter 1: Introduction 
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subspecies are given names (for example Salmonella enterica subspecies enterica serovar 
Paratyphi). Serovars belonging to other subspecies are denoted by their antigen typing 
formulas. Based on the clinical manifestation of infection, Salmonella serovars can be divided 
into two main groups. Typhoidal Salmonella (TS) and non-typhoidal Salmonella (NTS). TS 
infections are systemic in nature and are characterized by high fever. TS infections are 
typically caused by S. Typhi or S. Paratyphi. NTS infections result in acute, self-limiting (in 
most cases) gastroenteritis and are usually caused by S. Enteritidis and S. Typhimurium. 
Strains that cause TS infection are often host-restricted and share pseudogenes that relate to 
genes involved in causing virulence and gastroenteritis, which supports the hypothesis that 
pseudogene formation occurs during adaptation to a specific niche (Jacobsen et al., 2011).  
The strains S. Typhimurium LT2, ATCC14028 and SL1344 are commonly used laboratory 
strains. These strains mainly differ with regard to certain prophages in their chromosomes 
(Figueroa-Bossi et al., 2001). For this work, S. Typhimurium ATCC14028 is used as model 
organism. The complete genome sequence of this strain has been published in 2010 (Jarvik et 
al., 2010). ATCC14028 is a descendant of CDC 60-6516, a strain isolated in 1960 from pools 
of hearts and livers of 4-week-old chickens. Originally, ATCC14028 has been typed as LT2, 
based on phage sensitivity. However, the two strains were isolated decades appart making 
their genealogy and relationship vague. Analysis that is more recent predicted that they 
diverged from eachother between 3000 to 9000 years ago (Jarvik et al., 2010). 
 The Salmonella enterica pan-genome 
Changes to the Salmonella genome during niche adaptation can occur via horizontal gene 
transfer, rearrangement, duplication, gene excision and pseudogene formation (Bäumler, 
1997; Abby & Daubin, 2007; Jacobsen et al., 2011). Pan-genome analysis can provide insights 
into the genetics underlying host-preference and/or host-specificity of the different serovars 
(Abby & Daubin, 2007) . 
The pan-genome/ supra-genome is defined as the full complement of genes from all the 
sequenced strains of the same clade (Rouli et al., 2015). The pan-genome is composed of the 
core/universal genome (the genes common for all strains), the unique genome (the strain 
specific genes known as ORFans) and the periphery (genes that are present in a subset of 
strains) (Lapierre & Gogarten, 2009; Gordienko et al., 2013). The Salmonella pan- and core-
genomes were estimated based on 35 sequenced genomes (Figure 1 and Figure 2). The core 
genome of 35 sequenced Salmonellas contains 2,811 gene families, and the pan-genome 
10,015. Hypothetically speaking, if all the genomes were of the same size and each unique 
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gene family occurred only once, then the unique portion of gene families would be 10% for 
each hypothetical strain and the core genome would make up the remaining 90%. The 
corresponding numbers within the S. enterica subsp. enterica are 3,224 and 9,16. Note that 
the core genome becomes larger for the smaller sub-group, because some of the smaller 
group’s core genes are absent from other members of the larger group (Jacobsen et al., 2011). 
The Salmonellae were found to have quite high similarity in protein sequences and the identity 
between the genomes within Salmonella subsp. enterica ranges from 65% to 99%. It was 
concluded that the Salmonella core-genome is quite large compared to that of other bacterial 
genera and that the pan-genome is relatively small. Certain pathogenicity islands were found 
only in specific serovars where they undoubtedly play an important role in providing the 
genomes that host them with characteristic phenotypes. In addition to the Salmonella specific 
genomic islands, other genomic islands were also identified. Many of these were found to be 
of viral-origin and were strain-specific. Thus, genomic islands are important during 
Salmonella evolution and niche-adaptation (Jacobsen et al., 2011). Without a doubt, 
differences in the non-coding regions of strains that share very high similarity in protein 
coding genes would also have some impact on the phenotypic differences of closely related 
strains, because these differences may influence the regulation of gene expression. 
 Clinical and economic relevance of NTS Salmonella infections 
Salmonella is of significant clinical relevance in both developing and developed countries, 
where it is one of the most frequent causative agents of food-borne diseases and is a major 
cause of gastrointestinal illness (Vaagland et al., 2004; Vojdani et al., 2008; Majowicz et al., 
2010; Kozak et al., 2013; Fàbrega & Vila, 2013). According to information published 
on the Center for Disease Control (CDC) website (http://www.cdc.gov/Salmonella/general/in
dex.html) approximately 1.2 million illnesses and approximately 450 deaths occur due to NTS 
annually in the United States. These numbers could be much higher if one takes into account 
unreported or misdiagnosed cases. Children, the elderly and those with a weakened immune 
system are most at risk of severe infections. 
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Figure 1 Pan- and core genome plot of 35 Salmonella strains. The red and blue lines show the 
progression in the core and pan genomes, as more and more genomes are considered. The columns 
indicate the amount of novel gene families encountered. The color of the columns represents the 
associated serogroup (Jacobsen et al., 2011).  
 
 
Figure 2 Flowerplot of unique gene families in each Salmonella serovar. The figure presents the 
average number of gene families found in each genome as being unique to the serovar. Also given is 
the size of the core genome. The colour of the petals represents the S. enterica serogroups(Jacobsen et 
al., 2011). 
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1.4 Biofilm formation 
 Biofilm associated problems 
Bacteria can switch between a free-living planktonic lifestyle, which enables them to explore 
aquatic environments to a sessile multi-cellular biofilm mode of life that provides them with 
protection from several stressors and other advantages not associated with the planktonic 
lifestyle. Usually biofilms can be found on solid surfaces that are submerged or exposed to 
liquid, but they can also form floating mats on the surfaces of liquids. Under propitious 
conditions (such as in nutrient-sufficient ecosystems) bacteria are predominantly associated 
with biofilms (Stoodley et al., 2002). Many bacterial species also form biofilms in response to 
various stress conditions (Lapaglia & Hartzell, 1997; Otto & Silhavy, 2002; Boehm et al., 
2009; Landini, 2009). Although beneficial biofilms do exist, for example the fungal and lactic 
acid biofilms used for making fermented Kombucha tea (Jayabalan et al., 2014) or the 
activated sludge found in wastewater treatments (Sanz & Köchling, 2007), very often biofilms 
are detrimental to human health and industry. According to a public announcement by the 
National Institutes of Health (https://www.nih.gov), over 80% of microbial infections are 
biofilm associated. Biofilm infections include pneumonia in cystic fibrosis patients, dental 
caries, chronic wounds, chronic ear-infections and catheter- and implant-related infections 
(Costerton et al., 1987; Passerini et al., 1992; Costerton et al., 1999; Bjarnsholt, 2013). The 
biofilm mode of life has been stated as a contributing cause of emerging (multi)drug-resistance 
to disinfectants, antibiotics and sanitizers due to the protection of the biofilm matrix and 
adaptation mechanisms of the bacterial cells in the biofilms, see reviews by (Gilbert & Brown, 
1995; Mah & O'Toole, 2001; Stewart, 2002). Mechanisms by which biofilms can confer 
protection against antibiotics are summarized in Figure 3. In the food sector, biofilms are 
particularly problematic in green houses, breweries, meat- and dairy-processing factories. In 
these environments they compromise food safety and cause damage to equipment (for example 
by blocking pipes) and so cause significant economic losses (Simões et al., 2010).  
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Figure 3 Diagram illustrating five mechanisms by which biofilms can contribute to antibiotic tolerance 
to antimicrobial agents. Image credit Phil Stewart, Peg Dirckx (2011). This image is used with 
permission of Montana State University Center for Biofilm Engineering. 
 
 The switch to a biofilm mode of life 
Bacteria that are living in biofilms are substantially different to their free-living counterparts 
with respect to their morphological appearance, metabolic state and physiology (Valentini, 
Filloux 2016, JW, Z et al. 1995, Stoodley, Sauer et al. 2002). The defining feature of the 
biofilm mode of life is the production of an extensive extracellular matrix which includes 
polysaccharide components, surface-associated proteins and extracellular DNA (eDNA) 
(Costerton et al., 1987; O'Toole et al., 2000; Davey & O'Toole, 2000; Landini, 2009). The 
exact composition of the biofilm matrix depends on the bacterial species and environment. 
Biofilms can be made up of single- as well as mixed-species and the self-produced matrix can 
constitute up to 90% of the mature biofilm biomass (Flemming & Wingender, 2010). The 
biofilm matrix renders bacteria more resistant to UV stress, desiccation, antibiotic treatment, 
host-defenses and heat-stress amongst others. Furthermore the biofilm matrix also functions 
as an external digestive system by keeping extracellular enzymes in close proximity to the 
cells and so facilitates the metabolism of dissolved, colloidal and solid biopolymers 
(Flemming & Wingender, 2010). Sauer and colleagues (Sauer et al., 2002) have identified 5 
stages of biofilm development: (i) reversible attachment, (ii) irreversible attachment, (iii) 
maturation-1, (iv) maturation-2, and (v) dispersion. Each phase has a characteristic stage-
specific physiology.  
Van Puyvelde studied the dynamics of Salmonella biofilm formation in a petri-dish setup that 
allowed for separate analysis of free-living planktonic cells in the liquid phase and surface 
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attached biofilm cells (Van Puyvelde, 2014). The CFUs in each phase were determined at 
discrete time points over a course of 24 hours Figure 4. It was observed that the phenotypic 
switch from the planktonic lifestyle to biofilm based growth occurred at a distinct time interval 
(in this case, 8 – 10 hours post incubation). Initially the planktonic growth curve shows an 
exponential increase in cell numbers. Then there is a levelling off-phase, similar to the 
standard growth curves of shaking liquid cultures. However, after reaching a maximum, the 
number of planktonic CFUs starts to decrease. This coincides with a marked increase in the 
number of biofilm CFUs, suggesting that individual planktonic cells make the transition to the 
biofilm fraction. The biofilm fraction does not only increase due to additional planktonic cells 
that make this transition, but also because of cell division occurring within the biofilm. 
Inspection of the total CFUs (combination of biofilm and planktonic cells) at each time point, 
revealed that a fraction of cells become non-viable during the switch phase. Live-dead staining 
revealed that these cells belong to the planktonic fraction that does not join the biofilm fraction. 
In the case of Salmonella, whose lifestyle is characterized by periods of host colonization 
followed by periods outside the host, the ability to form biofilms contributes to its resistance 
and persistence in both host and non-host environments, as discussed below. 
 Relevance of Salmonella biofilms 
Salmonella can form biofilms on plastic, glass, cement, rubber, stainless steel, plant surfaces, 
epithelial cells and gallstones, for a review see (Steenackers et al., 2012). The most important 
structural components that play a role during Salmonella biofilm formation include cellulose, 
curli fimbriae, BapA, flagella, fatty acids, O-antigen capsule and colanic acid. The importance 
and presence of these structural components vary according to the surface on which the 
biofilms are grown and the prevailing environmental conditions.  
Typhoid fever-causing Salmonella have no known environmental reservoir and the chronic 
asymptomatic carrier state, where approximately 2-5% of typhoid patients do not fully clear 
the infection after recovery from acute typhoid fever, is thought to be centrally important for 
maintaining the presence of TS within human populations. Chronic carriers shed the bacteria 
into the local environment aiding the spread of the disease (Gunn et al., 2014). NTS strains 
have also been linked to infrequent persistent human infection (between 0.15-3.9% of patients 
treated for acute infection continue to shed NTS bacteria after recovery), although the duration 
of carriage is shorter than that of TS chronic infections (Musher & Rubenstein, 1973; 
Gonzalez-Escobedo et al., 2011; Gunn et al., 2014). Evidence suggest that chronic TS- and  
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Figure 4. Panel A:This graph shows a clear switch from predominantly planktonic to biofilm growth 
around 8-12 h after inoculation. Panel B: Fluorescence microscopy images after 8, 12 and 24 h of 
Salmonella biofilms formation revealed the presence of no, initial and more mature biofilms at these 
time points. Panel C:  During exponential, planktonic growth individual cells begin forming biofilm. 
Biofilm mass increases over time due to the transition of planktonic cells and replication of the biofilm 
cells themselves. 
 
NTS-infections are both associated with biofilms on gallstones (Musher & Rubenstein, 1973; 
Buchwald & Blaser, 1984; Cruickshank & Humphrey, 1987). 
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After passing through the host’s digestive system, Salmonella’s ability to form biofilms on 
abiotic surfaces enhances its survival in the often nutrient-poor hostile environment. In four 
out of six households where a family member recently suffered an attack of NTS, Salmonella 
cells persisted in the scaly biofilms adhering to the toilet bowls for up to four weeks, despite 
sanitation measures. However, Salmonella cells were not isolated from areas that are normally 
dry, such as toilet seats and flush handles. This indicates that Salmonella biofilms provide a 
considerable risk of spreading infective NTS to people who share bathroom facilities (Barker 
& Bloomfield, 2000). A large number of NTS outbreaks are linked to the consumption of 
contaminated agricultural produce (Barak et al., 2008). Microscopy analyses have revealed 
that salad leaves harbour a high number of bacteria, typically 105 per square millimetre, and 
that the bacteria are present in complex 3D aggregations. Moreover, washing of the salad 
leaves had a very small effect on the number of adherent bacterial cells (Warner et al., 2008). 
Since the survival of Salmonella, and other pathogens, on abiotic as well as biotic surfaces is 
largely reliant on their ability to produce biofilms, it is of great importance to get molecular 
insights into the process of biofilm formation and to use this knowledge to design effective 
treatments and preventative strategies. The following sections give a brief overview of various 
models for studying biofilm formation as well as factors involved in the regulation of 
Salmonella biofilm formation. 
1.5 Models for studying biofilm formation 
 Congo red Agar 
When grown at temperatures below 30ºC in low salt medium S. Typhimurium and E.coli 
produces the exopolysaccharide components cellulose and amyloid curli fibers. The 
production of these components influences the colony appearance on Congo red agar (Figure 
5). Colonies that produce cellulose appear pink, dry and rough (pdar). Colonies that produce 
curli fimbriae appear brown dry and rough (bdar). When both curli and cellulose are produced 
the morphology is red dry and rough, while the absence of both matrix components result in a 
smooth and white (saw) morphotype (Römling, 2001; Römling, 2005). In addition to curli 
fimbriae and cellulose, the rdar biofilm of S. Typhimurium is composed of other components 
which include the O-antigenic capsule, the large surface protein BapA, lipopolysaccharide and 
capsular polysaccharide (see reviews by (Steenackers et al., 2012; Ahmad, 2013; Simm et al., 
2014). The rdar morphotype and the regulator CsgD have been shown to be important for 
environmental adaptation, the survival of long term desiccation, adherence to and colonization 
of plant- and tumour-tissue and bacterial-host interactions (Barak et al., 2005; Barak et al., 
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2008; Brandl et al., 2011; Aviles et al., 2013; Ahmad, 2013). The production of an ample 
extracellular matrix, consisting of proteinaceous and exopolysaccharide components protects 
enclosed bacterial cells from adverse environmental conditions and so contributes to the 
persistent character of bacterial biofilms. The various morphotypes on CR agar provide a 
convenient way to assess the production of critical biofilm components. The rdar morphotype 
can be divided into three distinct zones (with some further subdivision within zones) which 
correspond to different developmental stages within the biofilm in which curli and cellulose 
production varies (Serra et al., 2013a; Serra et al., 2013b). This characteristic of displaying 
different developmental zones (Figure 6) makes the rdar morphotype a practical model to 
study biofilm development (Ahmad, 2013; Serra et al., 2013b).  
 
Figure 5. Morphotypes of S. Typhimurium expressing different matrix components from left to right: 
Semi-constitutive rdar morphotype (MAE52 [UMR1 PcsgD1]) with curli and cellulose. A pdar 
morphotype (MAE97 [MAE52 ΔcsgBA102]) that is cellulose positive and curli negative. A bdar 
morphotype (MAE171 [MAE52 ΔbcsA102]) which is curli positive but cellulose negative. A saw 
morphotype (MAE51 [UMR1 PcsgD2csgD101]) that is negative for cellulose and curli fimbriae. 
Finally a regulated rdar morphotype (UMR1 [wild type]). Image obtained from (Simm et al., 2007) is 
reproduced with permission of the author.  
 
 Calcofluor agar 
Calcofluor White (CW) is a fluorescent stain that binds strongly to structures containing 1-4-
β-D-glucan-based polysaccharides (Herth & Schnepf, 1980; Wood, 1980). The presence or 
absence of extracellular cellulose can conveniently be assessed by growing Salmonella on LB-
no salt agar containing 0.025% CW and observing colony fluorescence under UV light (Zogaj 
et al., 2001). S. enterica strains that are deficient in cellulose production, as determined by 
CW staining were also found to exhibit poor attachment to Aspergillus niger hyphae and chitin 
beads (Brandl et al., 2011). These results are an indication that differences in cellulose 
production under laboratory conditions are also applicable in in situ conditions and that 
Calcofluor staining is a reliable method to measure these differences. 
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Figure 6 Stereo microscopic image of a typical rdar colony morphotype of S. Typhimurium. The rdar 
colony is surrounded by a thin white and smooth zone (zone 1), which is the zone containing the 
youngest generations of cells. This zone can be divided into two distinct subzones, the outer most 
transparent subzone 1A and inner white subzone 1B. Curli and cellulose fibers are not secreted in Zone 
1.  Beneath Zone 1 is a thin red region that lacks 3D structure (Zone 2) where the cells have begun to 
excrete the matrix components. Zone 3 (containing the most mature cells) is the largest of the regions 
and is characterized by a web like 3D structure. A septum divides zone 3 into two subzones (3A and 
3B) which have similar but unique architectures. Figure is reproduced with permission of the author 
(Ahmad, 2013). 
 
 Crystal violet staining 
The Calgary Biofilm device provides a convenient high-throughput experimental setup for 
biofilm formation. This system consist of 96 polystyrene pegs on a lid which fits over a 
microtiter plate, with each peg hanging into a separate well. Biofilm formation occurs on the 
pegs at the air-liquid interface (Ceri et al., 1999). Crystal violet staining can be used to colour 
the biofilm matrix as well as cells that are present in the biofilm on the pegs. After de-staining 
the pegs in acetic acid, the intensity of the dissolved stain can be used to infer the degree of 
biofilm formation. The degree of planktonic growth can also be determined by measuring the 
optical density of the medium in the wells of the microtiter-plate. This high-throughput setup 
where biofilms and planktonic growth can be assessed simultaneously makes the Calgary 
setup ideal for studying inhibitory molecules and dose-responses. The observation that 
Salmonella strains which form strong biofilms on the polystyrene pegs also attach better to 
lettuce leaves while those that form weak biofilms also show defective attachment to lettuce 
leaves provides a link between in vitro and in planta biofilm formation, which is evidence that 
the Calgary biofilm setup is a suitable prediction model for real-life Salmonella biofilm 
formation (Kroupitski et al., 2009; Patel & Sharma, 2010).  
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 Fluorescent probes that bind specific EPS structures 
To visualize EPS components one can make use of fluorescently marked antibodies or other 
probes which specifically target the desired EPS component. The antibody-based approach is 
particularly useful for labelling protein components of the EPS, but it is more challenging for 
tagging sugar components. Recently a novel biofilm imaging probe CDy11, which binds to 
amyloid fibers (Figure 7), was demonstrated as an in vivo diagnostic tool for detecting biofilms 
(Kim et al., 2016a).  
 
Figure 7 The fluorescent probe CDy11 targets amyloid fibers in the P. aeruginosa biofilm matrix. 
Figure reproduced with permission (Kim et al., 2016a). 
 
1.6 Regulation of Salmonella biofilm formation  
As illustrated in Figure 8, a sophisticated and complex regulatory network controls the various 
biofilm components’ production. In the following subsections, a brief overview is given on 
the current understanding of this network and the interactions between its various components, 
particularly the master regulator CsgD.  
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Figure 8 Overview of the transcriptional regulatory network controlling Salmonella biofilm formation. 
Arrows and flat-headed arrows represent activation and repression respectively. Broken lines indicate 
putative links that need to be experimentally validated or further investigated. ‘P’ symbols represent 
transferable phosphorus groups of two component systems. Light blue rectangles represent the 
genomic organization of the genes encoding the major structural biofilm components, indicated by 
orange rectangles. The orange ‘Motility’ rectangle is an exception as it represents a community 
behavior related to biofilm formation, regulated through flagellar genes (dark green circles) and 
flagella (green rectangle). Light blue circles represent important regulators involved in the production 
of the major structural biofilm components. Light green circles, triangles and rectangles represent 
global regulators, the Crl protein and sRNAs, respectively, and lightning bolt symbols represent the 
input and integration of different environmental signals into the regulatory system. Orange circles and 
arrows indicate the link between PhoPQ and biofilm formation. The grey and purple circles indicate 
the role of metabolism and quorum sensing respectively. Dark blue and red circles represent EAL and 
GGDEF proteins, respectively, involved in c-di-GMP turnover. Red rectangles represent the different, 
but interconnected c-di-GMP pools. Figure reproduced with permission of the authors (Steenackers et 
al., 2012).  
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 CsgD, the master regulator 
The transcriptional regulator CsgD (previously referred to as AfgD) plays a major role in 
regulating biofilm formation in E. coli and Salmonella. It is a response regulator consisting of 
an N-terminal receiver domain with a conserved aspartate (D59) and a C-terminal LuxR-like 
DNA-binding motif (Römling, 2005). RpoS and MlrA activate CsgD expression in a coherent 
feed forward loop (Gómez-Gómez & Amils, 2014; Hosseinkhan et al., 2015). CsgD directly 
activates transcription of the divergently transcribed csgDEFG and csgBAC operons (Römling 
et al., 1998a; Römling et al., 1998b). The csgBAC operon encodes the structural subunits of 
curli fimbriae. Furthermore it also directly activates transcription of adrA, which encodes the 
diguanylate cyclase AdrA that positively regulates post-translational activation of cellulose 
synthase BcsAB (Römling et al., 2000; Gerstel & Römling, 2003; Kader et al., 2006; 
Zakikhany et al., 2010). Although the promoter region of the bapABCD operon contains a 
CsgD binding-site which is similar to that in the promotor region of adrA (Latasa et al., 2006), 
a combined bioinformatics and transcriptomics approach did not identify bapA as a CsgD 
regulated gene (Zakikhany et al., 2010). This is in contrast to another report (Latasa et al., 
2005) which concluded that CsgD regulates bapA transcription, because bapA mRNA levels 
in a ΔcsgD mutant was significantly lower than in the wild type. This apparent discrepancy 
can be possibly attributed to the different experimental procedures that were used (Hermans, 
2011).A csgD deletion mutant has a “saw” morphotype on CR agar, indicating the absence of 
cellulose and curli. Regulation of csgD transcription and translation is elaborate and tightly 
synchronized in response to a variety of environmental and intracellular cues and signals. 
Several global regulators affect csgD transcription in Salmonella, namely: RpoS, OmpR, H-
NS, MlrA, Crl and IHF (Gerstel & Römling, 2003; Gerstel et al., 2003; Robbe-Saule et al., 
2006; Jonas et al., 2009; Simm et al., 2014). Research in E. coli has shown that several small 
non-coding mRNAs play a direct role in downregulating CsgD expression on a post-
transcriptional level by binding to specific regions in the 5’UTR of csgD mRNA, thereby 
suppressing translation, see review by (Boehm & Vogel, 2012). Similar regulation by small 
RNAs have also been confirmed in Salmonella (Bordeau & Felden, 2014). CsgD is also a 
target of transcriptional and posttranscriptional control by c-di-GMP although the exact details 
of this regulation remain unclear. In E. coli a well-defined set of DGCs and PDEs tunes csgD 
transcription (Weber et al., 2006; Pesavento et al., 2008; Sommerfeldt et al., 2009; Römling 
et al., 2013). CsgD expression is highly correlated with the activities of the PDE YhjH and 
Chapter 1: Introduction 
 
16 
 
several DCS involved in motility regulation (Simm et al., 2007; Pesavento et al., 2008). In V. 
cholera VspT, a CsgD homologue, contains a c-di-GMP binding motif with the consensus 
W(F/L/M)(T/S)R. This motif is not present in Salmonella and other enterobacteria. Unlike 
VspT which undergoes a change in oligomerization upon c-di-GMP binding, CsgD is 
regulated by phosphorylation (Krasteva et al., 2012). The important role of c-di-GMP during 
the transition between motile and sessile modes of growth is discussed in the next paragraphs 
and Chapter 2.  
 Coordinating motility, virulence and biofilm formation 
Flagella and the chemotaxis machinery are important in the transition between motile and 
sessile modes of growth. Salmonella cells typically have between three and eight flagella per 
cell, the biosynthesis of which is controlled by FlhD4C2 (Guttenplan & Kearns, 2013). It seems 
rather evident that when bacteria switch to a sessile mode of growth, motility ought to be 
inhibited. In fact, mutations in various regulatory genes have opposing effects on biofilm 
formation and motility, as observed in different species (Yildiz & Schoolnik, 1999; Sauer & 
Camper, 2001; Yildiz et al., 2001; Blair et al., 2008; Verstraeten et al., 2008; Pesavento et al., 
2008). However, intact motility is important for attachment and early stage biofilm formation, 
as demonstrated by the biofilm defects of strains that lack FlhD4C2 or FliC (the flagella 
filament protein) (Pratt & Kolter, 1998; Guttenplan & Kearns, 2013). The regulation of the 
interplay between virulence, motility and biofilm formation is discussed below. 
The carbon storage regulator CsrA affects motility and biofilm formation in the following 
ways: (i) By promoting the expression of FlhD and FlhC by stabilizing the flhDC transcript 
and preventing it from RNaseE cleavage. (ii) By suppressing two degenerate EAL domain 
proteins (STM1697 and STM1344) which target FlhD4C2 on a posttranslational level to inhibit 
the expression of flagella genes. (iii) By suppressing the rdar morphotype and promoting 
motility by increasing the expression of the EAL-domain protein STM3611 (Yakhnin et al., 
2013; Ahmad, 2013). Nevertheless, at some stage during biofilm development the motile 
bacteria become sessile and embedded in a self-produced matrix. Research done on E.coli 
showed that curli production in early-stage biofilms is dependent on FlhD4C2 degradation by 
the protease CplXP (Pesavento et al., 2008).  
ClpXP and CsrA are also involved in regulating virulence in Salmonella. Deleting ClpP causes 
attenuation of virulence by affecting RpoS and CsrA (Knudsen et al., 2013). Deleting CsrA, 
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as well as overexpressing, it reduces the expression of genes that are important for invasion of 
epithelial cells (Altier et al., 2000).  
In general, high levels of the signalling molecule c-di-GMP are associated with biofilm 
formation and lower levels are usually associated with motility and virulence. In fact 5 EAL 
domain proteins (which break down c-di-GMP) STM0343, STM0468, STM2215, STM3611 
and STM4264 all play a role in stimulating HT-29 invasion. Nevertheless, unconventional 
phenotypes have been found for the DGC proteins (which make c-di-GMP) STM1283 and 
STM2123, which both stimulated invasion (Ahmad et al., 2011). The roles of CsrA, flagella, 
c-di-GMP and some other components that coordinate biofilm formation, motility and 
virulence are summarized Figure 9. 
 
  
Figure 9 Schematic model illustrating the roles of various GGDEF/EAL domain proteins and CsrA 
in regulating invasion, motility and biofilm formation (Jonas, et al., 2009). 
1.7 Concluding remarks 
This chapter briefly introduced the taxonomy of the pathogen Salmonella as well as the impact 
of biofilms in human health and industry. Factors regulating Salmonella’s ability to switch 
from a free-living to biofilm-based lifestyle were recapitulated. The following two chapters 
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are literature reviews in which the roles of nucleotides in biofilm formation and the potential 
of using nucleoside and nucleotide analogs as antibacterial agents are discussed. 
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Chapter 2 
2 The importance of nucleotides in biofilm formation 
2.1 Abstract 
Nucleotides and their derivatives have many important functions within the bacterial cell. This 
chapter provides an overview on the biosynthesis pathways that produce the purine and 
pyrimidine nucleotides. The importance of nucleotide biosynthesis during biofilm formation 
is reviewed and special focus is given to the nucleotide based second messengers, particularly 
c-di-GMP. 
2.2 Background 
 Introduction to the purine and pyrimidine biosynthesis  
Nucleotides have important functions within the cell including: as the building “blocks of life” 
(DNA and RNA), as co-factors in sugar and lipid metabolism, polyamine biosynthesis, 
methylation reactions, energy transfer, signalling, and as components of co-enzymes in redox-
reactions for instance NAD(P) and FAD (see review by (Jensen et al., 2008)). A nucleotide 
consists of three main parts: a purine/ pyrimidine base (nucleobase), a pentose-sugar that can 
either be a ribose or deoxyribose, and one to three phosphate groups (Figure 10). A nucleoside 
is nucleobase with an attached pentose-sugar. DNA and RNA are polynucleotides in which 
the base guanine pairs with cytosine and adenine pairs with thymine or uracil (for DNA and 
RNA respectively). Nucleotides can be formed de novo or via salvage pathways (Figure 11). 
The de novo synthesis of purines and pyrimidines occurs via two separate pathways which are 
both tightly regulated by end-products and intermediates, as will be further explained in the 
rest of this chapter. The salvage pathways have several functions: (i) To utilize exogenous, 
preformed nucleobases and nucleoside for nucleotide synthesis. (ii) To re-use nucleobases and 
nucleosides that were produced endogenously by nucleotide turnover. (ii) The catabolic 
processing of pentoid moieties of exogenous nucleosides and the amino groups of adenine 
components as carbon and nitrogen sources respectively (Zalkin & Nygaard, 1996). The 
salvage of free nucleobases and nucleosides in the medium suppresses de novo synthesis by 
suppressing the expression of the enzymes as well as by feedback inhibition of the de novo 
reactions.  
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Figure 10. Structural elements of common nucleic acid constituents. Because they contain at least one 
phosphate group, the compounds marked nucleoside monophosphate, nucleoside diphosphate and 
nucleoside triphosphate are all nucleotides (https://en.wikipedia.org/wiki/Nucleotide). 
 
 
Figure 11 Schematic and simplified outline of nucleotide metabolism. The arrow, indicating 
breakdown of RNA outside the cytoplasm, is flanked by parentheses, because E. coli and S. enterica 
do not secrete RNases to the periplasm or medium. The scheme applies to the metabolism of 
deoxyribonucleotides with noticeable exceptions: (i) these are formed de novo by reduction of 
ribonucleoside di- or triphosphates, (ii) no PRTase attaches a 5-phosphodeoxyribosyl group to a 
nucleobase, and (iii) phosphorolytic breakdown of DNA, generating dNDPs, does not occur. Figure 
adapted from (Jensen et al., 2008). 
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 Purine synthesis and regulation 
 Enzymatic reactions for de novo purine biosynthesis 
The de novo purine biosynthesis pathway (Figure 12) of Salmonella consists of 11 enzymatic 
steps which convert phosphoribosyl pyrophosphate (PRPP) to the first complete purine, 
inosine monophosphate (IMP). In the first step, the amide group of glutamine displaces the 
diphosphoryl group of PRPP. This results in the formation of PRA. The amino group of PRA 
(which will become N-9 pf the purine ring) reacts with the carboxyl group of glycine leading 
to the formation of GAR. This step requires one ATP molecule (the atoms of glycine will 
become the C-4, C-5 and N-7 atoms of the purine ring). Next, the primary amino group of the 
glycyl residue becomes formylated to produce FGAR (the formyl group will become C-8 of 
the purine ring). There are two alternatives for catalyzing this step: A carbon atom may be 
provided by either 10-fornyl-THF or formic acid. Subsequently, an amide group provided by 
glutamine is attached to the carboxyl carbon atom of FGAR yielding FGAM (the nitrogen 
from the amide group will become N-3). This is followed by an ATP-dependent closure of the 
imidazole ring of AIR. The subsequent carboxylation reaction introduces the C-6 atom of the 
purine ring, generating N5-CAIR. The carboxylation reaction requires ATP and bicarbonate. 
Next, the formyl moiety is transferred to the C-4 atom of the imidazole group to form CAIR. 
Two amination steps of CAIR then follow. In the first ATP-dependent amination step, 
aspartate is added to the carboxylate of CAIR to yield SAICAR. In the second amination step, 
fumarate is withdrawn, generating AICAR. The amination reactions are responsible for 
introducing the N-1 atom of the purine ring. Next, the final (C-2) atom of the purine ring is 
introduced when the formyl group of 10-formyl-THF is transferred to the amino group of 
AICAR resulting in FAICAR formation. The complete purine IMP is formed when the ring is 
closed in an ATP-independent dehydration step (Jensen et al., 2008). 
IMP is the branching point for the formation of AMP and GMP. AMP and GMP can be further 
converted to the di- and tri-phosphate nucleotides (Figure 12). The conversion of IMP to GMP 
requires ATP, and the conversion of IMP to AMP requires GTP, the energy donor 
requirements for these reactions probably contribute to the balancing of guanine nucleotide 
and adenine nucleotide pools. The conversion of IMP to AMP requires two steps with 
succynyl-AMP as an intermediate. The conversion of IMP to GMP also requires two steps and 
XMP is the intermediate (Jensen et al., 2008).  
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Figure 12 Biosynthesis and interconversion of purine nucleotides, nucleosides, and bases. The 
enzymes are indicated by their gene names. The inset with IMP shows the numbering of carbon atoms 
in the purine and ribosyl moieties of purine nucleotides. In most formulas the 5-phosphoribosyl moiety 
is indicated by an -R. For reasons of clarity, the co-substrates and products have been omitted from the 
reactions in the top of the figure but are apparent from the main text. Abbreviations: Ado, adenosine; 
Ino, inosine; Xao, xanthosine; Guo, guanosine; Ade, adenine, Hyp, hypoxanthine; Xan, xanthine; Gua, 
guanine. Other abbreviations, including the names of intermediates of the de novo pathway, are 
explained in the main text. Image reproduced (Jensen et al., 2008). Figure copyright belongs to the 
American Society for Microbiology. 
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 Purine salvage and interconversion 
The purine salvage and interconversion pathways are shown in Figure 13. Nucleobases that 
are assimilated from the environment are directly converted to the nucleotide level by a 
phosphribosylatin step that is subject to feedback inhibition. Salvaged nucleosides are mostly 
converted to nucleobases of which the major part is excreted again while the pentose moiety 
is further catabolized. Exogenous nucleotides may also be used as precursors for nucleic acids; 
however, this requires dephosphorylation to nucleosides by periplasmic enzymes. 
Endogenously, mRNA turnover results in large quantities of ribonucleotide monophosphates 
that are reutilized directly or after conversion to nucleosides or nucleobases (Nygaard, 1983; 
Zalkin & Nygaard, 1996). The deoxynucleotides dATP and dGTP are synthesized via ADP 
and GDP under aerobic conditions and directly from ATP and GTP under anaerobic conditions 
(Zalkin & Nygaard, 1996).The genes and enzymes involved in purine biosynthesis are listed 
in Table 1. 
 
 
Figure 13 Purine salvage and interconversion. The solid lines show known pathways, while the dashed 
lines indicate reactions demonstrated by (Xi et al., 2000) involving the hypothetical xanthine 
dehydrogenase genes. Abbreviations: PRPP, 5′-phospho-α-D-ribosyl-1-pyrophosphate; FGAR, 5′-
phosphoribosyl N- formylglycinamide; GPRT, guanine phosphoribosyltransferase; HPRT, hypoxanth
ine phosphoribosyltransferase; APRT, adenine phosphoribosyltransferase; XHD, Xanthine 
dehydrogenase;  AICAR, 5-aminoimidazole-4-carboxamide ribonucleotide; and sAMP, 
adenylosuccinate. Figure reproduced from (Xi et al., 2000). 
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 Regulation of the purine pathway 
Purine biosynthesis is regulated on the protein level via allosteric activation and inhibition of 
the enzymes of various steps in the pathway, enzyme production is controlled on a genetic 
level as well. The genes that are responsible for the 11 steps to IMP production are not located 
together in a single operon. Instead, they are distributed over the chromosome. The genes 
purT, purL, purC and purB are in monocistronic operons; purH and purD are located next to 
each other but are transcribed separately; the purine operons are purMN and purEK. The gene 
purF is part of the cvp purF dedF operon whose other members are not involved in purine 
metabolism (Zalkin & Nygaard, 1996; Jensen et al., 2008).  
The transcriptional regulation of the genes involved in IMP synthesis requires two regulatory 
elements: a purR-encoded repressor protein and a DNA operator site (Pur box) where the 
repressor binds. Hypoxanthine and guanine function as co-repressors in vivo (Houlberg & 
Jensen, 1983). The Pur box has the consensus sequence ACGAAACGTTTGCGT, and is 
present in front of the transcription start sites of all the operons involved in de novo IMP 
production, as well as purA, guaBA and purR itself. The position of the Pur box varies and in 
some cases more than one operator site is present. PurR represses the genes specifying IMP 
synthesis between 10- to 17-fold, while repression of purB , purA, guaBA and purR is between 
two to five- fold (Meng et al., 1990; Rolfes & Zalkin, 1990; Choi & Zalkin, 1992; Jensen et 
al., 2008). This regulatory pattern may have evolved to permit purines obtained from the 
medium or from RNA turnover to shut down the de novo pathway while still permitting GMP 
and AMP synthesis via the salvage reactions. Except for purA and guaBA, there is no evidence 
for additional regulation of the pur genes. In the case of purA, an uncharacterized adenine-
specific control system augments regulation by PurR (Zalkin & Nygaard, 1996). Research 
done on B. subtilis found an adenine dependent role for YabJ regulation of purA transcription, 
possibly via a YabJ-PurR interaction (Rappu et al., 1999). YabJ is present in E.coli and 
Salmonella but to my best knowledge, its role in regulating nucleotide metabolism was not 
studied in these organisms. For guaBA the 5-fold regulation by PurR is modulated to 15-fold 
by DnaA, which binds to two DnaA boxes (Tesfa-Selase & Drabble, 1992). It is thought that 
the regulation of guaBA by DnaA is important for coordinating purine nucleotide production 
with DNA replication (Zalkin & Nygaard, 1996). 
On an enzymatic level the first step in the de novo pathway, catalysed by glutamine PRPP 
amidotransferase, is inhibited by AMP and GMP. This reaction is also subject to feed-forward 
regulation by PRPP. The characteristics of the regulation is as follows: (i) AMP is a weaker 
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inhibitor than GMP. (ii) The inhibition by GMP and AMP is synergistic. (iii) Inhibition by 
AMP and GMP is competitive with the substrate PRPP. (iv) In the absence of inhibitors, 
saturation by PRPP is hyperbolic. When AMP is present saturation remains hyperbolic (i.e. 
the rate of the catalysis reaction depends on the substrate concentration) but is sigmoidal when 
GMP is present. (v) AMP and GMP exhibit positive cooperativity for inhibition (binding of 
one molecule increases the enzyme’s affinity for the other) (Zalkin & Nygaard, 1996). When 
the concentrations of PRPP is very high, the normal feedback inhibition by AMP and GMP is 
overcome and the rate of the reaction is increased. 
 
Table 1 Enzymes and genes of purine metabolism (Jensen et al., 2008). 
Enzyme name Gene Locus a  Proteins 
E. 
coli  
Salmonella  
De novo synthesis of IMP  
PRPP amidotransferase  purF  b23l2 STM2362 Tetramer 56.5 kDa 
GARsynthetase  purD  b4005 STM4175 Monomer 45.9 kDa 
GAR transformylase N  purN  b2500 STM2500 Monomer 23.5 kDa 
GAR transformylase T (FGAR 
synthase)  
purT  b1849 STM1883 Dimer 42.4 kDa 
FGAR amidotransferase  purL(purG)  b2557 STM2565 Monomer 141.4 kDa 
AIR synthase  purM  b2499 STM2499.S Dimer 36.9 kDa 
N5-AIR-carboxylase  purK  b0522 STM0533 Dimer 39.5 kDa 
N5-CAIR mutase  purE  b0523 STM0534 Octamer 17.8 kDa 
SAICAR synthetase  purC  b2476 STM2487 Trimer 27.0 kDa 
Adenylosuccinate lyase  purB  b113l STM1232 Tetramer 51.5 kDa 
AICAR transformylase  purH  b4006 
 
Dimer 57.3 kDa 
Bifunctional 
IMP cyclohydrolase  purH  b4006 STM4176 Dimer 57.3 kDa 
Bifunctional 
Biosynthesis of AMP 
Adenylosuccinate synthase  purA  b4177 STM4366 Dimer 47.3 kDa 
Adenylosuccinate lyase  purB  b1131 STM1232 Tetramer 51.5 kDa 
AMP kinase  adk  b0474 STM0488 Monomer 23.6 kDa 
Biosynthesis GMP 
IMP dehydrogenase  guaB  b2508 STM2511 Tetramer 52.0 kDa 
GMP synthase  guaA  b2407 STM2510 Dimer 58.7 kDa 
GMP kinase  gmk  b3640 STM3740 Dimer 23.6 kDa 
Purine interconversion and salvage 
GMP reductase  guaC  b0104 STM0141 Tetramer 37.4 kDa 
Guanosine kinase  gsk  b0477 STM0491 48.4 kDa 
Purine nucleoside phosphorylase  deoD  b4384 STM4570 Hexamer 26.0 kDa 
Xanthosine phosphorylase  xapA  b2407 STM2422 Hexamer 29.8 kDa 
Ribonucleoside hydrolase (Low 
expression)  
rihC  b0030 STM0051 Tetramer 32.6 kDa 
Hypoxanthine PRTase  hpt  b0125 STM0170 Tetramer 20.1 kDa 
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Enzyme name Gene Locus a  Proteins 
E. 
coli  
Salmonella  
Xanthine/guanine PRTase  gpt  b0238 STM0317 Tetramer 17.0 kDa 
Guanine deaminase  guaD  b2883 Not in 
Salmonellae 
Mer? 50.2 kDa 
Adenosine deaminase  add  b1623 SMT1463 Tetramer 36.4 kDa 
Adenine deaminase (cryptic)  adc  b3665 Not in 
Salmonellae 
Dimer 63.7 kDa 
Adenine PRTase  apt  b0469 STM0483 Dimer 19.9 kDa 
AMP nucleosidase  amn  b1982 STM2009 Hexamer 54.0 kDa 
S-Adenosyl homocysteine 
hydrolase  
mtn  b0159 STM0207 Dimer 24.3 kDa 
ATP PRTase  hisG  b2019 STM2071 Hexamer 33.4 kDa 
Purine regulatory protein 
Purine repressor  purR  b1658 STM1430 Dimer 38.2 kDa 
a  The loci labelled bXXXX refer to the ordered gene map of E. coli K-12 strain MG1655, while loci 
designated STMxxxx refer to the ordered chromosomes map of S. enterica serovar Typhimurium strain 
LT2.  
 
The pathway is also regulated after the IMP branch point. In in vitro experiments, the rate of 
AMP synthesis from IMP is inhibited by several nucleotides including AMP, GMP and 
ppGpp. The inhibition by ppGpp is very strong (Ki = 50µM), which suggests that amino-acid 
starvation might decrease the rate of AMP synthesis. The conversion of IMP to GMP is 
inhibited by GMP (Ki = 55µM) in a manner that is competitive with IMP (Km = 11 µM).  
 Pyrimidine synthesis and regulation 
 Enzymatic reactions for de novo pyrimidine biosynthesis 
The de novo synthesis of CTP and UTP occurs via an unbranched pathway in which dTTP is 
the ultimate end product, and UTP, CTP and dCTP are obligatory intermediates (Figure 14 ). 
The first step in the de novo pyrimidine biosynthesis is the formation of carbamoylphosphate 
from glutamine, bicarbonate and two ATP molecule (one is required for the formation of the 
reaction intermediate, the other for phosphorylating the enzyme-bound carbamate). This first 
reaction is also required for arginine biosynthesis. The next reaction involves the condensation 
of carbamoylphosphate and the amino group of aspartate to yield carbamoylaspartate, also 
known as ureidosuccinate. The pyrimidine ring is formed by cyclization followed by 
oxidation. First, the ring is closed to form dihydroorotate. Next, an enzyme that is linked to 
the electron transport system catalyzes the oxidation of dihydroorotate to orotate. PRPP 
donates a ribose-5 phosphate to yield orotidine 5’- monophosphate (OMP). OMP is 
irreversibly decarboxylated to produce UMP. UMP is subsequently phosphorylated to UDP 
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and then to UTP. UTP is aminated to CTP. CMP is not an obligatory intermediate in de novo 
CTP synthesis, but Salmonella possesses a CMP kinase that can re-phosphosphorylate CMP 
and dCMP from mRNA and CDP-diaglycerol turnover (Beck et al., 1974; Frick et al., 1990; 
Neuhard & Kelln, 1996). The genes and enzymes involved in pyrimidine biosynthesis are 
listed in Table 2.  
Table 2 Genes encoding enzymes that are involved in pyrimidine nucleotide synthesis, 
interconversion, and salvage  
Enzyme name Gene Locus a  Proteins 
E. coli  Salmonella  
Pyrimidine nucleotide biosynthesis de novo 
Carbomoylphosphate synthase  
   
A/B-monomer 
Glutaminase subunit  carA  b0032,  STM0066 41.5 kDa 
Synthase subunit  carB  b0033 STM0067 118 kDa 
Aspartate transcarbamoylase  pyrBI  
  
2C3/3R2  
Regulatory subunit (R)  pyrI  b4244 SMT4459 17.1 kDa 
Catalytic subunit (C)  pyrB  b4245 SMT4460 43.4 kDa 
Dihydroorotase  pyrC  b1062 STM1163 Dimer C: 39 
kDa 
Dihydroorotate dehydrogenase  pyrD  b0945 STM1058 Monomer 36.7 
kDa 
Orotate phosphoribosyltransferase  pyrE  b3642 STM3733 Dimer 26.4 kDa 
OMP decarboxylase  pyrF  b1281 STM1707 Dimer 26.4kDa 
UMP kinase  pyrH  b0171 STM0218 Hexamer 26.0 
kDa 
Nucleoside diphosphate kinase  ndk  b2518 STM2526 Tetramer 15.5 
kDa 
CTP synthase  pyrG  b2780 STM2953 Tetramer 60.5 
kDa 
Salvage reactions 
Uracil PRTase  upp  b2498 STM2498 Tetramer 22.5 
kDa 
Uridine-cytidine kinase  udk  b2066 STM2122 Dimer? 24.4 
kDa 
CMP kinase  cmk  b0910 STM0980 24.7 kDa 
Deaminases 
Cytidine deaminase  cdd  b2143 STM2183 Dimer 31.5 kDa 
Cytosine deaminase  codA  b0337 STM3334 Hexamer 47.6 
kDa 
Enzymes splitting the glycosyl bond nucleosides 
Uridine phosphorylase  udp  b3831 STM3968 Hexamer 27.2 
kDa 
Pyrimidine ribonucleoside hydrolase (Low 
expression)  
rihA  b0651 STM0661 33.8 kDa 
Pyrimidine nucleoside hydrolase (Silent)  rihB  b2162 Not in 
Salmonella  
Tetramer 33.7 
kDa 
Ribonucleoside hydrolase (Low expression)  rihC  b0030 STM0051 Tetramer 32.6 
kDa 
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a  The loci labeled bXXXX refer to the ordered gene map of E. coli K-12 strain MG1655,while loci 
designated STMxxxx refer to the ordered chromosomes map of S. enterica serovar Typhimurium strain 
LT2 (Jensen et al., 2008). 
 
 Pyrimidine salvage 
The de novo pyrimidine biosynthesis pathway generates UTP as well as CTP. Cytidine 
nucleotides can only be formed via the reaction catalysed by CTP synthase (encoded by pyrG). 
Furthermore, cytidine and cytosine compounds can only be converted to uracil compounds by 
deamination (enzymes encoded by cdd and codA). Pyrimidine nucleotide products from RNA 
breakdown are converted to diphosphates and triphosphates by the nucleoside monophosphate 
kinases (UMP kinase and CMP kinase), in combination with the nucleoside diphosphate 
kinase. While UMP kinase (encoded by pyrH also known as umk) is an integral part of both 
the de novo as well as salvage pathways, the CMK kinase (cmk) is only involved in salvage. 
Under aerobic conditions, CDP is the major pyrimidine substrate for ribonucleotide reduction, 
thus the salvage reaction catalysed by CMP kinase is of major importance as reviewed in 
(Jensen et al., 2008). See Figure 15 for a summary of the savage pathways for uracil and 
cytosine.  
Specific transport systems import free pyrimidine nucleosides and bases that are present in the 
growth medium into the cell (Jensen et al., 2008). Cytosine and cytidine are generally 
deaminated to uracil and uridine respectively. Then uridine is converted to UMP by uridine 
kinase (udk). Uracil can be directly converted to UMP by uracil PRTase (upp). There is no 
known cytosine PRTase (nor a reversible cytidine phosphorylase) identified in any organism. 
Furthermore, enteric bacteria do not possess a deoxycytidine kinase. Thus, the deamination of 
cytosine and deoxycytosine to their corresponding uracil compounds is the only way to utilize 
cytosine and deoxycytosine for nucleotide synthesis. Exogenous nucleosides can only be 
utilized under conditions that permit their dephosphorylation prior to uptake; this ability is 
repressed by high phosphate concentrations in the medium (Bonekamp et al., 1984; Neuhard 
& Kelln, 1996). 
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Figure 14 Biosynthesis and interconversion of pyrimidine nucleotides, nucleosides, and bases. The 
enzymes are indicated by their gene symbols (Jensen et al., 2008). Figure copyright belongs to the 
American Society for Microbiology. 
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Figure 15 Salvage pathways for uracil and cytosine. Gene names are used to represent the encoded 
proteins. Figure replicated from (Jensen et al., 2008). Figure copyright belongs to the American Society 
for Microbiology. 
 
 Regulation of pyrimidine biosynthesis 
Like the purine pathway, the pyrimidine pathway is also subject to regulation on the enzymatic 
as well as transcriptional level. Generally (aside from the carAB operon), the addition of 
preformed pyrimidines to the growth medium of wild type cells has quite a small effect and 
does not result in significant nucleotide pool changes. However, during extended partial 
pyrimidine starvation (for example due to leaky mutations or slow-feeding auxotrophic 
mutants) the changes in the nucleotide pool sizes and enzyme levels become more pronounced. 
Pyrimidine starvation causes a reduction in intracellular pyrimidine nucleoside triphosphates 
(especially UTP), but leads to a substantial increase in the size of ATP and GTP pools as was 
observed by (Vogel et al., 1991). 
The pyrimidine biosynthesis pathway is regulated on the level of gene expression by 
mechanisms that control the synthesis of the six enzymes that are required for the de novo 
production of UMP and of ribonucleotide reductase, which catalyzes the crossover reaction 
from ribonucleotides to deoxyribonucleotides (Neuhard & Kelln, 1996). The pyr genes are 
scattered on the chromosome and are organized in single transcription units or in small 
operons, together with genes that are seemingly unrelated. Unlike the purine pathway, there is 
no common pyrimidine repressor and each gene is regulated in a unique way (Jensen et al., 
2008). With the exception of the carAB operon, regulation depends largely on the behavior of 
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RNA polymerase as a function of the purine-and pyrimidine-nucleoside triphosphate pools 
(Jensen et al., 1982). Ribosome dynamics and PurR also play a role (Houlberg & Jensen, 1983; 
Jensen, 1988; Weissborn et al., 1994). The control of gene expression of all the steps up to 
UMP synthesis have been studied in detail. This part of the pathway is redundant in the 
presence of exogenous pyrimidine sources. On the other hand, not much is known about how 
the expression of the genes encoding enzymes that convert UMP to UTP and CTP is 
controlled. These enzymes are needed regardless of the presence of pyrimidines in the growth 
medium (Jensen et al., 2008) and as such are essential for survival. The mechanisms that 
regulate pyr gene expression can be divided into three categories: (i) Rho-independent 
transcriptional attenuation that is facilitated by a transcription terminator between the 
promotor and structural gene. Regulation depends on the distance between the elongating 
RNA polymerase and the first coupled ribosome a function of the UTP and GTP pools. (ii) 
UTP-dependent “slippery” RNA synthesis at a U-rich stretch in the ultimate 5’ end of the 
newly formed mRNA. When intracellular UTP concentrations are high, the RNA polymerase 
stays bound to the promotor and iteratively adds more U-residues, blocking productive 
initiation at the promotor. When intracellular UTP concentrations are low, the reiterative 
addition does not occur and extension completes successfully. (iii) The pool sizes of different 
nucleoside triphosphates influences the point from where transcription is initiated, which in 
turn affects mRNA translation. The three regulatory mechanisms are summarized in Figure 
16, Figure 17 and Figure 18.  
As if the above mechanisms of regulation are not complicated enough, evolution has conjured 
up an even more complex regulator mechanism for carAB gene expression. This mechanism 
involves the transcription factors IHF, PepA, RutR, PurR and ArgR as well as :slippery 
transcription”. Transcription can be induced from either the P1 or P2 promotor (Shimada et 
al., 2008; Nguyen Le Minh et al., 2015). Thymidine, uracil, arginine and purine molecules all 
act as regulatory signals. The biggest advantage of such a complicated mechanism is that 
regulation can be responsive to a large range of concentrations of effector molecules, with 
each mechanism sensitive to a different range of effector concentrations. It appears as if the 
IHF/PepA/RutR mediated regulation occurs when UTP levels are high. Regulation by 
reiterative transcription occurs when UTP levels are lower. The lowest levels of UTP occur in 
a pyrimidine auxotroph in limiting conditions or when a shift is made from a pyrimidine-rich 
to a pyrimidine poor medium (Turnbough & Switzer, 2008).  
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Aside from regulation on the level of gene expression, enzyme activity is also controlled. 
Allosteric regulation of the pyrimidine biosynthesis enzymes occurs at five strategic points: 
(i) the synthesis of carbamoyl phosphate; (ii) the formation of carbamoyl aspartate; (iii) the 
amination of UTP to yield CTP; (iv) the reduction of CTP to dCTP; and (v) the conversion of 
dCTP to dTTP. CPSase is inhibited by UMP and activated by ornithine, IMP and PRPP. The 
binding sites of IMP and UMP overlap and the result is that CPSase is feedback inhibited 
according to the metabolic needs of the cell.  In the event that carbamoylphosphate becomes 
limiting for arginine biosynthesis, ornithine accumulates and prevents inhibition by UMP. In 
the event that an excess of arginine is present, ornithine is not produced and the enzyme is 
controlled by UMP alone (Piérard et al., 1965). ATCase is activated by ATP and feedback 
inhibited by CTP. UTP alone has no effect, but it leads to synergistic inhibition with CTP. 
Activation by ATP probably serves the purpose of regulating pyrimidine production to match 
that of purine production (reviewed by (Jensen et al., 2008). UMP kinase is allosterically 
regulated by the positive effector GTP and the negative effector UTP. CTP synthase exhibits 
negative cooperativity for the substrate glutamine and the effector GTP, and positive co-
cooperativity for ATP and UTP, see review by (Jensen et al., 2008).  
  
Figure 16 Model for attenuation control of pyrBI expression in E. coli. The diagram shows the relative 
positions of RNA polymerase and the translating ribosome within the leader region when UTP 
concentrations are either low or high (Turnbough & Switzer, 2008). Figure copyright belongs to the 
American Society for Microbiology. Figure copyright belongs to the American Society for 
Microbiology. 
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Figure 17 Model for transcription start site switching and translational control of pyrC expression in 
E. coli and Salmonella. The nucleotide sequence of the pyrC promoter-regulatory region of E. coli is 
shown, with the −10 region, SD sequence, and pyrC initiation (Met) codon underlined and labelled. 
Asterisks indicate the four transcription start sites at the pyrC promoter, and the two major start sites, 
C7 and G9, are indicated. Inverted horizontal arrows indicate the region of dyad symmetry. The 
sequence and structure of transcripts initiated at start sites C7 (high CTP) and G9 (low CTP) are shown, 
with the SD sequence boxed. Only C7 transcripts form the hairpin that includes the SD sequence and 
prevents translation initiation (Turnbough & Switzer, 2008). Figure copyright belongs to the American 
Society for Microbiology. Figure copyright belongs to the American Society for Microbiology. 
 
  
Figure 18 Model for the regulation of pyrBI expression by UTP-sensitive reiterative transcription. 
DNA sequences in the transcription bubble are shown, and the sequence of the nascent transcript, 
starting at position +1, is italicized (Turnbough & Switzer, 2008). Figure copyright belongs to the 
American Society for Microbiology. 
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 Thymineless death 
In 1954 Barner and Cohen observed that a thymine-requiring mutant of E. coli lost viability 
when grown in a medium lacking thymine (Barner & Cohen, 1954). This phenomenon has 
also been found in other organisms including yeast and higher eukaryotes. Thymine starvation 
in E. coli can be induced in several ways that inhibit the synthesis of thymidylate either directly  
by inhibiting the conversion of dUMP to dTMP and subsequently to dTTP, or indirectly by 
interfering with folate metabolism. Thymineless death is a unique effect, since starvation of 
bacteria for the other nucleotides have bacteriostatic effects that can be reversed with 
supplementation with the required nucleotides. On the other hand, thymine starvation is 
bactericidal. Although his phenomenon has been studied extensively, its exact molecular 
mechanisms remained obscure for many decades (Sat et al., 2002). Throughout the years, 
thymineless death has been attributed to DNA damage and DNA recombination structures and 
their associated outcomes: SOS induction, filamentation, mutagenesis, loss of plasmids, or 
induction of suicide modules and prophages, among others. However, recent advances made 
by independent research groups have presented compelling evidence that the initiation of 
chromosome replication under thymine starvation is a key element in the phenomenon. In this 
scenario, degradation of the AT-rich oriC sequence leads to abortive attempts at replication 
and eventually results in cell death (Guzman & Martin, 2015).  
2.3 The role of nucleotide biosynthesis in biofilm formation 
Over the course of the past decade, various investigations using different bacterial models 
have been directed at uncovering the regulatory mechanisms that control the switch from a 
free-living planktonic state of growth to surface-attached biofilm growth. Some of the studies 
that have found roles for nucleotide biosynthesis in biofilm formation are briefly discussed 
next. 
Sauer and co-workers characterized transitional episodes in biofilm development by P. 
aeruginosa and found roles for enzymes involved in nucleotide biosynthesis. Using direct 
observation by microscopy, they evaluated biofilm morphology, matrix production and the 
activation of quorum-sensing (QS) regulated genes. They used this information to determine 
optimal sampling times for protein analysis by 2-D gel electrophoresis in order to compare the 
physiological characteristics of different phases of biofilm formation (Sauer et al., 2002). The 
sampling schedule for protein analysis was chosen as follows: planktonic cells from the 
chemostat; 8-h biofilm, reversible attachment; 1-day biofilm, irreversible attachment; 3-day 
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biofilm, maturation-1; 6-day biofilm, maturation-2; and 12-day biofilm, dispersion. 
Microscopic observations revealed that bacteria having the phenotypes from more than one 
biofilm phase could be present simultaneously. However, at the various sampling times the 
majority of bacteria displayed the same phenotypes. Protein mass-spectrometry (MS) results 
indicated that, after attachment proteins involved in carbon catabolism, amino-acid 
metabolism and co-factor biosynthesis were upregulated. Among these proteins were 
thioredoxin reductase and adenylate kinase, which are involved in pyrimidine- and purine 
biosynthesis respectively.  
Beenken and co-workers used micro-arrays to compare the gene expression profiles of 
planktonic and biofilm S. aureus isolates. They found that several operons of the pyrimidine 
nucleotide biosynthesis pathway were induced in biofilms (Beenken et al., 2004). In another 
study on Pseudomonas aeruginosa, 5850 transposon mutants were assayed for altered biofilm 
phenotypes (Ueda et al., 2009). Mutations caused by transposon insertions in the genes from 
the de novo pyrimidine synthesis pathway resulted in complete abolishment of biofilm 
formation. When exogenous uracil was applied to one such a mutant, biofilm formation was 
restored. Furthermore, whole transcriptome analysis revealed that pyrimidine starvation 
affected all three known QS systems in P. aeruginosa. This study found that purines were not 
required for biofilm formation (Ueda et al., 2009). Nevertheless, other research on other model 
systems has emphasized the importance of purine biosynthesis for biofilm formation and 
symbiosis with nematodes, insects or plant roots (Han et al., 2006; Ge et al., 2008; Kim et al., 
2014; Yoshioka & Newell, 2015). In these studies, defective biofilm formation and/or 
symbiotic interactions were observed for purine auxotrophic mutants.  
Oggioni and colleagues identified two principal patterns of pneumococcal behaviour in the 
host during infection: during bactearaemic sepsis S. pneumoniae exhibits planktonic growth 
behaviour, while tissue infection (like meningitis or pneumonia) bacteria are in a biofilm-like 
state (Oggioni et al., 2006). Yadav and colleagues (Yadav et al., 2012b)  compared the gene 
expression profiles of early phase biofilms to that of planktonic cells using cDNA microarrays. 
Genes involved in isoprenoid biosynthesis, cell-wall biosynthesis, translation and purine and 
pyrimidine nucleotide metabolic pathways were induced in the biofilms. 
These results suggest that nucleotide biosynthesis may be a universal requirement for biofilm 
formation of different microbial species. There could be various reasons why intact de novo 
nucleotide biosynthesis is important for biofilm formation, including: (i) a lack of nucleotides 
affects growth, and biofilm inhibition may be a direct result of reduced growth. (ii) A lack of 
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nucleotides may inhibit eDNA production which is an important component of the biofilm 
matrix for some organisms. (iii) Perturbations in the nucleotide pools may lead to changes in 
the concentrations of nucleotide derived signalling molecules (such as cAMP or c-di-GMP) 
which regulate biofilm formation. The roles of nucleotide derived signalling molecules in the 
bacterial cell are discussed next. 
 Nucleotide derived second messengers 
Prokaryotes and eukaryotes utilize cyclic and linear nucleotides to regulate a diversity of 
physiological processes in response to internal and external stimuli. It has become evident that 
in bacteria c-di-GMP, c-di-AMP cAMP and pp(p)Gpp all play important roles as second 
messengers involved in the coordination of virulence factor production, biofilm formation, 
carbon metabolism, stress response and cell cycle progression and more. These small 
molecules diffuse within as well as between cells and so contribute to the regulation of 
biological processes at different levels. Furthermore, different nucleotide-based signalling 
systems are often integrated with each other. For example in S. aureus high levels of c-di-
AMP activate the stringent response trough RelA/SpoT (enzymes that metabolize (p)ppGpp), 
in addition the phosphodiesterase enzyme GdpP is inhibited in a dose-dependent manner by 
ppGpp (Corrigan et al., 2013). In P. aeruginosa the cAMP-Vfr signaling pathway, which is 
involved in virulence regulation, is inhibited by c-di-GMP through a yet undiscovered 
mechanism (Almblad et al., 2015).  Evidence also points to an interaction between Quorum 
Sensing on the population level and c-di-GMP signalling within the individual bacterial cells. 
Research on this topic has been reviewed in (Srivastava & Waters, 2012). Some of the 
physiological processes that are regulated by nucleotide based second messengers are 
summarized in Figure 19 and briefly reviewed in the next sections. 
 cAMP 
cAMP is synthesized from ATP by adenylyl cyclases and hydrolysed by cAMP specific 
phosphodiesterases. The catabolic gene activator protein (also known as Cap or Crp) is a well-
studied cAMP receptor. Cap regulates the expression of more than 180 genes in E. coli 
(Robison et al., 1998; Zheng et al., 2004; Grainger et al., 2005). When cAMP binds to Cap its 
DNA-binding domain is activated enabling it to bind to specific DNA sequences near the 
promotor sequences, where it enables transcription by directly interacting with RNA 
polymerase. No doubt, the best-studied example of the role that cAMP-CAP plays in gene 
expression is the mediation of the glucose response or catabolic repression in E. coli. cAMP 
is produced by the cell only when glucose levels are low. When glucose levels are high, there 
  Chapter 2: Nucleotides 
37 
 
is no cAMP activation of Cap and RNA polymerase cannot interact with the promotor. When 
glucose levels are low and cAMP levels are high, cAMP-Cap interacts with the RNA 
polymerase and the lactose operon can be transcribed (if the lac repressor protein is not 
blocking the operator due to the absence of lactose in the medium). cAMP has also been shown 
to regulate the expression of virulence genes and genes involved in biofilm formation in a 
wide set of bacterial pathogens including Salmonella and E.coli (information obtained from  
the  Ecocyc webpage for cap/crp as well as the references listed therein (Keseler et al., 2013).  
 
 
Figure 19 Phenotypes or processes that are controlled by (a) c-di-GMP. (b) c-di-AMP. (c) cGMP. (d) 
cAMP. (e) ppGpp and pppGpp (Kalia et al., 2013). Figure reproduced with permission 
 
 (p)ppGpp 
The linear nucleotides guanosine tetraphosphate and guanosine pentaphosphate, collectively 
referred to as (p)ppGpp, are produced in response to starvation for the following nutrients: 
amino acids, phosphates, fatty acids, carbon and iron (Vinella et al., 2005; Battesti & 
Bouveret, 2006; Lapouge et al., 2008; Kalia et al., 2013) . The so-called “stringent response” 
results in the inhibition of RNA synthesis during amino acid starvation. This leads to reduced 
translation activity, in order to conserve the amino acids that are available. (p)ppGpp also 
upregulates amino acid uptake genes. In the Beta- and Gamma-proteobacteria the 
concentration of (p)ppGpp is regulated by the activity of two homologous proteins, SpoT and 
RelA. SpoT is a bifunctional hydrolase-synthase, which uses ATP and GDP or GTP to 
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generate ppGpp or pppGpp. RelA is a mono-functional synthase, which uses GTP and ATP to 
produce pppGpp, which is converted to ppGpp. Furthermore, RelA or SpoT also catalyze the 
hydrolysis of ppGpp and pppGpp. (p)ppGpp regulates bacterial physiology on various levels 
including: DNA-replication, transcription and translation (Kalia et al., 2013). (p)ppGpp has 
been implicated in the switch between the free-living lifestyle and biofilm formation by 
Lysteria, Streptococcus and Campylobacter because mutants that cannot synthesize (p)ppGpp 
are defective in biofilm formation (Dalebroux et al., 2010) 
 cGMP 
Until recently, the involvement of cGMP in bacterial signaling was quite controversial because 
the findings in early reports linking cGMP to physiological functions could not be reproduced 
(Black et al., 1980; Gomelsky & Galperin, 2013). However, that controversy has been laid to 
rest when Berleman and colleagues provided unambiguous evidence that Rhodospirillum 
centenum synthesizes cGMP and utilizes it for regulation of cyst formation and that it exerts 
its regulatory function through a specific transcription factor (Berleman r., 2004). Other cyst-
forming Alphaproteobacteria, Azospirillum brasilense and Sinorhizobium melioti also excrete 
cGMP during encystment (Marden et al., 2011; Gomelsky & Galperin, 2013). Furthermore, 
the genomes of several other cyst-forming bacteria encode guanylyl cyclase gene clusters. 
Research into cGMP signaling in bacteria is still in its infancy and the details of its regulatory 
role is only beginning to emerge (Kalia et al., 2013) therefore it remains to be seen if it plays 
a role in biofilm formation. 
  Cyclic dinucleotide second messengers 
The three major types of cyclic dinucleotide second messengers discovered to date are c-di-
GMP, c-di-AMP and most recently c-AMP-GMP.  The first cyclic dinucleotide messenger 
that was discovered is c-di-GMP which serves as a regulator of diverse processes in most 
bacterial lineages (Römling et al., 2013). Compared to the other two molecules, the c-di-GMP 
signaling systems are the best studied, although there are still a great many mysteries that 
remain to be solved. The signaling role of c-di-AMP was revealed in 2008 and was shown to 
be important for regulating sporulation and germination as well as the osmotic-shock response 
(Witte et al., 2008; Oppenheimer-Shanaan et al., 2011; Corrigan et al., 2013; Nelson et al., 
2013). Very recently c-AMP-GMP was discovered to control Vibrio cholera virulence (Davies 
et al., 2012), and has since been found to regulate Geobacter electrogenesis (Nelson et al., 
2015). Bacterial c-AMP-GMP is formed via two 3’5’ phosphodiester linkages, however an 
analogue with one 2’5’-phospodiester linkage and one 3’5’-phosphodiester linkage is 
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produced by metazoans (Zhang et al.,). It is possible to vary the nucleotide composition and 
manner in which they are joined, thus it is expected that many additional types of cyclic 
dinucleotides and signaling pathways are awaiting discovery, reviewed by (Nelson et al., 
2015). The following sections focus on c-di-GMP mediated signaling, with special emphasis 
on its role in biofilm formation. 
 A general overview of c-di-GMP signalling  
Benzinamn and colleagues first described the nucleotide based second-messenger c-di-GMP 
as an allosteric activator of cellulose production in Gluconacetobacter xylinis. (Ross et al., 
1986; Ross et al., 1987). Over the years, it has been established that c-di-GMP is a major 
player in the regulation of physiology across the bacterial kingdom. For instance cell 
differentiation, the switch from the free-living planktonic mode of growth to the sessile biofilm 
mode of growth as well as the transition from acute infection to chronic infection are all 
regulated by c-di-GMP (see reviews by (Römling et al., 2005; Hengge, 2009; Krasteva et al., 
2012)). Furthermore, it has become rather obvious that the c-di-GMP signalling cascades are 
far more complex than that of other known signal transduction systems. In canonical two-
component transduction systems, a signal stimulates a histidine kinase to phosphorylate its 
cognate response regulator, which subsequently alters the expression of a limited set of genes 
(Albright et al., 1989). In contrast, the c-di-GMP signalling cascades have a multilayer impact, 
which includes control at the transcriptional, translational and post-translational level. Proteins 
involved in c-di-GMP typically have a modular multi-domain architecture to allow for a 
diversity of regulatory inputs and/ or signal outcomes (Krasteva et al., 2012). Many bacterial 
genomes encode several copies of GGDEF and EAL domains, however the mechanisms by 
which the activities of parallel c-di-GMP signalling systems are segregated to avoid potential 
cross talk are not well understood (Seshasayee et al., 2010). 
 c-di-GMP metabolism and architecture of c-di-GMP metabolizing proteins 
The condensation of two GTP molecules to form c-di-GMP is catalysed by diguanylate cyclase 
domains (DGEs) with GGDEF motif. The enzymatic degradation of c-di-GMP occurs via 
hydrolyses by phosphodiesterase (PDEs) with EAL or HD-GYP domains. Many of the DGE 
or PDE proteins contain sensory domains that integrate cellular or environmental signals into 
the regulation of c-di-GMP production and breakdown (Figure 20).  
DGE proteins form homodimers and each monomer contributes a single bound GTP molecule 
to create a phosphodiester bond. Two divalent metal ions Mn+2 or Mg
+2
 are indispensable for 
the formation of the phosphodiester bond between the GTP molecules. The intermediate 
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product pppGpG is converted into c-di-GMP and two phosphor molecules are released (Ross 
et al., 1987; Wassmann et al., 2007; Paul et al., 2007). The two glycine residues in the 
GGD(D/E)F motif are important for GTP binding, the glutamate/aspartate residue in the third 
position is required for metal ion coordination and for catalysis and the glutamate residue in 
the fourth position also plays a role in metal ion coordination  (Chan et al., 2004; Wassmann 
et al., 2007). Approximately half of the proteins that have a GGDEF domain also contains a 
c-di-GMP binding site with a conserved RxxD motif. The RxxD site has an allosteric 
inhibitory function and is found close to the GGDEF site (Chan et al., 2004). This self-
inhibitory mechanism enables accurate control of the localized c-di-GMP pool and thereby 
avoids the diffusion of excess c-di-GMP, which could potentially interfere with other 
intracellular processes. 
c-di-GMP can be degraded into two GMP molecules or into pGpG by the activity of either 
HD-GYP or EAL domain containing PDEs respectively. EAL domain PDEs are much better 
studied than those with HD-GYP domains. EAL domain PDEs contain the highly conserved 
Glu-Ala-Leu sequence motif and hydrolyse c-di-GMP into pGpG which is subsequently 
converted to two molecules GMP. EAL domains function as dimers and require Mg2+ binding 
for catalytic activity (Rao et al., 2008). A conserved EGVE motif acts as a general base catalyst 
and accepts a proton from an H2O molecule. The resulting hydroxid ion performs the 
nucleophilic attack, which breaks the phosphodiester bond. The EAL domain contains another 
conserved motif, DFG (T/A)GYSS which is also thought to be essential for catalytic activity 
(Rao et al., 2008; Römling, 2009). Although EAL domain proteins typically function as 
dimers, some EAL domains can exhibit limited PDE activity as monomers (Tarutina et al., 
2006; Barends et al., 2009; Ahmad, 2013).  
HD-GYP domains are not as well studied as EAL domains, mostly because they are difficult 
to crystalize. By 2015 only the third structure of this class have been solved by X-ray 
diffraction and a recent search of the Protein Data Bank (http://www.rcsb.org) has not revealed 
any new structures (date of access 13 July 2016). The first high resolution HD-GYP domain 
that was studied by crystallography is BD1817 from B. bacteriovorus which lacks the active-
site tyrosine that is conserved between most HD-GYP domains (Lovering et al., 2011). For a 
few years, BD1817 was the best available model to deduce the catalytic mechanism of c-di-
GMP cleavage by HD-GYP domains. Sequence alignment with other HD-GYP containing 
proteins revealed that the majority of residues that make contact with the phosphate moiety of 
c-di-GMP, are conserved. However, it could not reveal the strategy that HD-GYP domains use 
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to cleave the two phosphate moieties of c-di-GMP (Kalia et al., 2013). PA478 from P. 
aeruginosa was the third HD-GYP domain PDE to be solved. It exhibited significant 
differences with its homologues in both the nature and the binding mode of the coordinated 
metals. This is an indication that HD-GYP domains have the ability to fine-tune their function, 
which would help to increase the chances of the bacterial cell to adapt to different 
environmental needs (Rinaldo et al., 2015). 
The catalytic GGDEF, EAL and HD-GYP domains can be organized in separate subunits or 
together in the same polypeptide. The tandem “GGDEF-EAL” domain arrangement is found 
in almost a third of proteins that contain a GDEF motif. On the other hand, the “GGDEF-HD-
GYP” arrangement is less common (Römling et al., 2013; Kalia et al., 2013). Interestingly, 
most of the studied proteins that possess hybrid GGDEF-EAL domains typically show either 
DGE activity or PDE activity, proteins with both activities are comparatively rare.  
Bioinformatics analysis of 11248 GGDEF and EAL domain-containing proteins from 867 
prokaryotic genomes revealed that a higher proportion of GGDEF domain proteins (23%) have 
lost their catalytic motif compared to only 16.8% of EAL domains. Out of all the proteins 
analysed, 5674 were GGDEF-only, 1805 were EAL-only and 3769 were hybrids (Seshasayee 
et al., 2010). In some instances, the catalytic inactive domain of the hybrid proteins function 
as an allosteric regulator. For example, the hybrid protein CC3396 from C. crescentus contains 
a catalytically inactive GGDEF domain which binds GTP leading to the allosteric activation 
of the EAL domain and enhanced PDE activity (Christen et al., 2005). 
 c-di-GMP effectors 
Following the production of c-di-GMP in response to an environmental stimulus, the signal 
must be relayed to the downstream c-di-GMP effectors. These effectors are highly diverse and 
include riboswitches, transcription factors with a variety of domain architectures, divergent c-
di-GMP turnover domains, and allosteric sites on active or degenerate DGCs (see review by 
(Krasteva et al., 2012)). Moreover, the structural diversity of c-di-GMP is not limited to the 
nucleotide-sensing modules, but c-di-GMP itself can adopt a number of different stable 
conformations. For example dimeric c-di-GMP bound to Alg44 is required for alginate 
polymerization by Pseudomonas aeruginosa (Whitney et al., 2015), whereas c-di-GMP binds 
in a monomer form to FimX to regulate twitching motility in the same organism (Huang et al., 
2003).  
Among the different groups of c-di-GMP effector modules, the PilZ family (named after a 
type IV pilus control protein in P. aeruginosa) was the first to be identified. In certain 
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instances, the PilZ domain is directly attached to the C-terminus of the GGDEF, EAL and/ or 
HD-GYP domains. In other cases it is linked to a domain that generates a molecular output, 
such as alginate production, cellulose synthesis or twitching motility, see review (Hengge, 
2009). When c-di-GMP binds to a RxxxR and DXSXXG motifs on the PilZ domain, 
conformational changes occur which affect the affinity for the protein to its interacting protein 
partner(s) (Amikam & Galperin, 2006; Habazettl et al., 2011). 
Some c-di-GMP effector proteins are members of protein families that generally sense or 
metabolize other small nucleotide signalling molecules. For example VpsR (of V. cholera) 
and FleQ (of P. aeruginosa) are members of the AAA+ superfamily of ATPases, but 
apparently function as c-di-GMP effectors independently of ATP binding or hydrolysis.  When 
FleQ is not bound to c-di-GMP it functions as a transcriptional repressor of the pel operon, 
which encodes enzymes for PEL polysaccharide synthesis. In the presence of c-di-GMP, FleQ 
binding to the pel promotor DNA is relieved and transcription can continue (Hickman & 
Harwood, 2008; Baraquet et al., 2012). 
Although degenerate GGDEF or EAL domains are enzymatically inactive as DGCs/ PDEs, 
they can bind c-di-GMP and thereby regulate downstream proteins. For example, the LapD 
protein (from P. fluorescens) which is an inner-membrane protein with both degenerate EAL 
and GGDEF domains, can bind c-di-GMP with high affinity. Binding to c-di-GMP occurs on 
the EAL domain. The formation of a c-di-GMP-LapD complex leads to the sequestration of 
LapG. LapG is a periplasmic protease and once it is interacting with LapD it loses its 
proteolytic activity towards the large adhesion protein LapA. As a result, LapA remains in the 
outer membrane, which stabilizes the biofilm matrix. Conversely, when c-di-GMP levels are 
low, LapG is released from LapD into the periplasm. LapG can then cleave LapA from the 
cell surface leading to biofilm dispersal (Newell et al., 2011). Another example is PelD (from 
P. aeruginosa), which contains a degenerate GGDEF domain and an I-site with an RxxD 
motif. When c-di-GMP binds to the I-site, which normally serves as an allosteric inhibition 
site for active DGCs, the production of PEL polysaccharide is activated and in turn biofilm 
formation is upregulated (Lee et al., 2007b). The activation probably occurs via PelD 
interaction with PelF, which is predicted to assemble the PEL polysaccharide from an 
unidentified sugar nucleotide precursor (Whitney et al., 2012). Figure 21 provides a summary 
of the modes of function of some c-di-GMP effector proteins.  
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Figure 20 c-di-GMP synthesis, degradation and signalling. Two molecules of GTP are converted to 
c-di-GMP by DGC proteins containing the GGDEF domain and c-di-GMP is degraded by PDE 
proteins with EAL or HD-GYP domains. Multiple numbers of DGCs and PDEs are often associated 
with sensor domains such as PAS for sensing gaseous ligands such as O2, CO2, NO etc. and BLUF 
for sensing light. c-di-GMP binds to receptor proteins such as PilZ or riboswitches or transcriptional 
regulators to regulate bacterial “lifestyle”. Figure reproduced from (Kalia et al., 2013) 
 
The regulation of cellular functions by c-di-GMP does not only involve allosteric regulation 
of protein functions or the regulation of gene expression via modulation of transcription 
factors. But, it also occurs via direct interaction with noncoding RNA molecules known as 
riboswitches (Valentini & Filloux, 2016) So far two classes of riboswitches that sense c-di-
GMP have been discovered (Lee et al., 2010; Nelson et al., 2013). Riboswitches are structured 
noncoding RNA domains that selectively bind a small molecule or ion and thereby trigger a 
change in the expression of associated genes (Breaker, 2011; Serganov & Patel, 2012; Nelson 
et al., 2015). See Figure 22 for the general architecture of Class I and Class II riboswitches 
and Figure 23 for a description of their function. These riboswitches are typically located 
upstream of the open reading frame (ORF) of DGC and PDE encoding genes or genes that are 
controlled by c-di-GMP. Binding of c-di-GMP can affect transcription or translation (Lee et 
al., 2010; Kalia et al., 2013; Nelson et al., 2013). Binding of c-di-GMP to a Class I riboswitch 
regulates gene expression via structural rearrangement of RNA molecules (Sudarsan et al., 
2008; Kalia et al., 2013). Binding of c-di-GMP to a Class II riboswitch stimulates the self-
splicing activity of the adjacent ribozyme, which renders the ribosomal binding site in the 
RNA molecule accessible. On the other hand, when c-di-GMP is absent, the ribosomal binding 
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site is inaccessible (Lee et al., 2010; Kalia et al., 2013). A subset of the Class I riboswitches 
are now known to bind the newly discovered signalling molecule c-AMP-GMP (Nelson et al., 
2015). 
Attempts to reveal undiscovered c-di-GMP-binding proteins are ongoing, and both deductive 
and inductive (or targeted) approaches are being used (Valentini & Filloux, 2016). Deductive 
approaches are based on affinity pulldown assays using whole cell lysates in combination with 
a c-di-GMP-conjugated Sepharose resin, biotin, or a tripartite c-di-GMP capture compound to 
detect c-di-GMP-binding proteins (Düvel et al., 2012; Nesper et al., 2012; Laventie et al., 
2015; Valentini & Filloux, 2016). The differential radial capillary action of ligand assay 
(DRaCALA) is a systematic screening protocol, which assesses protein expression libraries 
for their c-di-GMP binding activity (Roelofs et al., 2011; Valentini & Filloux, 2016). On the 
other hand, the inductive approaches are based on “educated guesses”. Several biochemical 
assays, such as isothermal titration calorimetry, DRaCALA, and a peptide array approach are 
used to test the c-di-GMP binding capacity of potential targets, which are functionally 
associated with c-di-GMP regulated processes (Roelofs et al., 2011; Whitney et al., 2015; 
Düvel et al., 2016; Valentini & Filloux, 2016).  
 Controlling the intracellular levels of c-di-GMP 
The intracellular pools of c-di-GMP can be regulated in response to environmental stimuli. 
This precise spatial and temporal regulation is made possible by the sensory domains that are 
often located at the N-terminus of GGDEF or EAL domains. The sensory domains are 
typically PAS/PAC, MASE or GAF domains. DGEs or PDEs containing such sensory 
domains can monitor cytoplasmic or periplasmic levels of their respective ligands, and alter 
the synthesis or hydrolysis of c-di-GMP in response to ligand binding. Some DGEs and PDEs 
can respond to the redox state, nitric oxide, light and oxygen (Chang et al., 2001; Barends et 
al., 2009; Wan et al., 2009; Tuckerman et al., 2009; Qi et al., 2009; Cao et al., 2010) The 
carbon storage regulator, CsrA, is another major role player and controls c-di-GMP 
metabolism on a post-transcriptional level. CsrA is a RNA binding protein, which functions 
as a homodimer with two RNA binding surfaces located on opposite sides (Schubert et al., 
2007). It regulates the expression of its target genes by binding to its mRNA transcripts. In 
E.coli, CsrA regulates the expression of at least seven of the 29 encoded GGDEF and/or EAL 
domain proteins (Simm et al., 2014) and has been shown to regulate some of the GGDEF 
and/or EAL domain proteins in Salmonella, directly or indirectly. 
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Figure 21. Modes of c-di-GMP effector function. Based on structural studies several modes of c-di-
GMP action on effector proteins have been described, including the release of auto-inhibitory 
interactions (A), allosteric regulation (B), major structural rearrangements (C) and/or dimerization (D). 
In addition, c-di-GMP itself can adopt several distinct conformations when bound to proteins. Figure 
obtained from (Krasteva et al., 2012)  
 
 
Figure 22 Comparison of c-di-GMP Class I and Class II riboswitches (reproduced from (Kalia et al., 
2013). 
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Figure 23 Mechanism of c-di-GMP riboswitch function. Image reproduced from (Kalia et al., 2013). 
 
 The role of c-di-GMP signaling in Salmonella 
The S. Typhimurium genome contains twenty-two proteins with GGDEF and/or EAL domains 
and no HD-GYP domain proteins (Jonas et al., 2009; Ahmad et al., 2017). The GGDEF/EAL 
domains can be divided into classes based on their catalytic activity and conserved residues. 
Class I GGDEF domain proteins contain all residues that are required for catalytic activity, 
while Class II GGDEF domain proteins are catalytically inactive. The S. Typhimurium 14028 
genome encodes eight Class I and four Class II GGDEF domain proteins. The EAL domain 
proteins are divided into 3 groups: In Class I EAL domains all resides required for c-di-GMP 
dependent phosphodiesterase activity are conserved. Class 2 EAL domain proteins lack the 
conserved loop 6, nevertheless some of these proteins have been demonstrated to possess PDE 
activity. Class 3 EAL domain proteins are predicted to be catalytically inactive. For the 
classification of GGDEF/ EAL domain proteins of Salmonella see Table 3. At least eight of 
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the GGDEF/EAL domain proteins in S. Typhimurium have been shown to contribute directly 
or indirectly to rdar biofilm formation. There are only two PilZ domain containing c-di-GMP 
receptors in S. Typhimurium, BcsA and YcgR; both of them influence motility. YcgR affects 
flagellar rotational switching and speed in response to c-di-GMP (Ryjenkov et al., 2006; Paul 
et al., 2007; Boehm et al., 2010). BcsA produces cellulose, which hinders swimming by 
sterically interfering with the flagella (Zorraquino et al., 2013; Le Guyon et al., 2015). 
The roles that the various GGDEF/EAL domain proteins play in S. Typhimurium biofilm 
formation, virulence and motility are summarised in Table 3. Redundancy of function for some 
GGDEF/EAL domain proteins has been reported (Ahmad et al., 2011). For example, four 
DGCs were found to be functionally redundant with regard to the induction of cellulose 
biosynthesis when single DGCs were re-inserted into the genome of a strain that contained no 
DGCs (Solano et al., 2009). Unfortunately c-di-GMP levels were not measured for the re-
insertion mutants, and thus no conclusion about the relationship between the phenotypic output 
and the c-di-GMP levels could be drawn (Massie et al., 2012). 
Nevertheless, Ahmad and colleagues (Ahmad et al., 2011) and Le Guyon and colleagues (Le 
Guyon et al., 2015) performed complementation and mutation studies to systematically couple 
GGDEF/EAL domain proteins to virulence, motility and biofilm phenotypes. Their results 
confirm that certain c-di-GMP signalling pathways are dedicated to the regulation of specific 
cellular functions, or to the regulation of similar cellular functions on different levels. For 
example, STM2672 inhibits motility through YcgR, while STM1987 appeared to work solely 
through BcsA (Le Guyon et al., 2015). These findings give support to the hypothesis that there 
exist a spatial and temporal compartmentalization of c-di-GMP and effector proteins (Christen 
et al., 2010).  
 Regulation of biofilm formation by c-di-GMP in Salmonella 
The regulation of biofilm formation in Salmonella is quite complex and involves the master 
regulator CsgD as well as c-di-GMP which activates several steps in the biofilm regulatory 
network (Kader et al., 2006). In its unphosphorylated form, CsgD activates csgB and adrA 
transcription (Zakikhany et al., 2010). CsgB is a major subunit of curli, which is an important 
component of the EPS matrix. AdrA is a DGC which synthesizes c-di-GMP to activate the 
cellulose biosynthesis complex subunit BcsA. Because transcription of the bcsABC operon is 
not affected by AdrA, cellulose production is regulated by AdrA on a post-transcriptional 
level. Furthermore, cellulose biosynthesis on CR agar relies on AdrA, but does not require 
CsgD to activate adrA expression (Zogaj et al., 2001; Simm et al., 2004). Deletion of AdrA 
Chapter 2: Nucleotides 
 
48 
 
caused a reduction in the intracellular c-di-GMP pool and furthermore resulted in white and 
non-fluorescent colonies on CR agar plates and Calcofluor plates respectively, which is typical 
of impaired cellulose production. Expressing AdrA from the pBAD30 plasmid in the adrA 
knockout strain led to the activation of cellulose biosynthesis as monitored by pdar colonies 
on CR agar as well as fluorescent colonies on Calcafluo plates (Simm et al., 2004). These 
results clearly showed that CsgD regulates cellulose production indirectly via affecting c-di-
GMP production by AdrA. 
 
 
Figure 24 Schematic model showing the role of various GGDEF domain proteins in S. Typhimurium 
UMR1. STM3388 and STM2132 have an additive effect on CgsD expression levels. AdrA primarily 
activates cellulose biosynthesis through the creation of a different c-di-GMP pool. The feedback 
regulation by c-di-GMP produced by AdrA on CsgD expression is observed in strain MAE52 but not 
in strain UMR1. Domain abbreviations are: HAMP (histidine kinases, adenine cyclase, methyl binding 
protein, phosphatases), HTH (helix tur helix), MASE1 and MASE2 (membrane associated sensors 1 
and 2), MHYT (integral membrane sensory domain containing a conserved motif), PAS/PAC (periodic 
clock protein, Ah receptor transnuclear translocator protein, single-minded protein). Deviations from 
the GGDEF or EAL motifs are also shown. Figure reproduced from Kader et al., 2006. 
 
CsgD itself is also regulated by c-di-GMP on a transcriptional and post-transcriptional level. 
Elevated concentrations of c-di-GMP mediated by the overexpression of plasmid encoded 
AdrA in S. Typhimurium UMR1 lead to enhanced expression of curli fimbria (detected on CR 
and Calcafluo agar plates) by inducing expression of CsgA and CsgD as measured by Western 
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blot (Figure 24). Furthermore overexpression of YhjH (STM3611 a PDE) using plasmid 
pRGS1 led to an almost white phenotype on CR agar indicating that a reduction in the c-di-
GMP pool negatively impacts cellulose and curli production. The effect of c-di-GMP on curli 
production was further confirmed by changes in the bdar morphotype of strain MAE222 which 
only expresses curli but not cellulose. It was determined by Northern blotting that high levels 
of c-di-GMP positively control CsgD production on a transcriptional level, while low levels 
of c-di-GM have a negative effect (Simm et al., 2004; Kader et al., 2006). The post-
transcriptional effect of c-di-GMP on CsgD production was verified by expressing CsgD from 
an arabinose inducible promotor while expressing YhjH (STM3611) from an IPTG inducible 
promotor in a strain containing a double deletion of csgD and bcsA. When YhjH levels were 
high, CsgD levels were lowered. Because the native Shine Dalgarno sequence of csgD was 
cloned into the plasmid it was concluded that post-transcriptional events from increased 
ribosome binding to diminished protein degradation could be responsible for controlling CsgD 
levels. AdrA and YhjH are not the only c-di-GMP metabolizing proteins to affect rdar biofilm 
formation. Reducing the intracellular c-di-GMP pool by deleting the DGCs STM2123 and 
STM3388 also negatively affected CsgD expression (measured by Western blot), and a double 
knockout mutant showed an additive effect (Kader et al., 2006). Although AdrA has a large 
impact on the generation of elevated c-di-GMP levels, chromosomally encoded adrA was not 
required for the expression of CsgD and curli fimbriae in strain UMR1. STM2123 was found 
to be important for early rdar morpohotype development while STM3388 contributed later. 
Single gene knockouts of STM2123 or STM3388 showed reduced csgD transcript levels as 
measured by Northern blot analysis; however the adrA knockout did not have an effect. On 
the other hand, all three single gene knockouts displayed a downregulation of csgA transcript 
levels. This indicates that although AdrA does not influence CsgD expression under native 
conditions, it does play a role in curli-biosynthesis, downstream of CsgD expression (Kader 
et al., 2006). Based on the above results it was concluded that c-di-GMP acts transcriptionally 
and post-transcriptionally on CsgD and that different GGDEF domain proteins have specific 
effects on CsgD expression at specific growth phases. By 2015 it was known that out of the 
twenty-two GGDEF and/ or EAL domain proteins in S. Typhimurium, 10 affect rdar biofilm 
formation or cellulose production. Of those that affect CsgD levels specificially, two GGDEF 
domains upregulate csgD expression while four EAL domains down-regulate csgD 
expression. Very recently another two GGDEF domain proteins were found to contribute to 
optimal csgD expression (Ahmad et al., 2017). The EAL domain protein STM4264 (yjcC) is 
the only protein that has been shown to regulate the rdar morphotype on both the level of csgD 
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expression and cellulose synthesis. This is not surprising, given that STM4264 downregulates 
the cellular c-di-GMP concentration approximately five-fold (Simm et al., 2007). The exact 
mechanism by which c-di-GMP regulates CsgD expression is not known. Although it has been 
found that the regulation of CsgD expression and rdar biofilm formation, by GGDEF/EL 
domain proteins, is mainly mediated by the enzymatic activities of the proteins. This is not the 
exclusive mechanism. The GGDEF/EAL domain protein ST1730 supresses the transcription 
of csgD by acting on the promotor upetram region from -208 to -340. It is hypothesized that 
STM1703 forms a complex with a high affinity c-di-GMP receptor. Furthermore it is thought 
that STM1703 degrades c-di-GMP produced from its own GGDEF domain, acting locally as 
a diguanylate cyclase. STM4264exerts its inhibitory effect on csgD by acting on a post-
transcriptional level (Figure 25). 
 
 
Figure 25 A model of c-di-GMP regulation proposed by Ahmad et al (2017). Green represents a 
diguanylate cyclase, blue a phosphodiesterase and magenta represents a diguanylate 
cyclase/phosphodiesterase; light grey not directly investigated by Ahmad et al (2017). There are at 
least three distinctive groups of c-di-GMP turnover proteins that regulate csgD expression. Regulation 
by STM1703 occurs on the transcriptional level. Regulation by the other group occur on unknown 
levels and are drawn arbitrarily. The group consisting of STM1987, STM4551 and STM3611 inversely 
regulate motility. EAL-like proteins STM1344 and STM1697 affect the c-di-GMP signalling network 
through post-translational inhibition of FlhD4C2, the regulator of the flagellar cascade and regulation 
of STM1703. Image reproduced from (Ahmad et al., 2017). Open access address, DOI: 
10.1186/s12866-017-0934-5. 
   
 
 
 
 
Table 3: GGDEF and EAL domain proteins of Salmonella. 
Gene ID and name Domain organization GGDEF/EAL b Enzyme activity c 
(class) 
Cellular function and regulation Reference 
STM0343 
 
EAL PDE 
(I) 
Stimulates invasion of the HT-29 cell 
line 
(Ahmad et al., 2011) 
STM0385 
(adrA/ yaiC) 
 
GGDEF DGC 
(I) 
Stimulation of cellulose biosynthesis 
and rdar development; upregulation of 
biofilm formation under LB (but not 
ATM) conditions; downregulation of 
motility; restoring cellulose production 
in a c-di-GMP lacking strain. Direct 
upregulation by csgD 
(Zogaj et al., 2001; Simm et al., 
2004; García et al., 2004; Solano et 
al., 2009; Zakikhany et al., 2010)  
STM1283 
(yeaJ/ dgcJ) 
 
GGDEF DGC 
(I) 
Invasion of HT-29 cells. Inhibition of 
IL-8 phenotype. Assuming role of 
STM1987 under ATM conditions 
(Ahmad et al., 2011) 
STM1344 
(cdgR) 
 
EAL No PDE 
(III) 
Indirect upregulation of csgD and rdar 
expression; downregulation of 
motility; role in virulence (survival in 
mice, antioxidant defense, macrophage 
killing). Direct repression by CsrA 
(Hisert et al., 2005; Simm et al., 
2007; Simm et al., 2009; Jonas et al., 
2009; Wozniak et al., 2009) 
STM1697 
 
EAL No PDE 
(III) 
Possible role in virulence, no obvious 
role in motility or biofilm formation 
(Ahmad et al., 2011) 
STM1703 
(yciR) 
 
GGDEF 
/EAL 
PDE, DGE 
(I, I) 
Strong downregulation of csgD 
(temperature suppressive effect), csgA 
and rdar expression, biofilm formation 
and cellulose synthesis. Negatively 
regulated by STM1344 and CsrA 
(García et al., 2004; Simm et al., 
2007; Simm et al., 2009) 
STM1827 
 
EAL PDE 
(I) 
Slight downregulation of cellulose 
biosynthesis, csgD, rdar development 
and biofilm formation; very little 
(Simm et al., 2004; Simm et al., 
2007; Jonas et al., 2009) 
  
 
Gene ID and name Domain organization GGDEF/EAL b Enzyme activity c 
(class) 
Cellular function and regulation Reference 
upregulation of swarming. Negatively 
regulated by CsrA 
STM1987 
 
GGEEF DGC 
(I) 
Upregulation of cellulose production 
and biofilm formation under ATM 
conditions (csgD independent); assume 
role of adrA under LB conditions; 
restoring cellulose production and 
ATM biofilm formation in a c-di-GMP 
lacking strain. Negatively regulated by 
CsrA 
(García et al., 2004; Jonas et al., 
2009; Solano et al., 2009)  
STM2123 
(yegE) 
 
GGDEF 
/WLV 
DGC 
(I) 
Assuming role of adrA and STM1987 
under LB and ATM conditions 
respectively; upregulation of csgD and 
rdar expression; restoring cellulose 
production and ATM biofilm 
formation in a c-di-GMP lacking strain 
(García et al., 2004; Kader et al., 
2006; Solano et al., 2009) 
STM2215 
(rtn) 
 
EAL PDE 
(II) 
Involved in fitness in mice. Does not 
affect motility, expressed on plates, 
and in liquid media at late exponential 
and early stationary phase. Stimulates 
invasion of HT-29 cells. 
(Ahmad et al., 2011; Zheng et al., 
2013) 
STM2410 
(yfeA) 
 
GGDEF 
/EAL 
No DGC activity, 
putative PDE 
(I, II) 
 
Reinstating swimming in a c-di-GMP 
lacking strain 
(Solano et al., 2009) 
STM2503 
 
SGHDL 
/EAL 
Probably PDE-like 
(I) 
Reinstating swimming in a c-di-GMP 
lacking strain. STM4264 and 
STM2503 degrade the c-di-GMP 
produced by STM1283 dedicated to 
inhibition of IL-8 induction. 
(Solano et al., 2009; Ahmad et al., 
2011) 
 
   
 
 
Gene ID and name Domain organization GGDEF/EAL b Enzyme activity c 
(class) 
Cellular function and regulation Reference 
STM2672 
(yfiN/ dgcN) 
 
GGDEF DGC 
(I) 
Unable to assume role of adrA and 
STM1987 under LB and ATM 
conditions respectively; restoring 
cellulose production and ATM biofilm 
formation in a c-di-GMP lacking strain 
(García et al., 2004; Solano et al., 
2009) 
STM3375 
(yhdA/csrD) 
 
HRSDF 
/ELM 
No PDE or DGC 
activity (in E. coli) 
(III, II) 
Upregulation of motility (swimming) 
and biofilm formation (in liquid LB 
without salt); destabilizing activity of 
sRNA csrB and csrC  along with 
RNase E, (in E. coli). Negatively 
regulated by CsrA 
(Simm, Morr et al. 2004, Simm, 
Lusch et al. 2007, Jonas, Edwards et 
al. 2009) 
STM3388 
 
GGDEF 
/EAL 
DGC 
(I) 
Assuming role of adrA and STM1987 
under LB and ATM conditions 
respectively; upregulation of csgD and 
rdar expression 
(García et al., 2004; Kader et al., 
2006; Solano et al., 2009) 
STM3611 
(yhjH) 
 
ELL PDE 
(II) 
Downregulation of cellulose 
biosynthesis, csgD, rdar and biofilm 
formation; upregulation of motility 
(antagonized by ycgR); involved in 
growth competition between different 
S. enterica strains. Negatively 
regulated by STM1344; positively 
regulated by CsrA and FlhDC via FliA 
(Simm, Morr et al. 2004, Simm, 
Lusch et al. 2007, Jonas, Edwards et 
al. 2009) 
STM3615 
(yhjK/ pdeK) 
 
SGYDF 
/EAL 
Probable PDE 
(I) 
Invasion of murine intestine. (Ahmad et al., 2011) 
STM4264 
(yjcC) 
 
EAL PDE 
(I) 
Strong downregulation of csgD (slight 
temperature suppressive effect), csgA 
and rdar expression, biofilm formation 
and cellulose (also csgD independent) 
synthesis. STM4264 and STM2503 
degrade the c-di-GMP produced by 
(Simm et al., 2007; Simm et al., 
2009; Ahmad et al., 2011) 
  
 
Gene ID and name Domain organization GGDEF/EAL b Enzyme activity c 
(class) 
Cellular function and regulation Reference 
STM1283 dedicated to inhibition of 
IL-8 induction 
STM4551 
 
GGEEF DGC 
(I) 
Assuming role of adrA and STM1987 
under LB and ATM conditions 
respectively; regain motility, curli 
(rdar)production, virulence and long-
term survival in a c-di-GMP lacking 
strain. Negatively regulated by CsrA 
(Solano, García et al. 2009, García, 
Latasa et al. 2004) 
STM0468 
(ylaB) 
 
EAL No PDE activity 
(III) 
Stimulates invasion of the HT-29 cell 
line 
(Ahmad et al., 2011) 
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Chapter 3  
3 Repurposing of nucleoside- and nucleobase-derivative 
drugs as antibiotics and biofilm inhibitors 
3.1 Abstract 
There is an urgent need for new antibacterial drugs that are robust against the development of 
resistance. Drug repurposing is a cost effective strategy to fast track the drug development 
process. Here we motivate why the nucleoside and nucleobase analog drugs in particular 
present an attractive class for repurposing. Some of these drugs have already been evaluated 
for their potential as antibacterial agents. In addition to inhibiting bacterial growth and 
survival, some also work synergistically with antibiotics, and as such can enhance the 
therapeutic spectrum of currently available antibiotics. Furthermore nucleoside and 
nucleobase analog drugs can inhibit bacterial virulence and biofilm formation. Biofilms are 
known to impart antibiotic tolerance and are associated with chronic infections. Targeting 
biofilm formation thus renders pathogens more susceptible to antibiotic treatment and host 
immune defenses. Moreover, specific analogs  have properties which make them less 
susceptible to the development of resistance. Thus, nucleoside and nucleobase analog drugs 
ought to be considered as new weapons in our fight against pathogenic bacteria. 
3.2 Introduction 
The discovery of antibiotics is without doubt one of the greatest medical achievements and 
proved to be a turning point in human history by saving countless lives and placing infectious 
diseases under control. However, there is a growing concern that we are approaching a post-
antibiotic era in which common infections or minor injuries might become life-threatening 
(Alanis, 2005). The widespread use of antibiotics in medicine, agriculture and other 
anthropogenic activities has been followed with the emergence and rapid dissemination of 
antibiotic-resistant pathogens (Aminov, 2009; Aminov, 2010; Davies & Davies, 2010). Most 
worrisome, in clinical environments there are increasing reports of extensive drug resistant 
infections (Falagas et al., 2005; Zhi-Wen et al., 2015). Indeed, the recent discovery of an E.coli 
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strain harbouring resistance genes to colistin and 14 other antibiotics on a plasmid is thought 
to herald the emergence of true pan-drug resistance(McGann et al., 2016). It is estimated that 
700 000 people die of resistant  infections every year, that number is feared to increase to 10 
million per year by 2050 (O’Neill, 2014). Aside from the tragic human cost, the economic 
impact of antibiotic resistance is enormous. The cost in terms of lost global production 
between now and 2050 is predicted to be 100 trillion USD (O’Neill, 2014). 
To continue our fight against pathogenic bacteria it is absolutely imperative that there should 
be no abatement in the quest for new antimicrobial agents. An emerging strategy is to 
repurpose drugs that are already approved for other uses. The antibiotic, anti-biofilm and anti-
virulence activities of diverse drugs including gallium compounds, alkylating agents, 
hormonal modulators and antimetabolites were recently reviewed (Younis et al., 2015; 
Rangel-Vega et al., 2015; Soo et al., 2016). Here we will examine the striking antibacterial 
properties of nucleoside and nucleobase analog drugs (abbreviated as ‘NNADs’). These drugs 
are important anti-proliferative therapies used against cancer and viral diseases. Although, 
application of these NNADs for antibacterial therapy has only been poorly evaluated (Landini 
et al., 2010) We, and others are of the opinion that these drugs could also have a significant 
impact on the clinical treatment of bacterial infections, with potentially a lower risk of 
resistance development, and that they could be a financially viable option for pharmaceutical 
companies. We argue that repurposing approved NNADs as bactericidal, bacteriostatic or anti-
biofilm agents could have potential to circumvent important hurdles related to traditional 
antimicrobial discovery and illustrate this with recent experimental evidence. Finally, factors 
that need to be taken into account to assess the likeness of resistance development against 
NNADs are discussed.  
 Nucleobase and nucleoside analogs have been in clinical use for 
several decades  
Nucleotides are the basic structural units of DNA and RNA, which direct and control the 
production of proteins. Nucleotides serve as cofactors in a wide range of metabolic pathways 
including lipid- and polyamine biosynthesis. Furthermore they function as energy carriers and 
are constituents of signaling molecules such as (p)ppGpp, cGMP and cAMP to name but a 
few. Because of this, NNADs’ that target enzymes of nucleotide metabolism constitute 
important parts of current anticancer and antiviral therapies. NNADs that are used for the 
treatment of cancer inhibit DNA replication and repair while antiviral NNADs inhibit 
replication of the viral genome (Van Rompay et al., 2003). In addition, certain analogs can 
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inhibit the enzymes that are involved in nucleotide biosynthesis and cause chain termination by 
depleting dNTP pools. There is also potential for other enzymatic cross-reactivity when 
analogs bind to regulatory sites where they cause activation or inhibition of enzymes (Ewald 
et al., 2008; Egeblad et al., 2012; Jordheim et al., 2013). Table 4 (at the end of this chapter) 
provides an overview of the 45 currently FDA approved NNADs. Some NNADs have been in 
clinical use for over 50 years, however these compounds are not routinely used against bacteria 
and only limited small scale investigations into their antibacterial properties have been.  
 Repurposing NNADs could overcome several hurdles in traditional 
antimicrobial discovery 
Just as cancer cells and viruses, bacteria are fast proliferating entities (O'Donnell et al., 2013), 
making them good candidate targets for drugs that interfere with DNA or RNA replication. 
Moreover, nucleotides and derived compounds have important functions as signalling 
molecules and cofactors in bacterial processes associated with biofilm formation, virulence 
and persistence (Römling et al., 2005; Lamprokostopoulou et al., 2010; McDonough & 
Rodriguez, 2012; Garavaglia et al., 2012), suggesting that NNADs might have interesting 
cross-activities against bacteria. Consistently, in recent years the bactericidal, anti-biofilm or 
anti-virulence activity of a subset of FDA approved NNADs has been demonstrated (Casado 
et al., 1999; Sandrini et al., 2007a; Attila et al., 2009; Antoniani et al., 2013), while other 
NNADs were shown to enhance the efficiency of classic antimicrobials (Nyhlén et al., 2002; 
Krishnan et al., 2009; Jordheim et al., 2012; Lele et al., 2016). However, the antibacterial 
effect of the majority of approved NNADs remains to be tested. Already reported activities 
against bacteria are listed in Table 4 (at the end of this chapter) and discussed in more detail 
in the following sections. Here we describe important hurdles associated with classical 
antimicrobial discovery and how repurposing of NNADs could overcome these. 
 NNADs are synthetic compounds without prior evolutionary history in 
ecological settings 
In ecological settings, natural antibiotics are thought to be “weapons” that are used during 
microbial competition (Abrudan et al., 2015). Antibiotic resistance mechanisms are 
considered to be akin to “shields” that protect target organisms, or detoxifying systems that 
protect antibiotic producers from their own weapons(Fajardo & Martínez, 2008). Antibiotics 
may also have a role in intra and inter domain communication, where they can act as 
cues/coercions in complex microbial communities (Linares et al., 2006; Aminov, 2009; 
Bernier & Surette, 2013). In this scenario, antibiotic resistance may serve as a mechanism to 
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attenuate signal intensity (Linares et al., 2006; Davies, 2006a; Martínez, 2008; Aminov, 2009; 
Davies & Davies, 2010; Romero et al., 2011). 
Regardless of their exact role in nature, it is now appreciated that resistance-conferring genes 
are the result of ancient evolution and not merely of the modern pressures of anthropogenic 
antibiotic use (Hall & Barlow, 2004; Garau et al., 2005; Song et al., 2005; Allen et al., 2008). 
This is worrying, as the majority of antibiotic resistance mechanisms seen in clinical settings 
are acquired through horizontal gene transfer from taxonomically unrelated bacteria (Aminov, 
2012; Nazaret & Aminov, 2014; van Schaik, 2015; von Wintersdorff et al., 2016). 
Given the ecological importance of natural antibiotics and the presence of ancient resistance 
mechanisms it seems sensible to focus on identifying new, synthetic compounds, such as 
synthetically modified NNADs, that do not have a microbial origin. Because bacteria do not 
have an ancient history of exposure to synthetic antibiotics, resistance development is expected 
to be less prominent. However, it should be noted that efflux systems that have evolved to 
protect bacteria from diverse natural toxic small molecules in certain cases offer cross-
protection against products of a synthetic origin. For example shortly after the introduction of 
fluoroquinolones into clinical practice in the 1980s, it became apparent that efflux systems 
provided Gram-negative bacteria with high levels of resistance (Poole, 2000). Thus care 
should be taken since bacterial genomes, and mobile genetic elements, can harbour protection 
against toxic agents even without a requirement for past exposure. 
 NNADs have potential as anti-virulence drugs, reducing the risk of resistance 
development 
Exposure to any compound that kills or inhibits growth of bacteria creates a strong selection 
pressure for resistance (Lipsitch & Samore, 2002). Even though resistance mechanisms are 
often costly to the bacterium in the absence of antibiotic, compensatory mutations that mitigate 
this cost rapidly spread so that the frequency of resistance does not decline when antibiotic 
use is cut down (Andersson & Hughes, 2010). Instead of targeting growth, emerging strategies 
focus on targeting virulence-associated phenotypes and/ or behaviours that affect the 
susceptibility of pathogenic bacteria to the host’s immune system or antibiotic treatment 
(Rasko & Sperandio, 2010; Rogers et al., 2012). It has been argued that targeting virulence 
without affecting bacterial growth, under certain circumstances, could generate much weaker 
selection for resistance than current antibiotics, while at the same time transforming 
pathogenic populations into a state that is less harmful to the host (Clatworthy et al., 2007; 
Cegelski et al., 2008; Imperi et al., 2013; Allen et al., 2014). As exemplified below, certain 
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NNADs have concentration ranges at which they inhibit the production of virulence factors 
without negative effects on growth  (Attila et al., 2009; Ueda et al., 2009; Imperi et al., 2013).  
 Specific NNADs are expected to have activity against antibiotic-tolerant biofilms 
Most antibiotics have been developed to target free-living bacteria, however, it is now widely 
accepted that bacteria grow in multicellular communities that are encased in self-produced 
matrixes, called biofilms (Costerton et al., 1987). Biofilm-associated growth can enhance 
tolerance to antibiotics by 10 to 1000 times (Nickel et al., 1985; Williams et al., 1997; 
Costerton et al., 1999; Ceri et al., 1999). To date there are no drugs in clinical use that were 
developed specifically for targeting biofilm-formation (Max V. Ranall et al., 2012; Bjarnsholt 
et al., 2013; Park et al., 2016). Anti-biofilm strategies can be directed at prevention of surface 
adhesion, colonization and matrix production by targeting specific cellular processes, as well 
as by interfering with quorum sensing (Blackledge et al., 2013; Wu et al., 2015). In vitro 
studies have shown that combining anti-biofilm treatments with antibiotics can lower the 
tolerance of antibiotic resistant pathogenic bacteria (Janssens et al., 2008; Reffuveille et al., 
2014). Thus targeting biofilm formation is an attractive strategy that would render bacteria 
more vulnerable to host defences and enhance the therapeutic spectrum of currently available 
antibiotics (Rogers et al., 2012; Hänsch, 2012; Bjarnsholt et al., 2013; Alhede et al., 2014; 
Roilides et al., 2015). Given the fact the major biofilm signalling molecule c-di-GMP is a 
nucleotide derivative, perturbations in the nucleotide pools due to the action of some NNADs 
are thought to cause reduced c-di-GMP levels and inhibition of biofilm formation (Antoniani 
et al., 2013). 
 The defined activity spectrum of NNADs could reduce microbiome disruption 
and resistance development  
NNAD based prodrugs have potential to be activated in a species-specific manner by bacteria, 
thus they can be used as species-specific antibiotics (Sandrini et al., 2007a). 
Sandrini and colleagues (2007) have shown that bacterial deoxyribonucleosides kinases 
(dNKs) activate certain nucleoside prodrugs in a species specific manner (Sandrini et al., 
2007a; Sandrini et al., 2007b). The differences in susceptibility to these drugs were attributed 
to variations in the presence of kinase encoding genes between the different taxonomic groups 
(Sandrini et al., 2007a). It is worthwhile to investigate whether other enzymes which are also 
involved in nucleotide metabolism (such as ribonucleotide reductases, thymidylate synthases, 
guanine deaminases and adenine deaminases) have species-specific interactions with 
nucleoside and nucleobase analog drugs. The specific affinity that different bacterial species 
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have towards the various analog drugs can be exploited for designing antibacterials that are 
effective against a narrow range of bacteria which would likely reduce microbiome disruption 
and resistance development. 
 Repurposing of NNADs is less costly and time-consuming than de novo drug 
discovery  
In addition to the problem of antibiotic resistance and tolerance in the clinical environment, 
there has been a reduction in new antibiotic approvals over the past decades (Center for 
Disease Control and Prevention, 2013). Other than rapid emergence of resistance, factors that 
hamper antibiotic development include the high cost of de novo drug discovery; and stringent 
regulatory requirements. The combination of these factors contributed to the reluctance of 
pharmaceutical companies to invest in the development of new antimicrobials (Projan, 2003; 
Davies, 2006b). Screening of already approved compounds to find those with desirable 
antibiotic, anti-biofilm or anti-virulence activities provides an interesting solution. This 
approach of drug repurposing takes less time than de novo drug discovery and is not associated 
with the same high costs and risks that typically accompany drug innovation. The drug 
repurposing strategy has already been proven to be useful for identifying compounds with 
desirable antibacterial activities. Some of the drugs were shown to alleviate infections in 
animal models (Chong & Sullivan, 2007; Younis et al., 2015; Rangel-Vega et al., 2015; 
Thangamani et al., 2015), and specific drugs, such as 5-fluorouracil, are now being used in 
human clinical tests (Rangel-Vega et al., 2015).  
 The safety profiles of NNADs are well established and risk factors associated 
with toxicity are known   
Because the safety profiles of approved drugs have already been established, and potential 
side-effects are already known, this information can be taken into account during drug 
repurposing studies. When considering the approved uses of NNADS, their narrow therapeutic 
margins are incontestable. Most healthy adult cells are quiescent, therefore targeting cancer 
cells with nucleoside analogs provides some level of selectivity. Nonetheless, certain tissues 
such as hair follicles, bone marrow and intestinal epithelium that are in a replicative state are 
vulnerable to the cytotoxic effects (Parker, 2009). Due to their lower activity on mammalian 
enzymes, antiviral NNADs typically have better tolerance profiles than those used for treating 
cancer (Jordheim et al., 2013). Nevertheless, long-term exposure to certain antiviral NNADs 
is associated with mitochondrial toxicity (Anderson et al., 2004). However, it is important to 
note that the mechanisms of toxicity for NNADs are selectivity/specificity problems. As such, 
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toxicity is strongly dependent on dosage and intracellular concentration (as reviewed) 
(Anderson et al., 2004). In addition, the duration of treatment is an important factor in 
cumulative toxicity (Lo et al., 2005). The antibacterial effects of the various NNADs reviewed 
in the following sections occur at concentrations that are extremely low compared to those of 
their approved uses and treatment of bacterial infections are typically shorter than for chronic 
viral infections, chronic inflammatory diseases and cancer. Moreover, even though the 
cytotoxic effects of NNADs may have hindered their utilization as antibiotics in the past, we 
are now faced with the threat of increasing antibiotic resistance. In certain cases, the risks of 
minor cellular injury by cytotoxic agents might be lower than the risks associated with 
infections that do not respond to conventional antibiotics.  
3.3 Examples of approved NNADs with activity against bacteria 
Here we describe approved NNADs and summarize the recent advances that have been made 
in evaluating their potential as antibacterial agents or biofilm and virulence inhibitors. Special 
emphasis is on how the specific NNADs contribute to solving the antimicrobial discovery 
hurdles described above. 
 5-Fluorouracil 
5-Fluorouracil is widely used in clinical settings as a systemic treatment for a variety of 
cancers as well as a topical treatment cancerous skin conditions. 5-Fluorouracil is analogous 
to uracil but contains a fluorine atom at the C-5 position instead of a hydrogen atom 
(Heidelberger et al., 1957). After entering the eukaryotic cell via the same facilitated transport 
mechanisms as uracil, 5-fluorouracil is converted into three main metabolites: FdUMP, 
FdUTP and FUTP (Longley et al., 2003). The major activation product, FdUMP, is a suicide 
inhibitor of thymidylate synthase (TS). TS inhibition causes dTMP starvation and thus affects 
DNA synthesis (Longley et al., 2003; Rangel-Vega et al., 2015). Furthermore, depletion of 
dTMP also causes perturbations in the levels of the other deoxynucleotides leading to severely 
disrupted DNA synthesis and repair. Another 5-FU metabolite FdUTP, causes point mutations 
when it is incorporated into DNA, as it base pairs with guanine instead of adenine. The 
combination of disrupted DNA repair and repeated nucleotide misincorporation ultimately 
results in DNA strand breaks and cell death. The third mode of 5-fluorouracil toxicity is due 
to the activation product FUTP which is incorporated into RNA. This negatively affects many 
aspects of RNA processing and functioning, including the formation of mature rRNA, the 
post-transcriptional modification of tRNA and the assembly and activity of snRNA/protein 
complexes, as reviewed in (Longley et al., 2003). In bacteria 5-fluorouracil is also converted 
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to FdUMP, FdUTP and FUTP (Figure 26) with similar mutagenic and cytotoxic outcomes as 
described for eukaryotic cells. The potent bactericidal effects of 5-fluorouracil against several 
bacterial pathogens was first established three decades ago. It was confirmed to inhibit the 
growth of S. aureus and S. epidermidis with an MIC50 ≤ 0.8 mg/L, and it was found to act 
synergistically with beta-lactams against Gram-negative strains (Ueda et al., 1983; Gieringer 
et al., 1986). The Fractional inhibitory concentration indexes (abbreviated as ‘FICs’, a FIC 
index lower or higher than 1 indicates synergy or antagonism, respectively) of 5-fluorouracil 
and cefazolin, piperacillin and carbenicillin against E. coli were 0.61, 0.68 and 0.64, 
respectively (Ueda et al., 1983). More recently, it was found that 50 mg/L 5-fluorouracil acts 
synergistically with sub-MIC concentrations of tobramycin against S. aureus leading to a 
>100-fold decrease in viable bacterial count after 3 hours of treatment compared to tobramycin 
alone (Nyhlén et al., 2002).  
Some bacteria show deviations from the canonical reactions. For example in M. tuberculosis 
the most likely route for 5-fluorouracil metabolism would be through its conversion to FUMP 
which is further processed into FUTP and FdUTP, while other pathways are considered 
unlikely given the absence of the enzymes thymidine kinase (tdk), uridine phosphorylase (udp) 
and uridine kinase (udk) (Singh et al., 2015). 
Recent investigation into the antimycobacterial action of 5-fluorouracil revealed that 5-
fluorouracil becomes incorporated into sugar nucleotides. Fluorinated versions of UDP-Gal, 
UDP-GlcNAc and UDP-MurNAc-pentapeptide were identified (Singh et al., 2015). The 
presence of 5-fluorouracil in sugar nucleotides interferes with their role to serve as activated 
sugar donors for the mycobacterial mycolyl arabinogalactan peptidoglycan complex 
production. These findings support earlier studies which provided evidence for inhibition of 
cell wall biosynthesis in E. coli and S. aureus by 5-fluorouracil (Rogers & Perkins, 1960; 
Tomasz, 1962; Stickgold & Neuhaus, 1967). Thus, in addition to DNA and RNA damage, 5-
fluorouracil also exerts its bactericidal effect via the inhibition of cell wall biosynthesis (Singh 
et al., 2015). The proposed pathways for 5-fluorouracil and 5-fluorocytosine metabolism in 
bacteria are summarized in Figure 26.  
The first evidence that 5-fluorouracil can inhibit biofilm formation by S. epidermidis was 
provided by (Hussain et al., 1992). More recent studies demonstrated that 5-fluorouracil 
inhibits biofilm formation and virulence in P. aeruginosa (Ueda et al., 2009) and 
enterohemorrhagic E. coli (Attila et al., 2009). The biofilm inhibitory effect of 5-fluorouracil 
is concentration dependent and influenced by the nutrient composition of the growth medium 
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with higher activity in lower nutrient conditions. In nutrient rich Lysogeny Broth medium, 
3.25 mg/L 5-fluorouracil decreased P. aeruginosa PA14 biofilm formation with about 70% 
while the specific growth rate was only decreased by 20% and 26.02 mg/L 5-fluorouracil 
inhibited biofilm production by more than 90% with a 50% reduction in the specific growth 
rate. In nutrient-poor M9 glucose medium, 1.3 mg/L 5-fluorouracil inhibited biofilm formation 
by 56% without affecting growth. The following quorum sensing regulated virulence factors 
were also inhibited: LasB elastase activity, pyocyanin production, rhamnolipid production, 
swarming motility and quinolone signal production. At higher concentrations (3.25 mg/L) 5-
fluorouracil, biofilm formation was inhibited by 61%, but growth was also inhibited (Ueda et 
al., 2009). In E. coli 5-fluorouracil reduced biofilm formation 5-fold with about 42% toxicity 
at 3.25 mg/L. The anti-biofilm activity of 5-fluorouracil relies on the presence of AriR (also 
known as YmgB), a regulatory protein which is upregulated in response to indole (Figure 26). 
The importance of indole in various bacterial processes including virulence induction, cell 
cycle regulation, acid resistance and biofilm formation is reviewed in (Hu et al., 2010). AriR, 
which is a repressor of biofilm formation (Lee et al., 2007a) was upregulated 3.7-fold in the 
presence of 1.3 mg/L 5-fluorouracil in LB medium. When 5-fluorouracil was added to an ariR 
deletion mutant, biofilm inhibition did not occur (Attila et al., 2009). Studies conducted by 
our own research group indicate that 5-fluorouracil also has potential as an anti- Salmonella 
treatment. At concentrations of ≥ 1.3 mg/L, 5-fluorouracil causes near complete inhibition of 
planktonic and biofilm growth, however at a concentration of 0.156 mg/L biofilm formation 
is reduced by 80% without affecting planktonic growth (Yssel et al, unpublished). 
Interestingly, AriR is not present in Salmonella and therefore 5-fluorouracil’s mechanism of 
biofilm inhibition in this genus is probably different than in E. coli. Perhaps the most 
significant finding regarding the use of 5-fluorouracil as antibacterial comes from large-scale 
randomized human trails, in which 5-fluorouracil was applied as a coating on central venous 
catheters. The aforementioned study by Walz et al (2010) showed that the anti-infective 
properties of 5-fluorouracil exceeded that of silver sulfadiazine and chlorhexidine. The 
approximate cumulative dose of 5-fluorouracil eluted over 28 days was 1 mg, which is below 
the lowest toxic dose in humans (6mg/kg/3days), which is associated with cardiac and 
respiratory side effects (Pottage et al., 1978). 5-Fluorouracil was undetectable when plasma 
samples from goats implanted with a 5-fluorouracil coated central venous catheters for a 
period of up to 21 days were analyzed by means of liquid chromatography/tandem mass 
spectrometry. Furthermore, histopathologic examination of the catheter/host tissue interface 
did not reveal any evidence of local tissue toxicity. Together these results strongly indicate 
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that using 5-fluorouracil as an anti-biofilm coating on medical implant devices would be safe 
(Walz et al., 2010).  
 
Figure 26 Proposed pathway for 5-FU and 5-FC metabolism in bacteria and the effects of these 
compounds on DNA, RNA, the cell wall and biofilm formation. Dashed lines indicate enzymes that 
are absent in M. tuberculosis but that are present in E.coli. Dotted lines indicate processes that have 
been observed in E. coli (Attila et al., 2009). Information on enzymatic reactions were obtained from 
literature (Warner & Rockstroh, 1980; Villela et al., 2011; Warner et al., 2014; Singh et al., 2015). 
Genes encoding enzymes responsible for 5-FU and 5-FC uptake and metabolic conversion are 
indicated in italic. 
 5-Fluorocytosine 
5-Fluorocytosine is a synthetic anti-mycotic compound with the brand name Ancobon and is 
used for treating serious infections caused by Candida or Chryptococcus neoformans. 5-
Fluorocytosine is a prodrug of 5-fluorouracil. 5-Fluorocytosine is not intrinsically toxic to 
fungi, but once taken up into susceptible fungal cells it is converted to 5-FU by cytosine 
deaminase (Vermes et al., 2000). Thereafter it is further metabolized to FUTP, FdUTP and 
FdUMP leading to disturbed protein and DNA synthesis as described before Figure 26. 
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Imperi and colleagues studied the effect of 5-fluorocytosine on P. aeruginosa pathogenicity. 
They found that 5-fluorocytosine did not affect P. aeruginosa growth (MIC ˃ 1291mg/L) 
(Imperi et al., 2013). However it had a very high inhibitory activity against pyoverdine 
production (IC50 values of 0.3873 mg/L). In addition to pyoverdine inhibition, other critical 
virulence factors such as exotoxin A and protease PrpL were also inhibited. Using a mouse 
model of pulmonary infection they showed that an intraperitoneal dose of 30 mg/kg/day 
suppressed virulence without affecting the viability of the bacterial cells (Imperi et al., 2013). 
This dose is far below the mouse LD50 of 1190 mg/kg and below the dosage range of 
50 to 150 mg/kg/day recommended for humans (http://www.drugs.com/dosage/flucytosine.h
tml). (Grunberg et al., 1963; Drugs.com, 2017). Although the exact molecular mechanism by 
which 5-fluorocytosine inhibits P. aeruginosa virulence factors is unknown, it was shown that 
5-fluorocytosine toxicity relies on its metabolic conversion to 5-fluorouracil by cytosine 
deaminase (encoded by codA). Mammals and other higher eukaryotes do not have counterparts 
for cytosine deaminase, making 5-fluorocytosine an ideal drug for selectively targeting 
organisms capable of assimilating and activating the prodrug (Imperi et al., 2013). Aside from 
its low toxicity in humans, other clinically desirable characteristics of 5-fluorocytosine include 
its ready absorption after oral administration, high bioavailability and efficient penetration 
throughout the body (Vermes et al., 2000). Moreover, the dosing levels that are currently 
recommended for treating fungal infections lead to serum levels that are 40-fold higher than 
the levels needed to inhibit P. aeruginosa virulence. This suggests that typical doses are 
sufficiently potent for use in treating P. aruginosa infection (Imperi et al., 2013). The in vitro 
and in vivo activity of 5-fluorouracil and 5-fluorocytosine against a variety of bacterial species 
paves the way for further clinical trials on the anti-virulence and anti-biofilm efficacy of these 
compounds in humans. 
  5-Azacytidine 
5-Azacytidine is an analog of cytidine, which is sold under the trade name Vidaza and is 
mainly used in the treatment of myelodysplastic syndrome. It possesses cytotoxic, 
antineoplastic, abortive, and mutagenic activity (von Hoff et al., 1976). The cytotoxic effect 
of 5-azacytidine proceeds via two mechanisms: at low doses it interferes with gene regulation 
by inhibiting DNA methylation by methyl transferases (MTases), leading to inappropriate 
gene activation (Glover & Leyland-Jones, 1987). It is also an inhibitor of RNA methylation 
(Schaefer et al., 2009). At higher doses its derivatives, 5-azacytidine triphosphate and 5-
azadeoxycitidine triphosphate, get incorporated into RNA and DNA respectively (Dapp et al., 
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2009). The hypomethylating effect of 5-azacytidine depends on the altered C5 position 
(Gowher & Jeltsch, 2004). Other cytidine analogues such as 6-azacytidine or gemcitabine do 
not have this property. In fact gemcitabine prevents demethylation of DNA leading to 
hypermethylation which also affects gene regulation and DNA repair (Schäfer et al., 2010).  
The Activated Methyl Cycle (AMC) is an important biosynthesis pathway that produces L-
methionine for protein synthesis as well as S-adenosyl-L- methionine (SAM), the major 
methyl donor in the cell. When SAM donates its methyl group, it is converted to S-adenosyl-
L-homocysteine (SAH). SAH can be recycled back to SAM via the AMC (Figure 27). In 
bacteria, the quorum sensing molecule, AI-2, which is an important regulator of biofilm 
formation, (Vidal et al., 2011) is formed as a by-product of the AMC. Because of the inhibitory 
effect of 5-azacytidine on DNA MTases and the involvement of MTases in the AMC, Yadav 
and colleagues were interested in the effect of 5-azacytidine on AI-2 production and biofilm 
formation by S. pneumoniae (Yadav et al., 2012a). They found that the inhibitory effect of 5-
azacytidine is higher for biofilm growth than for planktonic growth. At 24.42 mg/L 5-
azacytidine, the degree of biofilm inhibition nearly doubled that of planktonic growth 
inhibition. Scanning electron microscopy revealed that 5-azacytidine disrupted biofilm 
organization, since the treated biofilms were thin, cells were scattered in clumps, and micro-
colonies were absent. Expression analysis of 11 genes involved in AI-2 synthesis, competence 
and DNA repair and synthesis was conducted. Genes that were found to be downregulated by 
5-azacytidine include: luxS, metK, pfs and cmk (Yadav et al., 2012a). The enzymes encoded 
by luxS and pfS are both involved AI-2 biosynthesis and detoxification of 
methylthioadenosine/S-adenosylhomocysteine (MTA/SAH) which are toxic byproducts of the 
AMC and metK is involved in SAM production (Figure 27). Cytidylate kinase (encoded by 
cmk) catalyses the transfer of a phosphoryl group from ATP to CMP or dCMP, thus its 
downregulation would interfere with DNA synthesis. The authors indicated that it is unclear 
whether the biofilm inhibition by 5-azacytidine is due to the downregulation of AI-2 
production, changes in SAM levels, or due to the accumulation of toxic by-products of the 
AMC (Yadav et al., 2012a). Although insightful, the gene expression analysis of the above 
study was limited to a small set of genes analysed with RT-qPCR. Further comprehensive 
transcriptome analysis would likely yield additional insights into how interfering with the 
AMC affects S. pneumoniae biofilm growth and quorum sensing. Some compelling 
supplementary information was obtained in a very recent investigation into the effect of 5-
azacytidine on the transcriptome of E. coli. Expression changes for 63 genes were observed, 
the majority of which were up-regulations. It was found that transcription was affected by two 
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mechanisms, one involving loss of DNA methylation, and the other involving a DNA-damage 
response mechanism that is independent of methylation loss (Militello et al., 2016). Because 
5-azacytidine impacts the transcription of many genes the possibility that biofilm related 
processes which are unrelated to AI-2 production and the AMC are affected certainly exists.  
 
  
Figure 27 Diagram showing the activated methyl cycle (AMC) of S. pneumoniae. Black text in white 
rectangles denote pathway intermediates and black solid arrows indicate enzymatic reactions. 
Abbreviations for pathway intermediates are: S-adenosylmethionine (SAM), 5-Methylthioadenosine 
(MTA),5-Methylthioribose (MTR), S-adenosylhomocysteine (SAH), S-ribosylhomocysteine (SRH). 
The effects of 5-azacytidine white oval) on AI-2 production and biofilm formation are shown with 
dashed arrows indicating genes that are downregulated in the presence of 5-azacytidine. 
 
Chapter 3: Repurposing NNAD drugs 
68 
 
Further encouraging results were obtained with the non FDA-approved compounds 1-(4-
bromophenyl)-5-(2-furylmethylene)-3-phenyl-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione 
(from here on simply referred to as pyrimidinedione) and sinefungin. Pyrimidinedione is a 
potent inhibitor of DNA adenine methyltransferase (DAM), an enzyme unique to bacteria. It 
was found that pyrimidinedione significantly inhibits pneumococcal biofilm growth at 
concentrations that are not cytotoxic to human epithelial cells (Yadav et al., 2015). Sinefungin 
which is an experimental drug, is structural analog of SAM. Sinefungin reduces the production 
of AI-2, affecting cell-to-cell connections and disrupting pneumococcal biofilm formation 
(Yadav et al., 2014). The results obtained with azacytidine, pyrimidinedione and sinefungin 
highlight the potential of interfering with biofilm formation and AI-2 production via disrupting 
the AMC (Yadav et al., 2014) and give strong support for testing other methyltransferases, 
such as decitabine, for the treatment of pneumococcal infections.  
 Azathioprine and 6-Mercaptopurine 
Azathioprine (brand name Imuran, originally developed as an anti-cancer drug) and its 
derivative 6-Mercaptopurine (brand name Purinethol) are widely used immunosuppressive 
drugs for treatment of ulcerative colitis, Crohn’s disease, myasthenia gravis, atopic dermatitis 
and intractable pruritus (Kim et al., 1999; Timmer et al., 2007; Maley & Swerlick, 2015; Lee 
et al., 2015; Rae et al., 2016).  
Studies published almost a decade ago revealed that azathioprine and 6-mercaptopurine inhibit 
the growth of Mycobacterium avium subspecies paratuberculosis (MAP), a bacterium that is 
associated with Crohn’s disease (Greenstein et al., 2006; Shin & Collins, 2007). Interestingly 
other rapidly growing mycobacteria, M. avium and M. smegmatis were resistant to 
azathioprine and 6-mercaptopurine (Shin & Collins, 2007). Synergy between 6-
mercaptopurine and the antibiotics azithromycin, clarithromycin, rifampicin, rifabutin and 
ethambutol was also reported (Krishnan et al., 2009). More recently it was demonstrated that 
azathioprine inhibits biosynthesis of c-di-GMP (a signal molecule that plays an important role 
in regulating biofilm formation), by interfering with intracellular nucleotide pool availability. 
Exposure to 25 mg/L azathioprine resulted in 50 % reduction of intracellular c-di-GMP levels 
in E.coli and prevented biofilm formation. In silico docking experiments suggested that 
azathioprine has high affinity to the cyclohydrolase domain of AICAR transformylase (a key 
enzyme in the purine biosynthesis pathway). Binding of azathioprine to AICAR 
transformylase might interfere with purine nucleotide biosynthesis by inhibiting the enzyme’s 
activity. It is possible that even a slight reduction in GTP pools can negatively impact c-di-
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GMP synthesis by directing available GTP towards transcription and translation instead of 
signal molecule production (Antoniani et al., 2013). c-di-GMP is ubiquitous in bacteria, where 
it regulates multiple cellular processes including motility biofilm formation and virulence 
(Römling et al., 2005; Hengge, 2009; Lamprokostopoulou et al., 2010; Ahmad et al., 2011; 
Römling et al., 2013).Thus, drugs that interfere with c-di-GMP signalling could have activity 
against diverse bacterial species.  
 Caffeine  
Caffeine is a methylated xanthine analog which is not only consumed in copious amounts by 
coffee lovers, but is also used to prevent and treat bronchopulmonary dysplasia and apnea in 
premature babies (Schmidt, 1999; Schmidt, 2005). Methylated xanthine analogues act as 
adenosine receptor antagonists in humans (Biaggioni et al., 1991).  
In bacteria methylated xanthine analogues affect bacterial physiology by interfering with the 
following processes: (i) inhibition of thymidine uptake; (ii) inhibition of the conversion of 
thymidine to dTTP; (iii) inhibition of DNA synthesis  and repair; (iv) reduction of RNA and 
protein synthesis; (v) increase in cAMP levels due to inhibition of cAMP phosphodiesterase 
(Lieb, 1961; Grigg, 1968; Sideropoulos & Shankel, 1968; Sandlie et al., 1980; Kawamukai et 
al., 1986; Selby & Sancar, 1990). 
The first evidence that caffeine can disrupt quorum sensing was put forth by Norizan and 
colleagues in 2013 (Norizan et al., 2013). They showed that 100 to 1000 mg/L caffeine 
inhibited short-chain AHL production by P. aeruginosa PA01 in a concentration-dependent 
manner with only trace amounts of AHLs produced at 1000 mg/L. The reduction in AHLs was 
not due to degradation by caffeine and the applied concentrations did not affect bacterial 
growth. The mechanism by which caffeine inhibit the synthesis of AHLs remains unsolved. 
Given the importance of AHLs in the regulation of virulence and biofilm formation, it could 
be interesting to investigate the anti-virulence or anti-biofilm properties of caffeine and other 
xanthine analogs, such as aminophylline and pentoxifyline.  
 Azidothymidine  
Azidothymidine (also known as AZT or zidovudine) is an analog of thymidine in which the 
3’hydroxy group is replaced with an azido group. Upon entry into an HIV infected cell it is 
phosphorylated. The triphosphorylated form acts as an HIV-reverse transcriptase inhibitor by 
inducing DNA chain termination due to the absence of the 3’-OH group.  
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The antibacterial activity of azidothymidine has already been demonstrated three decades ago 
(Elwell et al., 1987; Lewin et al., 1990a). It was shown that the antibacterial activity relies on 
the presence of a thymidine kinase with the ability to phosphorylate azidothymidine. 
Azidothymidine is active against Gram-negative bacteria while it has no effect on Gram-
positive bacteria. Recent research by Sandrini and colleagues provided strong evidence that 
species specific activation of azidothymidine by bacterial thymidine kinases is important for 
the drug’s selective activity (Sandrini et al., 2007a). A comprehensive investigation by 
Doléans-Jordheim and colleagues into the mechanism of azidothymidine’s effect against 
several bacterial species showed that it is particularly active against the enterobacteria 
(Doléans-Jordheim et al., 2011). These results are in agreement with observations that HIV-
positive patients that are treated with azidothymidine are less likely to develop Salmonella 
infections (Casado et al., 1999). It was demonstrated that azidothymidine acts in synergy with 
aminoglycosides. The most effective association is with gentamicin (mean FIC value of 0.40). 
With regards to side-effect, azidothymidine is quite well tolerated in an anti-HIV setting, 
however the effective doses for treating bacterial infection remain to be established (Doléans-
Jordheim et al., 2011). 
 Gemcitabine 
Gemcitabine is a pro-drug used for the treatment of various cancers. It is an analog of 
deoxycytidine in which the hydrogen atoms on the 2’ carbon are replaced by fluorine. When 
transported into the human cell, it is activated by deoxycytidine kinase. Both gemcitabine 
diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP) inhibit processes required for 
DNA synthesis. Incorporation of dFdCTP instead of dCTP into DNA is thought to be the major 
mechanism by which cell death is induced. Following incorporation of dFdCTP on the end of 
the elongating DNA strand, one more deoxynucleotide is added and thereafter, the DNA 
polymerases are unable to proceed. Proofreading enzymes are unable to remove gemcitabine 
from this position. Furthermore, the unique actions that gemcitabine metabolites exert on 
cellular regulatory processes serve to enhance the overall inhibitory activities on cell growth 
(Plunkett et al., 1995). 
The activity of Gemcitabine against bacteria was recently investigated by Sandrini and 
colleagues. It was found that gemcitabine is active against Gram-positive bacteria and inactive 
against Gram-negative bacteria (Sandrini et al., 2007a; Sandrini et al., 2007b). Although the 
exact mechanisms of action of gemcitabine in bacteria is not yet clearly understood, the 
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enzyme deoxyadenosine kinase was shown to be responsible for species specific activation of 
the drug (Sandrini et al., 2007a; Sandrini et al., 2007b). 
Adult mice that were infected intraperitoneally with lethal doses of Streptococcus pyogenes (a 
beta-haemolytic bacterium) did not develop systemic infection if they received 100 µg 
gemcitabine after infection. It was determined that exponential growth is a perquisite for the 
efficacy of gemcitabine and that stationary phase profoundly diminishes the susceptibility of 
bacterial cells. In vitro concentrations that can effectively kill S. aureus and S. pyogenes, are 
0.002 mg/L and 0.2 mg/L respectively (Sandrini et al., 2007b). This is a clinically achievable 
range which is much lower than the plasma concentrations (2.99~5.99 mg/L) produced by the 
standard treatment dose for acute leukaemia (Wang et al., 2007), with potentially lower side 
effects. Jordheim and colleagues performed pre-clinical investigation into the antibacterial 
activity against MRSA strains and the association with gentamicin. Their experiments showed 
that gemcitabine and gentamicin act synergistically (Jordheim et al., 2012).Their results 
provide strong support for the use of nucleoside analogs in hospital settings, where multidrug-
resistant nosocomial infections are increasingly problematic. Implant associated osteomyelitis 
caused by S. aureus is a significant complication for orthopaedic patients following surgery. 
Given that the number of total hip and knee replacements are projected to grow significantly, 
by 2030 in the United States alone (Kurtz et al., 2007), we propose that gemcitabine be added 
to gentamicin impregnated cement spacers to reduce complications associated with infection.  
3.4 Resistance development against NNADs 
When bacteria are exposed to agents that kill them or inhibit their growth there is a positive 
selection of bacteria that have acquired resistance mechanisms. Both strategies that reduce 
acquisition of resistance mechanisms or that reduce positive selection pressure on resistant 
strains are expected to result in lower resistance development.  
Reduced acquisition of resistance can be achieved when multiple genes determine the 
structures of the molecular targets. In this case multiple mutations are required to offer high-
level resistance, reducing the likelihood of high-level endogenous resistance(Silver, 2007).  
If a resistance mechanism were to arise, the trade-off between the cost and benefit of resistance 
is an important factor in determining whether resistance becomes established (Andersson & 
Hughes, 2010). Emerging strategies aim to circumvent the spread of resistance by not directly 
targeting growth but rather targeting virulence or biofilm related factors (so called anti-
virulence-drugs). In the opinion paper by Allen and colleagues (2014), key predictions on the 
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direction of selective pressure on strains resistant to anti-virulence drugs are discussed (Allen 
et al., 2014). It is hypothesized that anti-virulence drugs will generate weaker selection for 
resistance or even select against resistance under the following circumstances: (i) the targeted 
factor confers no benefit to the pathogen at the site of treatment; (ii) the targeted factor confers 
collective benefits to a well-mixed population; (iii) the targeted factor is conditionally 
beneficial and/or conditionally expressed; (iv) the drug reduces the supply of quorum-sensing 
signals in a well-mixed population (Allen et al., 2014). In the following paragraphs we argue 
that, based on the above criteria, NNADs may have properties which make them less 
susceptible to the development of resistance: 
 NNADs can have multiple targets within the bacterial cell 
Nucleotides have a multitude of roles within the bacterial cell and interact with many enzymes. 
NNADs (or their activation products) may thus have multiple enzymatic targets with which 
they can potentially cross-react to disrupt cellular functioning. As such, they could be more 
robust against acquisition of resistance mechanisms and resistance development. Although 
there are potential sources for endogenous resistance, as is discussed below, the use of drug 
combinations with diverse targets could reduce the likelihood of its emergence. 
 Combining treatment with antibiotics can prevent the establishment 
of resistance against NNADs 
Combination therapy is a widely used strategy to combat the emergence of resistance not only 
in bacteria, but also during treatment of HIV and cancer. Combination therapies that have 
multiple molecular targets would require multiple mutations to achieve resistance. Synergistic 
combinations can also reduce the evolution of resistance by clearing the infection faster so that 
resistant mutations have less time to arise in the population. However, if resistance to one drug 
provides collateral resistance to the other drug, the combination will not be very effective in 
preventing the evolution of resistance. In the case of enteric bacterial resistance against 
azidothymidine, resistance was conferred by changes in the thymidine kinase enzyme, and no 
cross protection against other antibiotics was observed. Combination with gentamicin 
therefore completely prevented re-growth of azidothymidine resistant bacteria (Doléans-
Jordheim et al., 2011). The framework provided by Munck and colleagues (Munck et al., 
2014) for aiding the rational selection of antibiotic combinations that limit resistance evolution 
can be applied to NNADs to reveal suitable combinations with antibiotics. 
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 Mutations providing resistance to NNADs are potentially 
disadvantageous 
Endogenous resistance mechanisms against NNADs can occur amongst others by alteration 
of enzyme activity or uptake mechanisms. For example, several NNAD pro-drugs are 
activated by nucleotide salvage enzymes, and these enzymes have been implicated in 
resistance devolpment (Lewin et al., 1990a; Lewin et al., 1990b; Sandrini et al., 2007a; 
Doléans-Jordheim et al., 2011). However, mutations in nucleotide salvage pathways may 
become quite costly under conditions where salvage is required. In addition to inactivation of 
salvage pathways, increased activity of analogue-degrading enzymes or reduced nucleoside 
uptake could also reduce susceptibility but may negatively affect the fitness or competitive 
ability of mutants by causing imbalances in the pools of pathway intermediates or by placing 
more strain on the de novo pathways (Sandrini et al., 2007a). 
 NNADs can inhibit virulence and/ or biofilm formation without 
impacting in vitro growth 
Several drugs discussed in this work have concentration ranges in which they affect quorum 
sensing, virulence and/or biofilm formation without impacting in vitro growth. According to 
Allen et al. (2014), a good understanding of the in vivo fitness benefits and costs of the affected 
virulence factors and their group-beneficial character is required to evaluate the potential of 
resistance development (Allen et al., 2014). Pyoverdine, for example, which is targeted by 5-
fluorocytosine, is a well-known group-beneficial virulence trait (Lamont et al., 2002), 
therefore it is expected that there will be selection against resistance. Indeed, resistant cells are 
expected to share the advantage of resistance, i.e. access to pyoverdine, with surrounding 
susceptible cells, but not the production cost, resulting in inferior performance of resistant 
cells. Sinefungin and 5-azacytidine on the other hand inhibit AI-2 production, while caffeine 
inhibits AHL production. These substances are thus quorum sensing signal supply inhibitors. 
Selection is expected to be neutral because susceptible and resistant cells will likely equally 
sense and respond to signals produced by resistant strains, and thus experience the same 
benefits and costs.  
3.5 Conclusion  
On average, it takes about 15 years from discovery before a drug becomes available for clinical 
use, and only a small fraction of identified novel molecules pass the clinical trial phases 
(Freeman & Dervan, 2011). Since 1962 only two new classes of antibiotics have made it onto 
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the market (Coates et al., 2011). Given the high attrition rates of pharmaceutical development, 
repurposing may be the only feasible approach to treat recalcitrant bacterial infections in the 
near future.  
Although efforts to utilize NNADs for the inhibition of bacterial growth, virulence and biofilm 
formation are relatively new, we have exemplified some feasible candidates with promising 
in vitro (and in some cases in vivo) activities. The antibacterial actions of the drugs that we 
have discussed are diverse and range from interfering with methylation activity, inhibiting c-
di-GMP biosynthesis by disturbing nucleotide pool concentrations, to interfering with quorum 
signaling. More extensive searches will likely continue to yield new, promising drugs that 
target a variety of processes. Differences between target enzymes in bacteria and mammals 
can be taken into account during the selection process in order to single out specific inhibitors 
with low host-toxicity. Egeblad and colleagues have developed an approach for identifying 
interactions between NNADs and human enzymes involved in nucleotide metabolism. A 
thermal shift assay based on light scattering was used to measure enzyme-ligand binding 
between the purified enzymes and 45 FDA approved NNADs (Egeblad et al., 2012). To 
facilitate the identification of NNADs that act selectively against bacteria or specific groups 
of bacteria, the protocol developed by Egeblad et al. could be modified to include bacterial 
enzymes. Moreover, the family of NNADs is expected to grow with the anticipated approval 
of additional drugs in the near future. The review by Jordheim and colleagues (2013) focussed 
on 53 such new compounds which are in various phases of development. The new agents are 
expected to have reduced long-term toxicity, amongst other improved properties (Jordheim et 
al., 2013).  
Following the identification of compounds with promising antibacterial properties, their 
potential therapeutic applications need to be considered. Topically applied NNADs can, for 
example, be used to treat infected skin ulcers or burn-wounds, while intravenously 
administered NNADs can be useful against systemic infections. Because pharmacokinetics, 
pharmacodynamics, safety and adverse effects have already been determined, certain steps in 
the drug development path can be skipped. Typically, drug repurposing reduces the drug 
development process with 5 or more years (Chakraborty & Trivedi, 2015). In order to facilitate 
the repurposing of NNADs as antibacterial agents it is vital to move from small scale in vitro 
studies to in vivo proof of concept experiments and finally phase II and III clinical trials. Given 
that various animal models for studying a wide variety of bacterial infections are already 
established (Siebenhaar et al., 2007; DeLeon et al., 2009; Malachowa et al., 2013; Watson et 
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al., 2016), preclinical tests ought to be relatively straightforward. The most progress towards 
clinical implementation of NNADs as antibacterial agents were made with 5-FU. Indeed, 
catheters coated with 5-FU were shown to prevent implant associated biofilm formation in 
human trials (Walz et al., 2010) and Angiotech received FDA approval to manufacture them 
commercially in 2008 (FDA, 2008). 
We hope that this short review will encourage others to evaluate yet untested NNADs for their 
potential as antibacterial compounds, either on their own or in combination with antibiotics 
that are currently on the market. Furthermore, we hope that (pre-) clinical investigations aimed 
at verifying the efficacy of these compounds will become a priority. 
  
 
Table 4 Summary of FDA approved NNADs and their activities. Information on mechanisms of action were obtained from the National Center for Biotechnology 
Information PubChem Compound Database (https://pubchem.ncbi.nlm.nih.gov)(Kim et al., 2016b) 
Type of agent Drug Analog of Mechanism of action Approved Report on antibacterial activity  
Anticancer 
agents 
Fludarabine deoxyadenosine Inhibits DNA synthesis. 1991  
Clofarabine deoxyadenosine Inhibits DNA synthesis and 
repair. 
2004  
Nelarabine deoxyguanosine Incorporates into DNA leading to 
fragmentation and apoptosis.  
2005  
Gemcitabine deoxycytidine Metabolic products inhibit DNA 
synthesis, synthesis of dNTPs and 
are incorporated into DNA. 
1996 Active against M. pneumoniae, Listeria, Bacillus, 
Enterecoccus and Staphylococcus(Sandrini et al., 
2007a; Sun & Wang, 2013).  
Cytarabine deoxycytidine Not clearly understood, but may 
involve inhibition of DNA 
polymerase. 
1969  
Capecitabine uracil Converted to fluorouracil, 
inhibits DNA synthesis and RNA 
processing. 
1998  
Cladribine deoxyadenosine Converted into 2-chloro-2′-
deoxyadenosine 5′-triphosphate, 
which is incorporated into DNA 
resulting in breakage. 
1993  
Floxuridine deoxyuridine Blocks enzymatic conversion of 
cytosine nucleosides to deoxy-
derivatives. 
1970 Active against M. pneumoniae, Listeria, Bacillus, 
Enterecoccus and Staphylococcus (Sandrini et 
al., 2007a; Sun & Wang, 2013). 
Thioguanine guanine Interferes with the synthesis of 
guanine nucleotides. Incorporated 
into DNA and RNA. 
1996 Inhibits M. pneumoniae growth (Sun & Wang, 
2013). 
5-Fluorouracil uracil Blocks the conversion of 
deoxyuridylic acid to thymidylic 
acid, interfering with DNA 
synthesis. 
1962 Synergism with beta-lactams and tobramycin. 
Inhibits Staphylococcus growth. Inhibits biofilm 
formation by S. epidermis, P. aeruginosa and 
E.coli(Gieringer et al., 1986; Nyhlén et al., 2002; 
Attila et al., 2009; Ueda et al., 2009). 
  
 
Type of agent Drug Analog of Mechanism of action Approved Report on antibacterial activity  
Pemetrexed folic acid, 
deoxyuridine* 
Inhibits folate-dependent 
enzymes involved in purine and 
thymidine synthesis.. 
2008  
 Mercaptopurine guanine, adenine Inhibits several enzymatic 
reactions related to purine 
synthesis. 
2004 Increases susceptibility of Mycobacterium to 
antibacterials (Krishnan et al., 2009).  
Demethylating 
agents 
Azacytidine Cytidine Disrupt transcription and 
translation after incorporation 
into DNA/RNA. 
2004 Inhibits S. pneumoniae biofilm formation. 
(Yadav et al., 2012a) 
Decitabine deoxycytidine Incorporated into DNA resulting 
in hypomethylation. 
2006  
Antiviral 
agents 
Ganciclovir 2′-deoxy-
guanosine 
Incorporation into the DNA 
strand prevents chain elongation. 
1989  
Acyclovir guanosine Inhibits DNA synthesis. 1982  
Vidarabine deoxyadenosine Inhibits replication of viral DNA. 1976  
Trifluridine deoxyuridine Inhibits viral replication by a 
mechanism that is not yet fully 
understood.  
1995 Inhibits M. pneumoniae growth (Sun & Wang, 
2013).  
Ribavirin guanosine Diverse effects involving 
nucleotide biosynthesis, RNA 
synthesis and translation. 
1998  
Idoxuridine deoxyuridine Inhibits viral replication by 
substituting thymine. 
1963  
Zidovudine deoxythymidine After metabolic conversion to its 
active 5-‘triphosphate form it 
inhibits the activity of HIV-1 
reverse transcriptase via chain 
termination. 
1987 Active against M. pneumoniae, Listeria, Bacillus, 
Enterecoccus and Staphylococcus (Sandrini et 
al., 2007a; Sun & Wang, 2013). 
Didanosine deoxyadenosine Active metabolites incorporate 
into viral DNA terminating 
synthesis. 
1991  
  
 
Type of agent Drug Analog of Mechanism of action Approved Report on antibacterial activity  
Abacavir  guanosine Active metabolites incorporate 
into viral DNA terminating 
synthesis 
1998  
Lamivudine deoxycytidine Terminates viral DNA synthesis. 1995  
Valacyclovir guanosine Inhibits viral DNA replication by 
competitive inhibition of viral 
DNA polymerase, and by 
incorporation into the growing 
viral DNA chain. 
1996  
Cidofovir acyclic dCMP Selectively inhibits viral DNA 
polymerase. 
1996  
Stavudine deoxythymidine Active metabolites incorporate 
into DNA, terminating synthesis. 
1994 Inhibits M. pneumoniae growth (Sun & Wang, 
2013). 
Zalcitabine deoxycytidine Interferes with viral RNA-
directed DNA polymerase. 
1992  
Valganciclovir guanosine Prodrug for ganciclovir. 2001  
Emtricitabine deoxycytidine Competes with deoxycytidine 5'-
triphosphate and incorporates into 
nascent viral DNA, inhibing 
reverse transcription of viral 
RNA. 
2003  
Adefovir  acyclic 
deoxyadenosine 
monophosphate 
Competes with deoxyadenosine 
triphosphate for incorporation 
into viral DNA. 
2003  
Tenofovir acyclic 
deoxyadenosine 
monophosphate 
Inhibits HIV reverse transcriptase 
by competing with 
deoxyadenosine 5’-triphosphate 
and, by causing DNA chain 
termination. 
2001  
Entecavir deoxyguanosine Inhibits all three steps in the viral 
replication process. 
2004  
Famciclovir guanine Prodrug for pencilovir. 2007  
  
 
Type of agent Drug Analog of Mechanism of action Approved Report on antibacterial activity  
Penciclovir guanosine Triphosphate form inhibits viral 
DNA polymerase by competing 
with deoxyguanosine 
triphosphate 
2002  
Telbivudine L-isomer of 
thymidine 
Causes chain termination during 
DNA synthesis. 
2006  
Antifungal 5-Flucytosine cytosine Prodrug of 5-fluorouracil. 2011 Inhibits virulence factor production in 
Pseudomonas (Imperi et al., 2013). 
Other uses Azathioprine guanine Prodrug of mercaptopurine. 2007 Inhibits Mycobacterium growth, affects 
production of extracellular structures in E. coli 
(Shin & Collins, 2007; Antoniani et al., 2013). 
Pentoxyfilne Xanthine Inhibits erythrocyte 
phosphodiesterase, non-selective 
adenosine receptor antagonist. 
1997  
Theophylline Xanthine Phosphodiesterase inhibitor, 
adenosine receptor blocker, and 
histone deacetylase activator. 
1982 Causes abnormal cell growth in E. coli 
(Kawamukai et al., 1986). 
Caffeine xanthine Inhibits cyclic nucleotide 
phosphodiesterases, antagonises 
adenosine receptors, and 
modulates intracellular calcium 
handling. 
1987 Retards growth of E.coli, Enterobacter 
aerogenes, Proteus vulgaris, Pseudomonas 
aeruginosa and B. subtilis. Interferes with 
quorum sensing in P. aeruginosa, inhibits AHL 
production (Dash & Gummad, 2008; Norizan et 
al., 2013). 
Theobromine xanthine Inhibits cyclic nucleotide 
phosphodiesterases and 
antagonises adenosine receptors. 
No label, 
generally 
recognized as 
safe 
Lowers MIC of antibiotics against Burkholderia 
cepacia (Rajyaguru & Muszynski, 1998). 
Dyphylline xanthine Inhibits phosphodiesterase 
causing an increase in cyclic 
AMP. 
1951  
  
 
Type of agent Drug Analog of Mechanism of action Approved Report on antibacterial activity  
Allopurinol hypoxanthine Inhibits xanthine oxidase, 
blocking the conversion of 
oxypurines to uric acid. 
1986  
Adenosine adenosine Activates purine receptors and 
inhibits calcium uptake. 
2007  
Chapter 4: Pyrimidine starvation and biofilm inhibition 
 
81 
 
Chapter 4  
4 Pyrimidine starvation inhibits biofilm formation 
despite high c-di-GMP levels 
4.1 Abstract 
We studied the role of pyrimidines during the initiation of biofilm formation by S. enterica 
serovar Typhimurium. When the de novo pathway for UMP production was disabled, 
planktonic growth and biofilm formation were abolished. Planktonic growth was restored at 
lower concentrations of exogenous uracil than biofilm growth, indicating a special role of 
pyrimidines in biofilm formation. Remarkably, quantification of intracellular metabolites 
revealed an increase in c-di-GMP concentration under pyrimidine starved conditions. This is 
in contrast to the standard paradigm of high levels of c-di-GMP being associated with high 
levels of biofilm formation. 
4.2 Introduction 
Salmonella enterica serovar Typhimurium is a frequent colonizer of animal hosts. During its 
complex lifestyle it comes across a great variety of conditions inside and outside of its host 
such as exposure to acid, bile, increased osmolarity, peroxide, anoxia, and nutrient limitation 
amongst others (Kröger et al., 2013). To survive in such vastly different conditions, evolution 
has endowed bacteria like Salmonella with elaborate mechanisms to sense and respond to the 
multitude of environmental cues that they encounter. Typical responses involve the regulation 
of gene expression and the modulation of protein activity. Cross-talk can occur between the 
various response systems of a cell. Therefore, to prevent undesirable reactions, sophisticated 
regulatory networks evolved (Filloux, 2012).  
An effective response to environmental stress is the production of multicellular biofilms 
(O'Toole & Stewart, 2005; Gotoh et al., 2010). In the case of Salmonella, biofilm formation 
plays a crucial role in survival outside as well as inside the host (Steenackers et al., 2012). 
Induction of biofilm formation is coordinated by the master regulator CsgD which controls 
the production of curli and cellulose (Römling, 2005). The regulatory role of CsgD has been 
extensively reviewed recently and will only be briefly summarized here (Simm et al., 2014). 
In its unphosphorylated form, CsgD directly facilitates curli production by initiating 
transcription of the csgBAC operon (Hammar et al., 1995; Brombacher et al., 2003; Kader et 
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al., 2006) and indirectly stimulates cellulose biosynthesis by initiating transcription of adrA 
(Römling et al., 2000; Gualdi et al., 2008). AdrA in turn produces cyclic diguanylic acid (c-
di-GMP) which relieves auto-inhibition of the cellulose synthase BcsAB (Römling et al., 
2000; García et al., 2004; Kader et al., 2006; Morgan et al., 2014). Regulation of CsgD itself 
is quite complex and involves various mechanisms acting from the transcriptional to post-
translational level. These mechanisms include: various transcriptional regulators, sRNAs and 
the c-di-GMP signalling system (Boehm & Vogel, 2012). The c-di-GMP-mediated inverse 
regulation of adhesion and motility has been the subject of rigorous study, for an overview see 
the review by Hengge (Pesavento & Hengge, 2009). It was reported in 2009 that in Salmonella, 
CsgD production is induced at the transcriptional and post-transcriptional level by the activity 
of at least two diguanylate cyclases (DGCs) and inhibited by at least four phosphodiesterases 
(PDEs) (Schmidt et al., 2005; Kader et al., 2006; Simm et al., 2007; Simm et al., 2009). Five 
years later, ten DGC/PDEs have been proven to regulate processes associated with matrix 
production, but despite the advances in the field the exact molecular mechanism by which c-
di-GMP regulates CsgD expression remains uncertain (Simm et al., 2014).  
Ueda and colleagues (Ueda et al., 2009) revealed the important role that pyrimidine 
availability plays in Pseudomonas aggregation. They demonstrated that transposon insertions 
in genes encoding enzymes of the de novo synthesis pathway (carA, carB, pyrB, pyrC, pyrD 
or pyrE) lead to decreased biofilm formation, and that the wild type phenotype can be restored 
by addition of uracil to the medium. Moreover, certain uracil analogues used as anti-cancer 
drugs, were shown to possess potent biofilm inhibitory activity (Ueda et al., 2009; Attila et 
al., 2009). In Escherichia coli, transcription of the curli operon was shown to be 
downregulated under low pyrimidine nucleotide availability. Inactivation of de novo UMP 
production of E. coli MG1655 impaired biofilm formation in LB 1/4 medium, and the addition 
of 0.25 mM uracil restored the wild type phenotype. Furthermore cellulose production was 
shown to be triggered by exogenous uracil via the DGC, YedQ (Garavaglia et al., 2012). It 
was postulated that perturbations in the nucleotide pools, caused by mutations in the 
pyrimidine biosynthesis pathway, could lead to changes in c-di-GMP production which in turn 
would explain the effects on curli and cellulose production. However, no significant changes 
in c-di-GMP levels were observed when carB (encoding the large subunit of carbamoyl 
phosphate synthetase, which catalyzes the first reaction in the de novo pyrimidine biosynthesis 
pathway) was deleted (Garavaglia et al., 2012), leaving the link between pyrimidine synthesis 
and matrix production open for further exploration.  
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The de novo pyrimidine biosynthesis pathway can be considered a linear series of enzyme-
catalysed reactions in which orotidine monophosphate (OMP) is the first pyrimidine 
nucleotide that is formed (Supp. Figure 1). The first reaction in the pathway is catalysed by 
carbamoyl phosphate synthetase, encoded by carAB, and yields carbamoyl phosphate, which 
is also a precursor for arginine biosynthesis. The second step of pyrimidine biosynthesis, 
which converts carbamoyl phosphate to carbamoyl aspartate, is catalysed by aspartate 
carbamoyltransferase, encoded by pyrBI. Another three steps (enzymes encoded by pyrC, 
pyrD and pyrE) lead to the formation of OMP which is sequentially converted to UMP, UDP 
and UTP (respective enzymes encoded by pyrF, pyrH and ndk). Finally, CTP is formed by 
ATP-dependent amination of UTP using glutamine as an amino group donor (enzyme encoded 
by pyrG). Additionally, Salmonella possesses salvage enzymes which allow the de novo 
synthesis of pyrimidines to be bypassed when exogenous pyrimidine nucleoside and 
nucleotides are present in the environment and also enables the reutilization of nucleic acid 
fragments generated by nucleic acid turnover. For a more detailed review of the pyrimidine 
biosynthesis pathway the reader is referred to EcoSal (Jensen et al., 2008). 
Building on prior work done at the CMPG using a ΔcarA mutant that is defective in the first 
step of pyrimidine biosynthesis, and inspired by the research of other groups as described 
above, we aimed to further unravel the link between pyrimidine biosynthesis and the 
regulation of biofilm-associated processes. We were particularly interested in the earliest stage 
of biofilm formation, known as the “switch-phase” (vide supra, Chapter 1).  
We first studied the effect of pyrimidine limitation on the ability of Salmonella 
enterica subsp. enterica Typhimurium 14028 to produce biofilm on plastic surfaces. We 
observed that under our experimental conditions, limited pyrimidine availability causes 
reduced biofilm formation and changes in the c-di-GMP pools of Salmonella. Surprisingly, it 
was not a reduction but an increase in c-di-GMP that was detected. Thus, inhibition of biofilm 
formation under conditions of pyrimidine starvation occurs despite high levels of c-di-GMP. 
These results indicate that the established paradigm of low c-di-GMP levels being equated 
with reduced biofilm formation, while high c-di-GMP levels being associated with increased 
biofilm formation, needs to be nuanced and underscores the importance of other mechanisms 
that regulate adhesion and matrix production. 
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4.3 Results  
 Pyrimidine starvation is a limiting factor for biofilm formation of S. 
Typhimurium  
To test the effect of pyrimidine starvation on the ability of S. Typhimurium 14028 to form 
biofilms on hydrophobic surfaces, mutants containing single-gene deletions of carA and pyrB 
or kanamycin insertions in pyrI, pyrC, pyrD, pyrE or pyrF, were complemented with a dilution 
series of uracil. Their biofilm and planktonic growth were measured after 24 hours of 
incubation in the Calgary biofilm device (Ceri et al., 1999). With the exception of strain S. 
Typhimurium 14028 pyrI::Km, lacking the regulatory subunit of ATCase which renders the 
enzyme insensitive to feedback-inhibition by CTP and UTP, all mutants had a growth defect 
and required the addition of uracil to the growth medium (Figure 28). Addition of 17.5 µM 
uracil was sufficient to restore planktonic growth (determined by measuring OD600 of the 
liquid phase) to ≥50% of wild type levels. Despite the restoration of planktonic growth, biofilm 
formation (as measured by crystal violet staining of bacteria and matrix adhering to the plastic 
pegs) was still severely impaired when 17.5 µM uracil was applied. Only upon addition of 35 
µM uracil or more, biofilm formation could be restored to near wild type levels (Figure 28). 
For further experiments 70 µM uracil was used to study the biofilm restorative effects of uracil. 
When the wild type strain was grown in the presence of exogenous uracil, no changes in 
planktonic growth or biofilm formation were observed. Crystal violet staining of biofilms 
formed on the bottom of petri-dishes gave results, which were comparable to observations 
from the Calgary biofilm setup. It should be noted that the ΔcarA mutant is also auxotrophic 
for arginine, however the TSB 1/20 growth medium can supply this need as it is a complex 
medium containing various amino acids, including arginine. Furthermore, because carA and 
carB form an operon, disrupting the carA gene by replacing it with a kanamycin-resistance 
cassette (and removing it), may cause downstream effects on carB transcription as well, this 
will be discussed in Chapter 7.  
Chapter 4: Pyrimidine starvation and biofilm inhibition 
85 
 
 
Figure 28 Panels A and B show the concentration dependent restoration of planktonic growth and 
biofilm formation for various mutants of the de novo pyrimidine biosynthesis pathway of S. 
Typhimurium. The results are represented here as percentages of the wild type grown in TSB1/20 
without added uracil (red dotted lines). Without addition of uracil, all mutants (excluding pyrI::Km) 
are defective in planktonic growth and biofilm formation. Restoration of planktonic growth (panel A; 
red box) to more than 50% of wild type levels requires the addition of ≥17.5 µM uracil to the medium. 
Restoration of biofilm formation to near wild type levels (panel B, blue box) requires a higher 
concentration (≥35 µM uracil) than what is needed for restoring planktonic growth. Data are 
represented as means ± standard deviations (n = 3 to 6). 
 
Confocal laser scanning microscopy of biofilms grown on the surfaces of petri-dishes revealed 
that wild type biofilms were thick, heterogeneously organized and cells were interconnected 
with each other in clusters. In the case of the pyrimidine starved ΔcarA mutant, the number of 
cells were greatly reduced, the thin layer of cells were disorganized and scattered over the 
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surface. When grown in the presence of 70 µM uracil, the mutant displayed a biofilm 
phenotype that was similar to that of the wild type (Figure 29). These results, together with 
those from the Calgary assay, indicate that an inadequate supply of pyrimidines is a limiting 
factor for biofilm formation in S. Typhimurium 14028. On the other hand, the availability of 
excess uracil has no noteworthy effect on biofilm formation by the wild type. 
 
 
Figure 29 Confocal laser scanning microscope images (500x) of 24 hour old biofilms from: (A) wild 
type; (B) ΔcarA with 17,5 µM uracil; and (C) ΔcarA with 70 µM uracil. The wild type biofilm is thick 
with an organized three-dimensional structure, while the pyrimidine starved mutant has a limited 
number of cells on the surface which lacks organization and only a few clumps are present. The 
addition of 70 µM uracil to the mutant increases the number of surface attached cells as well as the 
three-dimensional organization 
 
To determine the time point at which the switch between the motile and sessile lifestyles 
occurs, we used the petri-dish setup and plated out serial dilutions onto LB agar at regular 
intervals (every 2 or 3 hours). In the case of the wild type, it was clear the cells undergo a 
switch from the free-living planktonic mode to a biofilm-based lifestyle 8 to 10 hours post 
inoculation. Because the ΔcarA mutant has a growth defect on LB agar, we used crystal violet 
staining and optical density measurements for quantification. The severely inhibited biofilm 
formed by the pyrimidine starved ΔcarA mutant, 10 hours post-inoculation, indicates that this 
switch does not occur (Figure 30). 
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Figure 30 Graph showing the pattern of planktonic growth (solid green line) and biofilm formation 
(dotted purple line) of S. Typhimurium 14028 wild type based on estimated colony forming units 
(CFUs). Between 8 and 10 hours (shaded period), there is a decline in the number of viable planktonic 
phase cells This coincides with an increase in the number of viable biofilm cells, indicating that a 
phenotypic switch occurs. The total cell (indicated as a dashed blue line) shows a deceleration of 
exponential growth between 8 to 10 hours. This is followed by a reduction in the number of viable 
cells (a dying off phase) which stabilizes at around 14 hours. Error bars represent the standard 
deviations of 3 technical repeats. The bottom images indicate planktonic and biofilm growth of wild 
type, ΔcarA 10 hours post inoculation, determined by optical density and crystal violet staining. The 
data represents the mean values and standard deviations (n =3 to 6), p-values for t-tests are indicated 
above the strains that were compared.  
 
In order to compare the role of pyrimidines in biofilm formation in Salmonella and E. coli 
under our experimental conditions, we tested the effect of complementing various deletion 
mutants of the de novo and salvage pathway of E. coli BW25113 (Supp. Table 1). Our findings 
were complementary to the results of previously published work also done in E.coli (Supp. 
Figure 2). It should be noted that, like other E. coli K12 strains, BW25113 is a poor biofilm 
former due to disrupted expression of curli (Hammar et al., 1995; Brombacher et al., 2003) 
Chapter 4: Pyrimidine starvation and biofilm inhibition 
88 
 
and cellulose (Zogaj et al., 2001; Da Re & Ghigo, 2006). We observed that addition of 27 µM 
uracil enhanced biofilm formation of the wild type 4-fold. Interestingly this strain (and other 
K12 variants) carries a mutation that causes low frequency of transcription of pyrE, resulting 
in dysregulated nucleotide metabolism during growth on a pyrimidine-free medium and 
perpetually reduced pyrimidine pools (Jensen, 1993; Jensen et al., 2008). Restoration of the 
pyrimidine pools by exogenous uracil could thus explain the observed increase in biofilm 
formation. As in the case of S. Tyhimurium, the pyrimidine deletion mutants of E. coli were 
affected in free-living growth and biofilm formation in TSB 1/20. Addition of 17.5 µM uracil 
could restore the free-living growth defects of the mutant strains and concentrations above 35 
µM uracil enhanced biofilm formation to 200 - 600% of the parental control levels. We 
hypothesize that the addition of uracil to the growth medium helps to overcome both the 
negative effects on biofilm formation of the deletion mutation and the low transcription of 
pyrE, which is also present in wild type strain.  
Upon uptake into the cell, uracil is converted to UMP by the action of uracil 
phosphoribosyltransferase (encoded by upp). The forward directions of the de novo pathway 
are thermodynamically favoured, thus UMP cannot be converted to OMP or upstream 
intermediates of the de novo pathway. The fact that exogenously applied uracil could restore 
biofilm formation in the deletion mutants thus indicates that uracil, UMP or another 
downstream intermediate is required for biofilm formation. To elaborate on this we then tested 
the biofilm formation of a Salmonella double mutant carA::Km-Δupp. The enzyme UPRTase 
encoded by upp is responsible for converting uracil taken up from the medium to UMP. Thus, 
the double mutant cannot make its own UMP de novo, nor can it utilize uracil from the 
medium. We compared this mutant to the ΔcarA strain, Δupp and the wild type. The Δupp 
mutant formed the same amount of biofilm (50% of wild type levels) regardless of the 
concentration of added uracil. The ΔcarA strain responded as already described. The double 
mutant consistently had less than 5% biofilm regardless of the presence of uracil in the medium 
(Figure 31). However, the double mutant also had a severe growth defect, no doubt due to a 
lack of pyrimidines, and thus it was hard to draw a conclusion from these results. Therefore 
we also tested an E. coli BW25113 upp::Km mutant and found that it is not responsive to 
stimulation of biofilm formation by 30 µM uracil, whereas the amount of biofilm formed by 
the parental strains was nearly quadrupled (Supp. Figure 3). This suggests that UMP as 
opposed to uracil is the effector that influences the switch to biofilm formation in E. coil, and 
probably in Salmonella as well. Based on our results for Salmonella and E. coli we conclude 
that in a pyrimidine deficient environment, an intact de novo UMP synthesis pathway is 
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required for biofilm formation. When the de novo pathway is disrupted, biofilm formation is 
dependent on the presence of extracellular uracil that can be taken up and converted to UMP.  
 
 
Figure 31 Biofilm formation and planktonic growth of S. Typhimurium WT, ΔcarA, Δupp and 
carA::Km-Δupp in different concentrations of uracil. Data are represented as means ± standard 
deviations (3 biological repeats were further divided into 3 technical repeats each). 
 
In the following sections, we attempt to elucidate the mechanisms by which pyrimidine levels 
affect biofilm formation by measuring the levels of key nucleotide derived metabolites. 
Previous work in E. coli has shown that pyrimidine availability affects both cellulose and curli 
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biosynthesis. It was hypothesized that these effects may be due to changes in nucleotide pool 
levels, which may in turn have an influence on intracellular c-di-GMP concentrations and 
cellulose and curli production (Garavaglia et al., 2012). To test whether changes in pyrimidine 
availability influences the intracellular concentrations of c-di-GMP and UDP-glucose (the 
substrate for cellulose biosynthesis), we measured their levels in planktonic samples at the 
time point where free-living cells switch to biofilm based growth.  
 UDP glucose levels are unaffected by pyrimidine starvation 
Cellulose is synthesized by the cellulose synthase complex (BcsA-BcsB) which links UDP-α-
D-glucose units into long polymers . UDP-α-D-glucose is formed by the addition of UTP to 
α-D-glucose 1-phosphate in a reaction catalysed by uridylyl transferase, encoded by galU 
(Weissborn et al., 1994). Since cellulose (and thus by association, UDP-glucose), is of high 
importance for matrix production by Salmonella as well (Steenackers et al., 2012), we wanted 
to determine whether disruptions in the pyrimidine pathway can lead to altered UDP-glucose 
levels and so impair biofilm formation. 
HPLC-MS/MS analysis was performed on cellular extracts from planktonic S. Typhimurium 
wild type and ΔcarA cultures, at the time point where early biofilm formation occurs for the 
wild type (~10 hours). These measurements indicated that the UDP-glucose levels for the 
ΔcarA mutant complemented with 17.5 or 70 µM uracil were not different than those of the 
wild type (Supp. Figure 4). This suggests that reduced biofilm production is likely not 
attributable to a lack of substrate for the cellulose synthase complex (BcsA-BcsB), as the 
intracellular UDP-glucose levels are at least within the concentration range of the wild type 
strain. However, it should be kept in mind that the sizes of the UDP-glucose pools are 
determined by the balance between synthesis and utilization, although the pool sizes for the 
different strains were similar their fluxes might differ.  
As a control experiment, we were interested in determining the extent to which cellulose and 
curli contribute to biofilm formation under our experimental conditions. Therefore, we 
compared the biofilm phenotypes of a curli-defficient mutant (csgB::Km), a cellulose 
deficient-mutant (bcsA::Km) and a mutant deficient in both components (csgD::Km). Based 
on these results it appears that cellulose biosynthesis does not make a noteworthy contribution 
to biofilm formation, and that curli plays the most important role (Supp. Figure 5). Therefore, 
pyrimidine starvation probably affects curli biosynthesis rather than cellulose production. The 
signalling molecule c-di-GMP is known to affect both cellulose and curli production in 
Salmonella, by affecting the transcription of csgD (Ahmad et al., 2017). Thus, in an attempt 
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to uncover the cause of the biofilm defect of the pyrimidine starved ΔcarA mutant we next 
determined the intracellular concentrations of c-di-GMP. 
 A lack of pyrimidines is associated with an increase in c-di-GMP  
Given the fact that c-di-GMP plays a central role in biofilm formation by regulating the 
expression of CsgD at the transcriptional and posttranscriptional level (Kader et al., 2006), we 
were interested in quantifying c-di-GMP levels at the time of the switch between lifestyles. 
Intracellular c-di-GMP concentrations were determined from extracts of wild type and ΔcarA 
mutants complemented with various concentrations of uracil. Extractions were performed on 
planktonic and biofilm cells during the early stages of biofilm formation in petri-dishes, as 
described above. The pyrimidine-starved mutant did not form sufficient biofilm on the bottom 
to allow for the extraction and detection of metabolites. The c-di-GMP concentration from 
each sample was determined by mass spectrometry and normalized according to the sample’s 
optical density for planktonic samples (Figure 32) and protein content for biofilm and 
planktonic samples (Supp. Figure 6). The different normalization methods did not give the 
same fold changes for the pyrimidine-starved mutant compared to the wild type; however the 
general patterns were similar as explained below and in the Supplemental section. 
There was no significant increase in c-di-GMP concentration of the wild type biofilm cells 
compared to the wild type planktonic cells (Supp. Table 2). However, we were surprised to 
find that the c-di-GMP levels of the ΔcarA mutant complemented with 17.5 µM uracil 
(sufficient to restore planktonic growth but not biofilm formation) were 20-fold higher than 
those of the wild type. On the other hand, when complemented with 70 µM uracil (enough to 
also restore biofilm formation), c-di-GMP concentrations were reduced again to a level similar 
to that of the wild type (Figure 32). Results for E. coli also showed an increase in c-di-GMP 
concentration during pyrimidine starvation (Supp. Figure 6). Together, these results suggest 
that a lack of pyrimidines inhibits biofilm formation, despite high levels of c-di-GMP. It is 
well known that the complex interplay between c-di-GMP, csgD, the alternative sigma factor 
rpoS and other regulators controls aggregative behavior, with high c-di-GMP levels usually 
associated with biofilm formation and reduced motility. However, this paradigm does not 
always hold true. Sanchez-Torres et al. (2010) reported that early-stage biofilm formation 
occurs only when motility is not inhibited by the activity of certain DGCs (Sanchez-Torres et 
al., 2010). In that particular study no differences in total intracellular concentrations of c-di-
GMP were detected upon deletion of these DGCs, accentuating the possibility that there may 
be various segregated c-di-GMP pools within the cell. Here we report a measured increase in 
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total c-di-GMP concentration, which is associated with a defective biofilm phenotype. Our 
results support the notion that there is an ambiguous relationship between biofilm formation 
and intracellular c-di-GMP concentration.  
 
Figure 32 Concentration of c-di-GMP from cellular extracts of S. Typhimurium 14028 wild 
type and ΔcarA strain as determined by LC-MS/MS. Metabolites were extracted from 
biologically independent cultures and normalized according to sample optical density. The 
error bars represent standard deviations of the three independent experiments. When the ΔcarA 
strain was grown in the presence of 17.5 µM uracil (enough to restore planktonic growth but 
not biofilm formation) the c-di-GMP concentration differed significantly from that of the wild 
type planktonic phase (unpaired t test, 95% confidence interval, p value = 0.0011). There was 
also a significant difference in c-di-GMP concentration of the ΔcarA strain grown in 17.5 µM 
versus 70 µM uracil (unpaired t-test, 95% confidence interval, p value = 0.0010). The 
experiment was repeated for a second time on a different day and a similar pattern was 
observed. 
 
4.4 Conclusion 
Salmonella species are a leading cause of acute gastroenteritis and are estimated to be 
responsible for more than 2.8 billion cases of diarrheal illnesses per year (Majowicz et al., 
2010). Biofilms are known to be associated with chronic infections and environmental 
persistence of Salmonella, as this mode of life facilitates enhanced surface colonization and 
host transmission (Gonzalez-Escobedo et al., 2011). Salmonella biofilm formation is 
particularly problematic in the agricultural and food industry (Marin et al., 2009; Schonewille 
et al., 2012). Prompted by the need to develop new methods to combat biofilm formation, we 
investigated the role of the de novo pyrimidine biosynthesis pathway as a potential anti-biofilm 
target. With this work we showed that pyrimidine availability affects a diversity of processes 
in Salmonella that are linked to matrix production. Although a similar work has been published 
for E.coli (Garavaglia et al., 2012), we were of the opinion that the role of pyrimidine 
biosynthesis in biofilm formation by Salmonella needed to be clarified as well. It is clear from 
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our study that in the absence of intact de novo biosynthesis, extracellular pyrimidines are a 
requirement for biofilm formation in S. Typhimurium 14028 and E. coli BW25113 (similar to 
the previous publication). However, in wild type S. Typhimurium, the addition of exogenous 
uracil did not enhance biofilm formation, indicating that the presence of extracellular uracil 
has effects that are distinct from those in E. coli.  
We showed that pyrimidine metabolism has an effect on the c-di-GMP pool size of S. 
Typhimurium, albeit in an unexpected way, as a lack of pyrimidines coincides with reduced 
biofilm formation in spite of increased levels of c-di-GMP. This suggests either that 
pyrimidine availability regulates biofilm production in a manner that is decoupled from 
regulation by c-di-GMP, or that local c-di-GMP pools are affected differently. Although it is 
established that the relationship between c-di-GMP concentration and biofilm formation is not 
perfectly linear and that low c-di-GMP levels are important for motility and initial attachment 
(Wood et al., 2010; Sanchez-Torres et al., 2010), to our knowledge this is the first time that 
defective biofilm formation is linked to a measured increase in total c-di-GMP production. 
From a clinical perspective, the prevention of biofilm formation is an important step to treat 
pathogens. Our results complement and expand observations that advocate the therapeutic 
potential of interfering with pyrimidine biosynthesis to prevent the transition from free-living 
growth to growth as part of matrix-embedded communities. Furthermore, we shed more light 
onto the different effects that pyrimidine starvation has on biofilm formation by Salmonella 
compared to E.coli.  
Nevertheless, key questions remained unanswered. Therefore further investigation was needed 
to shed light on the following: (i) The link between pyrimidine starvation and increased c-di-
GMP production. (ii) The mechanism of biofilm inhibition, despite increased c-di-GMP levels. 
(iii) The global effect of pyrimidine starvation on cellular processes. To address these 
questions we used a network based approach to analyse the effects of pyrimidine starvation on 
the transcriptome in the next chapter. 
4.5 Materials and Methods 
 Bacterial strains and growth conditions 
Bacterial strains and plasmids used in this study are listed in Table 5.  Prior to experiments 
strains were stored at -80˚C and inoculated onto Lysogeny broth (LB) agar plates, containing 
the relevant antibiotics if needed. Once inoculated, LB agar plates were incubated at 37˚C 
overnight, and subsequently stored at 4˚C. Single colonies were used to inoculate liquid LB 
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cultures (containing antibiotics if needed), and were incubated overnight at 37˚C with shaking. 
Antibiotics used were ampicillin (100 µg/ml) and kanamycin (50 µg/ml). Antibiotics and uracil 
were obtained from Sigma. Biofilm formation and reporter fusion assays were performed 
using 1:20 diluted tryptic soy broth (TSB) from Becton Dikinson.  
 
 Construction of deletion and complementation mutants 
Deletion mutants S. Typhimurium 14028 ΔcarA and S. Typhimurium 14028 ΔpyrB were 
constructed using the Datsenko and Wanner procedure (Datsenko & Wanner, 2000). The 
entire coding regions (plus ~10bp before and after the coding regions) were replaced by 
kanamycin or chloramphenicol resistance cassettes which were subsequently removed by FLP 
recombinase. Plasmids used in Chapter 4 and 5 are listed in Table 5 and Table 6.  
 
Table 5 Salmonella strains and plasmids used in this study. Salmonella promoter fusions used in this 
study were published by . More detailed descriptions of the various genes listed can be found in the 
review by (Steenackers et al., 2012)  
Strain  Relevant 
genotype  
Source Reference 
S. Typhimurium14028 Wild type ATCC strain collection  
 ΔcarA This work  
 ΔpyrB This work  
 ΔcsgD In house strain collection  
    
 ΔcsgDΔcarA This work  
 ΔcsgDΔupp This work  
S. Typhimurium14028 Wild type Parental strain of McClelland collection 
(Porwollik et al., 2014)  
 
 pyrD::Km (Porwollik et al., 2014)  
 pyrC::Km (Porwollik et al., 2014)  
 pyrF::Km (Porwollik et al., 2014)  
 pyrI::Km (Porwollik et al., 2014)   
 uraA::Km (Porwollik et al., 2014)   
 purR::Km (Porwollik et al., 2014)   
Plasmids for constructing knockout mutants (datsenko; wanner, 2000) 
pKD4    
pKD3    
pKD46    
pCP20    
pFPV25 promotor-gfp fusions* 
pFPV25 Promoterless 
gfpmut3  
(Addgene plasmid # 20668) (Valdivia; 
Falkow, 1996) 
pFPV25.1 rpsM Constitutive gfpmut3  
pCMPG10408 bcsA Component of cellulose synthase  
pCMPG10405 adrA c-di-GMP production, regulates 
cellulose biosynthesis 
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Strain  Relevant 
genotype  
Source Reference 
    
pCMPG5539 csgB Minor curlin subunit (Hermans et al., 
2011) 
pCMPG5521 csgD Master regulator of biofilm formation  
pCMPG10433 purA Purine synthesis, adenylosuccinate synthetase  
pCMPG10434 purF Purine synthesis, 
amidophosphoribosyltransferase 
 
pCMPG11011 prsA Synthesis of PRPP This work 
Overexpression from plasmid 
pFAJ1708-CSGD  csgD expression from the nptii promoter  (Hermans, 2011) 
    
*For each fusion, the corresponding gene of the promoter sequence, inserted into the pfpv25 vector, is 
indicated. Promotor sequences are all from S. Typhimurium 14028. 
 
Table 6. Primers used for constructing deletion mutants and quantifying mRNA levels. a STM numbers 
refer to the locus tags of the gene from the Salmonella  LT2 genome, b STM14 numbers are the locus 
tags in the 14028 genome 
PCR Target for 
gene deletion 
Nucleotide sequences of primers 
carA GGGTGTTTTGATTAAGTCAGCGCTATTGGTTCTGGAGTGTAGGCTGGAGC
TGCTTC 
TCCTGATTATTTCGCGGACTGACGGTATTGCTCAATCATATGAATATCCT
CCTTAG 
pyrB AGAGCTGAGTATAATCGCGGACAATTTGCCGGGAGGAAGCGTGTAGGCT
GGAGCTGCTTC 
CAACCTGCAGTTTGTTATCGTGTGTCATCGTTTTTCTCCCCATATGAATAT
CCTCCTTA 
upp TCCGGCGATTTTTTTTGTGGTTGCCAGTCATCTGAGGATAGGAGAAGAGT
GTGTAGGCTGGAGCTGCTTC 
TATTCAAAAAAAAGCCGACTCTTAAAGTCGGCTTTTAATTATTTATTCAC
CATATGAATATCCTCCTTA 
Primer extension Nucleotide sequences of primers 
dusB-fis 5’-UTR 
fragment 
determination 
5’-Hex TTCCCACACTTGCGGGTTAGAAGACATCATCTCGGATACTG 
 
dusB -fis promotor 
region sequencing 
TTCCCACACTTGCGGGTTAGAAGACATCATCTCGGATACTG 
GTCACTATCCGTCTGGATAAACAGCTGCTACCAGCGGAC 
RT-
qPCR 
Targeta 
 
Locus tagb Nucleotide sequences of primers Source Amplicon 
size  
(base pairs) 
adrA STM14_0
455 
GAAGCTCGTCGCTGGAAGTC 
CGAACAGAAGCGGATACAACATAAT 
In house 63 
csgD STM14_1
306 
ACGCTACTGAAGACCAGGAACAC 
GCATTCGCCACGCAGAATA 
In house 62 
csgB STM14_1
309 
TCAGGCGGCCATTATTGGT 
TTGATCCTTCCTGGCGTACTCT 
(Hermans et al., 
2011) 
66 
bcsA STM14_4
358 
AGTTGTAGCCCGACCTCATT 
GGAAGGGCAGAAAGTGAATC 
In house 102 
gcpA/ 
STM19
87a 
STM14_2
408 
CGGCGTGCGGTGGTT 
GTCACTTTTTTCTGCTCGTCAGTAAC 
In house 60 
Chapter 4: Pyrimidine starvation and biofilm inhibition 
96 
 
PCR Target for 
gene deletion 
Nucleotide sequences of primers 
STM16
97a 
STM14_2
047 
GCCATTAGTTTGCGGGTGTT 
TGAGACAAAAAAGCTGCGATCA 
(Jonas et al., 2009) 58 
STM18
27a 
STM114_
2209 
GCGCGAGCTGCATCGT 
TCCTGTGCCAAAATCATCG 
(Jonas et al., 2009) 55 
STM33
88a 
STM14_4
086 
CCGTACCGCACTACTTGCCT 
CGTGTTTTCCCGATTCGCT 
(García et al., 
2004) 
151 
yciR/ 
STM17
03a 
STM14_2
058 
CCAACGCCTGTTCTTATTTCG 
GCCGGTGACGGTGTCTGTAT 
(García et al., 
2004) 
151 
ydiV/ 
STM13
44a 
STM14_1
632 
TTGATACTGAGGCGATGTTTG 
CCCTGGAATGCGCTAAAC 
(Jonas et al., 2009) 58 
yegE/ 
STM21
23a 
STM14_2
620 
CTGTTGATGTGGAGTGCGGT 
GCAGCCACGGCATATTGAC 
(García et al., 
2004) 
151 
yhdA/c
srD/ 
STM33
75a  
STM14_4
070 
CCGATGATGTACGCGACCTT 
TGGACCGCGACTTTATCAAA 
(Jonas et al., 2009) 58 
yhjH/ 
STM36
11a 
STM14_4
346 
CTGCTGCTGCAACTGATGAAC 
CTCCACGCCCTCGACAAT 
(Rouf et al., 2011) 57 
yjcC/ 
STM42
64a 
STM14_5
126 
AAAAACGCGTCAGCATTCAGT 
CCGCGCTCAGTCACTTCAA 
(Rouf et al., 2011) 60 
yjiE 
/STM4
551a 
STM14_5
467 
ATCCGGCGTTAGGCCATTAT 
TTACCGTTCAGCCACAGGC 
(García et al., 
2004) 
151 
yfiN/ 
STM26
72 
STM14_3
275 
TGGCAGTGCTGACAGGATGT 
GGTACCCGGCGTGAAAAATT 
(García et al., 
2004) 
151 
yeaJ/ 
STM12
83a 
STM14_1
553 
CAACCTGACCCGGCATAATT 
CCCGTGACTATGGTCGTCCT 
(García et al., 
2004) 
151 
STM25
03a 
STM14_3
068 
GCGTTGGAGCACGATCATTT 
CATGGTAAACGTCCCCACGA 
 In house 70 
rfaH STM14_4
783 
GTCAGGCAACTTACCGCTTGT 
AAACGCGGGCAACTTCAG 
In house 62 
recA STM14_3
417 
ACGGCGCGGCGATT 
TGTCGTGGGTAGCGAAACG 
In house 56 
gyrA STM14_2
804 
CGCACGGCCAACAATGA 
CAACATTGAGGAGGAGCTGAAGA 
In house 67 
16S 
rRNA 
gene 
STM14_4
686 
CGGGGAGGAAGGTGTTGTG 
GAGCCCGGGGATTTCACATC 
(Tabak et al., 
2007) 
178 
 
 Phenotypic switching between planktonic and biofilm mode of growth 
of S. Typhimurium 14028 wild type 
The optical densities of overnight cultures were determined at 595 nm. Following 
centrifugation at 3000 × g for 5 minutes, the optical densities of the overnight cultures were 
normalized to an OD595 of 1.5 by suspending the pellets in the appropriate amount of TSB 
Chapter 4: Pyrimidine starvation and biofilm inhibition 
97 
 
1/20. Petri-dishes containing 20 ml TSB 1/20 were inoculated with 200 µL bacterial cells and 
incubated at 25 ºC. Colony forming units (CFUs) of the planktonic cells from the liquid phase, 
as well as the biofilm on the bottom of the petri-dishes, were determined by plating out serial 
dilutions onto LB agar plates at regular intervals over a course of a day. Planktonic cells were 
harvested by carefully pouring off the liquid phase and removing the remaining liquid with a 
pipette. Biofilm encased cells on the bottom of the plate were harvested by adding 10 ml 
medium to the petri-dish and scraping the biofilm off the plate. Clumps were dispersed by 
passing the harvested cells through a needle with a diameter of 0.9 mm, fitted to a syringe.  
 Assaying biofilm formation 
The optical densities of overnight cultures were determined at 595 nm and normalized as 
described above. High-throughput biofilm assays were performed using the Calgary biofilm 
device, which is a standard 96-well plate with a lid that has pegs which fit into the wells (Ceri 
et al., 1999). All experiments were performed using TSB 1/20 as growth medium to which 
additional compounds were added if required (see main text for details). Wells were filled with 
200 µl medium and inoculated with 1 µl bacteria from the normalized overnight cultures. 
Biofilm plates were incubated statically at 25˚C. After 24 hours, the lids were removed and 
stained with a crystal violet solution consisting of 0.1% crystal violet dissolved in isopropanol, 
methanol and phosphate buffered saline (PBS) in a (1:1:18) ratio (modified protocol (Fletcher, 
1977). The pegs were de-stained with acetic acid and biofilm formation was quantified by 
measuring the optical density at 575 nm of the resolubilized stain using a Synergy Multimode 
reader. The optical density of the planktonic phase was determined at 600 nm. Experiments 
were performed in triplicate using biologically independent overnight cultures, with two to 
three technical repeats each, as indicated in the relevant results section. Data processing was 
done using Microsoft Office Excel 2013 and GraphPad Prism 6. 
The average values of biofilm formation and planktonic growth of the reference strain were 
calculated per biologically independent experiment after subtraction of the blank. The 
reference values of each 96-well plate were then used to calculate the percentage of planktonic 
growth and biofilm formation at a given concentration for each mutant from the same plate. 
The mean growth percentages and standard deviations for each concentration were calculated 
from the values of the biologically independent experiments. 
Low-throughput biofilm assays were performed using standard petri-dishes containing 20 ml 
of the appropriate growth medium. After pouring off the planktonic phase, biofilms on the 
bottom of the plate were quantified by CFU counting (after scraping off the biofilm) or staining 
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with crystal violet. After de-staining with acetic acid, biofilm formation was quantified as 
described above.  
 Microscopy 
Biofilms formed on the bottoms of petri-dishes for 24 hours, as described above, were 
visualized with a Zeiss confocal laser scanning microscope (LSM 700), with digital camera 
(AxioCam MRm) and the associated Zen 2011 software. Strains used for microscopy 
expressed GFP constitutively from plasmid pFPV25.1. 
 Metabolite extraction and mass spectrometry analysis 
Prior to metabolite extraction, the optical densities of overnight cultures were determined as 
described above and normalized to an OD595 of 1.5 by suspension of pelleted cells in the 
appropriate volume of TSB1/20. Petri-dishes containing 20 ml TSB1/20 (with the appropriate 
amounts of uracil added) were inoculated with 200 µl overnight culture. Petri-dishes were 
incubated statically at 25˚C for 8 to 10 hours before cells were harvested by pouring off the 
liquid growth medium (containing the free-living planktonic cells). This time point was 
selected because it corresponds to the time when S. Typhimurium enters late exponential phase 
and switches from a planktonic lifestyle to early biofilm formation. A 15 ml fraction of the 
harvested planktonic cells was used for metabolite extraction. The remaining 5 ml fraction 
was used for determining culture optical density, colony forming units and protein content by 
bicinchoninic acid (BCA) assay. When applicable, cells attached to the bottom of the plate 
(biofilm cells) were harvested by adding 10 ml TSB 1/20 to the petri-dish, scraping the biofilm 
off the plate and dispersing the clumps by passing them through a needle as described before. 
The harvested biofilm cells were divided into two aliquots of 5 ml, which were subsequently 
used for metabolite extraction, colony forming unit determination and protein quantification 
by BCA assay.  
An extraction method with cold acetonitrile was used for c-di-GMP (Burhenne; Kaever, 2013). 
The extraction solution contained HPLC grade acetonitrile, methanol and water in a 2:2:1 
volume ratio. For the extraction UDP-glucose 0.1 M formic acid was added to the extraction 
solution, and the heat-inactivation step was omitted to prevent dephosphorylation of the tri-
phosphates. Final extracts were evaporated with Speed-Vac. Prior to mass spectrometric 
analysis, residues were dissolved in 200 µL H2O. 
The concentration of c-di-GMP was determined with LC-MS/MS as described in (28). A 
different LC-MS/MS method was applied for the quantitation of linear nucleotides and UDP-
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glucose. Briefly, a Hypercarb 30 x 4.6 mm 5 µm column (ThermoFisher) protected by a 2 µm 
column saver (Supelco Analytical) and a C18 security guard (Phenomenex) was applied. 
Eluent A was 10 mM ammonium acetate in HPLC-gradient grade water adjusted to pH 10.0 
with ammonium hydroxide. Eluent B was acetonitrile. A linear gradient from 4% B (v,v) up 
to 60% B (v,v) over 8 min was applied, followed by an equilibration phase of further 4 min at 
4% B (v,v). The injection volume was 20 µl per sample and the flow rate was constantly held 
at 0.6 ml/min. Specific mass transitions (UDP and UTP in negative ionization mode, all other 
analytes in positive ionization mode) were recorded by a tandem mass spectrometer 
(5500QTRAP, ABSCIEX). All experiments were conducted in triplicate starting from 
biologically independent overnight cultures. Data were processed with Microsoft Office Excel 
2013 and GraphPad Prism 6. 
Concentrations of metabolites were normalized according to optical density (for planktonic 
samples) and protein content (for planktonic and biofilm samples taken at the time of c-di-
GMP extraction). Due to impaired growth of the ΔcarA mutant on LB agar, CFU 
determination was not considered a reliable method for quantification. 
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Chapter 5 
5 The impact of pyrimidine starvation on the 
transcriptome and the switch to biofilm growth 
5.1 Abstract 
This chapter studies the mechanisms behind reduced biofilm formation and increased c-di-
GMP levels, using a network based approach to analyse transcriptome data. RNAseq data are 
verified with the use of GFP-promoter fusions and RT-qPCR. We found that the increase in 
c-di-GMP levels are probably driven by an increase in purine biosynthesis. Furthermore, 
biofilm inhibition occurs via inhibition of csgD transcription, possibly through the action of 
Fis and RpoS. 
5.2 Introduction 
As described in chapter 1, Van Puvelde (2014) showed that Salmonella SL1344 biofilm 
development in nutrient-poor liquid media could be divided into three distinct phases: (i) The 
planktonic pre-switch phase, (ii) the interphase-switch and (ii) post-switch biofilm growth. In 
this thesis it was reported that the same pattern was observed for strain wild type strain 
ATCC14028, and that a pyrimidine starved ΔcarA mutant does not undergo such a switch. 
 Transcriptome analysis by Van Puyvelde indicated that core biofilm genes (such as csgDCBA 
and bapABCD) were already activated in the planktonic phase. In some cases, there was a 
time-shift in the activation/repression of genes when comparing biofilm and planktonic 
samples at the time points 7, 8, 9 and 10 hours (the pre-switch and switch timepoints). In other 
words, biofilm cells had gene expression levels at a certain time-point that were comparable 
to expression levels in planktonic cells at a later time-point. Van Puyvelde concluded that 
genes which were differentially expressed in this fashion might be necessary for sub-
populations of planktonic cells to switch to biofilm mode (in other words, some planktonic 
cells switch to a biofilm lifestyle before others, and this switch happens after the genes’ 
expression levels change). The set of regulatory genes that were predicted to play a role in this 
switch consist of PrpR, PhoB, BaeR, KdgR RpoE, OmrA and OmrB (Van Puyvelde, 2014). 
What is striking is that some of these genes are part of the outer membrane (OM) stress 
systems. OM remodelling and biofilm formation are related processes, due to the role that the 
cell surface plays in biofilm formation. Many of the biofilm components, such as curli, 
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fimbriae and lipopolysaccharides are associated with the OM. Several components involved 
in environmental signalling are also shared between the OM and biofilm regulatory pathways. 
Thus, one can conclude that the aforementioned regulators probably play a role in changing 
the OM in a way that enables bacteria to attach to the surface and produce a biofilm matrix. 
During the post-switch phase, pathways involved in oxidative stress, carbohydrate 
metabolism, starvation-related systems, virulence genes and iron-sulphur cluster assembly are 
activated (Van Puyvelde, 2014).  
Based on our observations that pyrimidine starved cells have impaired biofilm formation, we 
were interested in determining how pyrimidine starvation prevents the switch to biofilm-based 
growth. Although a number of insights were obtained in the previous chapter, some very 
important questions remained unanswered: (i) Why are c-di-GMP levels increased in the 
ΔcarA mutant supplemented with low levels of uracil (17.5 µM)? (ii) By which mechanism is 
biofilm formation down regulated? (iii) What are the other effects of pyrimidine starvation 
Thus, to get a global overview of the transcriptional differences between the pyrimidine 
starved cells compared to the wild type planktonic cells that are preparing to enter the biofilm-
mode, we sampled RNA 10 hours past inoculation when planktonic phase cells switch to 
biofilm based growth. Further validations were done using GFP-promoter fusions, RT-qPCR 
and mutant studies. 
5.3 Results 
In order to study the transcriptional changes that affect the switch from free-living to biofilm 
growth in the wild type and pyrimidine starved ΔcarA mtant, RNA samples were taken from 
the planktonic phase at the time of the switch between lifestyles. The optical densities of the 
planktonic phases were determined and the biofilms on the surface of the plates were coloured 
and measured (to verify that the pyrimidine starved mutant did not make biofilm and that it 
does not have a growth defect). As expected, the pyrimidine-starved samples exhibited a 
severely reduced biofilm phenotype and slightly increased planktonic culture densities.  
RNA sequencing of the planktonic samples was performed by BGI. Reads were mapped to 
the S. Typhimurium LT2 genome and gene expression levels were quantified using 
Rockhopper (McClure et al., 2013). More than 96% of the reads coming from each sample 
aligned to the S. Typhimurium LT2 chromosome and approximately 1% of the reads aligned 
to the LT2 plasmid (Supp. Table 3, Supp. Table 4) . We defined genes that are significantly 
up/down-regulated as those with a log2fold change of 1 or -1 (expression levels are 2x 
higher/lower compared to the wild type control) and a q value smaller than 0.05. According to 
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these selection criteria, 849 genes are significantly differentially regulated (roughly 20% of 
the genome) with 450 being up-regulated and 399 being down-regulated. The LT2 genome 
was used as a reference for assembly because subsequent analyses were done on a publicly 
available LT2 interactions network. As a control the ATCC14028 genome was also used as a 
reference: assembly results and gene expression predictions were similar. Genes with very 
high differential expression (absolute log2 fold change >2 and low q-values) are listed in 
(Supp. Table 5). 
The expression data were analysed using a network-based approach. The networks that were 
generated by PheNetic (DeMaeyer et al., 2013) were vizualised in Cytoscape (Shannon et al., 
2003). PheNetic predicts the most probable interaction and regulatory networks that lead to 
the observed transcriptional changes. For analysis, a reduced gene list (size 427) was submitted 
to Phenetic after increasing the log2fold cutoff to 1.5. Due to the way in which the algorithm 
works, genes that do not appear in the gene list but that are part of the connection path between 
other genes in the list are also added as nodes in the network. Thus, important interactions 
involving genes with smaller absolute log2 fold changes were also visible. To identify 
downstream pathways that are triggered by differentially repressed/ activated in the pyrimidine 
starved strain, PheNetic was run in “Downstream” mode. The network produced by the 
“Downstream mode” mostly contains genes with similar functionalities or that are involved in 
the same pathways and are together differentially up or down regulated. From these results, it 
was possible to identify affected pathways which include, purine metabolism, pyrimidine 
metabolism, curli biosynthesis, chemotaxis, invasion, the TCA-cycle and lipopolysaccharide 
biosynthesis amongst others. 
In order to identify and prioritize the regulatory mechanisms potentiating the observed 
differential expression of genes in the pyrimidine starved ΔcarA strain, PheNetic was run in 
“Upstream mode” to identify the regulatory mechanisms behind the global transcription 
profile. Some of the most interesting/relevant pathways and their regulatory mechanisms are 
discussed in the rest of this Chapter. Figure 33 presents a global view of both networks 
produced with PheNetic. 
In the following sections, we will first discuss the effects that pyrimidine starvation has on the 
highest hierarchical levels of the gene regulatory networks and the processes that are affected, 
and then we will shed more light on the mechanisms behind the increase in c-di-GMP and 
biofilm inhibition.  
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Figure 33 Global overviews of the upstream and downstream networks predicted by Phenetic. 
Networks were visualized in Cytoscape. The upstream network shows regulator pathways that can 
explain the observed changes in transcription. The size of a node correlates to the amount of targets 
connected to that particular node. The downstream network shows pathways that are activated or 
deactivated because of changes in transcription. Genes that are down-regulated are shown in blue and 
genes that are upregulated are shown in yellow.  
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 Pyrimidine limitation affects global regulators 
The mechanisms that co-ordinate the regulation of gene expression are complex and 
hierarchic. This co-ordination is critical for sustaining a balanced gene expression profile in 
response to varying environmental conditions while maintaining cellular homeostasis. Two 
different, yet complimentary means are used to achieve this balance. On the one hand 
transcription factors compete with other regulators to redirect the RNAP to transcribe a set of 
genes. Transcription factors can also prevent the transcription of certain genes. On the other 
hand, sigma factors compete with other sigma factors for the scarce RNAP core. The fact that 
total RNAP is a limited resource in the cell, is a pivotal aspect for the successful functioning 
of this regulatory mechanism through competence. The alternate activation of different sigma 
factors leads to an efficient reprogramming of global gene expression in response to sudden 
changes in the environment. The specificity that sigma factors confer to the RNAP for certain 
promoters allows it to “bypass” the transcriptional regulatory proteins currently active (in 
response to a previous condition), thereby enabling a specific and efficient response to the new 
condition. The availability of sigma factors is managed at multiple levels by specific signal 
transduction pathways that are activated in response to distinct environmental conditions or 
stresses. Anti-sigma factors bind to sigma factors to inhibit their activity; as such anti-sigma 
systems provide the cell with a negative feedback system to silence the expression of genes 
that are not required in a particular biological context (Trevino-Quintanilla et al., 2013). For 
example, Rsd mediates the transition from exponential growth, where RpoD is the most 
important sigma factor, to stationary phase where RpoS is the most abundant. Rsd’s main 
function is to allow for the redistribution of RNAP to RpoS-specific promoters by sequestering 
RpoD. Thus Rsd plays a vital role in maintaining cellular homeostasis (Jishage; Ishihama, 
1998; Mitchell et al., 2007; Campbell et al., 2008). 
By running Phenetic in the upstream mode it was possible to extract and visualize a regulatory 
network that is involved in processes that were differentially regulated between the pyrimidine 
starved strain and the wild type. The network consists of a large- and a small subnetwork. The 
large regulatory network consists of 240 nodes. The smaller network has three nodes. From 
the large network, it was possible to identify a number of regulatory hubs, many of which are 
known to be involved in matrix production and other biofilm related processes. Other 
regulators with delineated functions in bacterial metabolism are also visible. At the highest 
hierarchical layer of the network are the global transcription factors and sigma factors. The 
most highly connected hubs (with  between 52 to 10 target nodes) are fnr, ihfA, fis, arcA, crp, 
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lrp, rpoS, fliA, rpoN, rpoE, fur, purR, csgD and oxyR (Table 7). It should be noted that the 
primary sigma factor RpoD was not included in the interaction network because its high 
connectivity would mask other interactions. However, expression of rpoD was down-
regulated with a log2 fold change of -1.27.  
Table 7. Summary of regulators identified with the network based approach.Regulators identified to 
be involved in controlling the observed gene expression patterns. The value in the “Out-degree” 
column is an indication of how many targets a particular node has. The column showing changes in 
transcription level is colour coded. Blue genes are down-regulated in the mutant, while yellow genes 
are up-regulated. The intensity of the colour corresponds to the log2 fold change. *H-NS was not in the 
regulatory network produced by PheNetic (perhaps because its q value did not meet the cut-off 
criteria).**RpoD was not included in the interactomic network used as input for PheNetic because it 
is so highly connected it would mask other interactions. Information on function was obtained from 
ecocyc.org and uniprot.org 
Classification Process/Role Gene name STM identifier Out-degree log2 fold change 
Global transcriptional regulators     
 
DNA supercoiling, affects replication, 
recombination and expression ihfA STM1339 31 -0.83 
 
DNA-binding and bending. Modulates 
transcription, replication, DNA 
inversion, phage integration/excision  fis STM3385 22 1.87 
 
Respiration mode, anoxic redox 
control arcA STM4598 41 -1.12 
 
Respiration mode, transition from 
aerobic to anaerobic metabolism, acid 
resistance, chemotaxis, cell structure 
and other processes fnr STM1660.S 52 0.73 
 
Condensing and supercoiling DNA, 
transcriptional silencer of genes with 
high AT content *H-NS STM1751 * 0.13 
 Regulator of Carbon metabolism crp STM3466 47 -0.36 
 
Regulator of amino acid metabolism, 
nutrient transport and other cellular 
functions. Induces many genes on 
entry into stationary phase lrp STM0959 15 -0.61 
Sigma factors      
 
Primary Sigma factor, exponential 
growth 
**rpoD STM3211 * -1.27 
 General stress response. rpoS STM2924 36 -1.45 
 Cytoplasmic stress, heat shock rpoH STM3568 9 0.36 
 
Motility and flagellar genes synthesis, 
implicated in virulence fliA STM1956 15 -1.42 
 Nitrogen metabolism rpoN STM3320 12 -0.90 
 
Extra cytoplasmic stress, extreme heat 
shock rpoE STM2640 12 -0.93 
Other transcriptional regulators     
 
Transcriptional dual regulator controls 
genes involved in iron homeostasis, 
flagellum chemotaxis, purine 
metabolism, gluconeogenesis, 
respiration and other processes. fur STM0693 24 0.68 
 
Controls expression of genes involved 
in purine biosynthesis. purR STM1430 12 0.92 
 
Transcriptional regulator, biofilm 
components. May respond to 
starvation and high cell density csgD STM1142 10 -3.74 
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Classification Process/Role Gene name STM identifier Out-degree log2 fold change 
 
Regulates the expression of 
antioxidant genes inr eponse to 
oxidative stress. oxyR STM4125 10 0.81 
 
Regulates expression of anaerobic 
electron transport genes and 
fermentation-related genes in response 
to nitrate or nitrite. narL STM1767 9 0.75 
 
Regulates expression of curli and 
motility. Abundant during post-
exponential growth phase. fliZ STM1955 9 -1.54 
 
Controls genes involved in envelope 
stress response, pilus assembly, 
secretion, motility, biofilm formation 
and others. cpxR STM4059 9 -0.22 
 
Activates expression of genes in 
response to environmental Pi phoB STM0397 7 1.92 
 
Member of the two-component 
regulatory system phoQ/phoP 
involved in adaptation to low 
Mg2+ environments and the control of 
acid resistance  phoP STM1231 7 0.31 
 
Pyrimidine sensor regulates 
degradation of pyrimidines, glutamate 
transport, glutamine synthesis, 
pyrimidine synthesis and degradation 
of purine and argenine ompR STM3502 7 -0.77 
 
Regulates the expression of the 
components of a secondary pathway of 
iron-sulfur cluster assembly, iron-
sulfur proteins, anaerobic respiration 
enzymes, and (E.coli) biofilm 
formation yfhP (iscR) STM2544 7 0.96 
 SOS response lexA STM4237 7 2.30 
 
Controls expression of genes of 
diverse functions such as acid 
tolerance, curli fimbria formation and 
anaerobic respiration. rstA STM1475 6 -0.39 
 
Represser of genes involved in 
argenine biosynthesis, histidine 
transport. Activator of genes involved 
in argenine catabolism. argR STM3360 5 0.60 
 
McbR: MqsR-controlled colanic acid 
and biofilm regulator. 
yncC 
(mcbR) STM1588 5 -1.12 
 Activates expression of invasion genes hilA STM2876 5 2.00 
 
FlhD and FlhC forms a complex that 
regulates flagellum biogenesis and 
swarming migration. flhD STM1925 4 0.51 
 
Transcriptional activator, response to 
superoxide and nitric oxide soxS STM4265 4 0.77 
 
repressor of the glycine cleavage 
enzyme system, which is a secondary 
pathway for production of C1 units gcvA STM2982 3 0.81 
 
Target genes are involved in antibiotic 
resistance, tolerance to organic 
solvents and heavy metals. rob STM4586 3 0.87 
 
The principal regulator that controls 
the transcription of operons involved 
in the transport of molybdenum and 
synthesis of molybdoenzymes and 
molybdate-related functions, among 
others modE STM0779 3 -1.15 
 
The DcuR/DcuS two-component 
regulatory system regulates genes 
involved in C4-dicarboxylate dcuR STM4303 2 0.79 
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Classification Process/Role Gene name STM identifier Out-degree log2 fold change 
metabolism as well as some genes for 
lipopolysaccharide biosynthesis, 
anaerobic nitrate and nitrite 
respiration. 
 
Transcription factor involved in 
disaccharie melibiose degradation melR STM4297 2 0.55 
 
Transcription factor that controls 
expression of genes involved in 
proprianate catabolism. prpR STM0367 2 0.65 
 
The BasS/R system regulates 
expression of genes involved in 
lipopolysaccharide modification to 
prevent exessive Fe(III) binding. basR STM4292 2 0.35 
 
Controls expression of genes involved 
in transport and catabolism of L-
lactate. lldR STM3693 2 2.05 
 
Controls transcription of genes 
involved in arginine transport and 
DNA replication.  Regulates DNA 
opening at OriC. iciA (argP) STM3064 1 0.61 
 
Pyrimidine sensor regulates 
degradation of pyrimidines, glutamate 
transport, glutamine synthesis, 
pyrimidine synthesis and degradation 
of purine and argenine rutR (ycdC) STM1122 1 -0.81 
 
Transcriptional repressor and 
chaperone. Involved in gluocside 
utilization stpA STM2799 1 2.21 
 
Transcriptional regulator for the 
expression of type II secretion system 
SPI1 effector proteins. invF STM2899 1 1.00 
Effect via protein-protein interaction, metabolism and other  means  
 
Involved in the biosynthesis of iron-
sulfur clusters, thio-nucleosides in 
tRNA, thiamine, biotin, lipoate and 
pyranopterin (molybdopterin). nifS STM2543 2 0.84 
 
Chaperone protein, interacts with 
RpoH to control the heat shock 
response.  dnaK STM0012 1 -1.39 
 
Synthetase component of the 
carbamoysl synthase complex.  carB STM0067 1 4.87 
 
ATP-dependent protease that degrades 
misfolded proteins and regulatory 
proteins lon STM0450 1 -1.03 
 
Substrate-binding component of 
maltose ABC transporter. malE STM4229 1 1.87 
 Citrate synthase gltA STM0730 1 1.55 
 
Cell invasion protein, stimulates actin 
polymerization and counteracts F-
actin destabilizing proteins. sipA STM2882 1 2.17 
 
Bifunctional hydroperoxidase I (HPI) 
with catalase and peroxidase activity. katG STM4106 1 -1.66 
 
UDP-3-O-acyl-N-acetylglucosamine 
deacetylase (LpxC) catalyzes the 
second reaction and the first 
committed step in lipid A 
biosynthesis.  lpxC STM0134 1 0.62 
 
DNA-damage inducible gene of SOS 
regulon.  yebG STM1882 1 1.62 
 
AdhE is a homopolymeric protein with 
three Fe2+-dependent catalytic 
functions: alcohol dehydrogenase, 
coenzyme A-dependent acetaldehyde 
dehydrogenase, and pyruvate formate- adhE STM1749 1 -1.45 
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Classification Process/Role Gene name STM identifier Out-degree log2 fold change 
lyase deactivase (the latter is called 
into question due to lack of 
reproducibility). 
 AHL receptor*  srgC PSLT008 1 -0.57 
small regulatory RNAs      
 
Regulates protein composition of 
outermembrane by effect on ompT, 
cirA, fecA, fepA, ompR, csgD and flhD 
mRNAs omrA  6  
 
Regulates outermembrane 
composition by negative effect on 
levels of ompT, cirA, fecA, gntP, 
ompR, csgD and flhD omrB  6  
 
Postranscriptional control of csgD and 
genes involvbed in amino acid 
biosynthesis gcvB  5  
 
Mediates positive Fur-regulon 
response rhyB  2  
 
Effect on transcription and translation. 
Overcomes transcription silincing by 
H-NS. Promotes translation of RpoS.  drsA  2  
 
Targets include ompA, phoPQ, ompX 
and other mRNA's micA  2  
 
Some of the anti-sigma factors and adaptor proteins that regulate sigma factor activity were 
also differentially expressed (Table 8). The role of anti-sigma factors in regulating biofilm 
formation and swarming motility has been studied in Pseudomonas. It is possible that the 
interplay between sigma factors and anti-sigma factors can also contribute to the impaired 
ability of the pyrimidine starved carA strain to switch to a biofilm mode of life, by affecting 
the expression of genes that are part of the RpoS regulon. However this possibility was not 
explored further in this thesis. Portions form the upstream network showing the various sigma 
factors and the netto effect on expression of their direct targets are in the supplemental section 
(Supp. Figure 7, Supp. Figure 8, Supp. Figure 9, Supp. Figure 10 and Supp. Figure 11)  
Two of the most highly connected regulatory hubs are the global regulators FNR 
(STM1660.S) with 52 targets and ArcA with 41 targets (Figure 34). These two global 
transcription factors regulate the adaptation to changes in O2 availability. FNR is a fast-
reacting direct O2 sensor, whereas the ArcBA two-component system senses O2 indirectly by 
monitoring the redox state of the quinone pool and is slow reacting. (Khoroshilova et al., 1997; 
Georgellis et al., 2001; Partridge et al., 2007). FNR and ArcBA cooperate to regulate some 
operons such as cydAB (encoding cytochrome bd) and focA-pflB (encoding pyruvate formate-
lyase)(Sawers, 1993; Govantes et al., 2000). The expression of arcA is regulated by FNR 
(Compan; Touati, 1994).  
Chapter 5: Mechanisms behind biofilm inhibition 
110 
 
The ability of FNR to sense and respond to cellular O2 levels depends on its [4Fe-4S](2+) 
cluster. In the presence of O2, the [4Fe-4S](2+) cluster is converted to a [2Fe-2S](2+) cluster, 
which inactivates FNR as a transcriptional regulator (Khoroshilova et al., 1997). Thus, when 
O2 is limited enzymes involved in aerobic respiration are repressed and the synthesis of 
enzymes required for anaerobic respiration is increased (Salmon et al., 2003; Kang et al., 
2004). FNR also regulates the transcription of many genes with other functions, such as acid 
resistance, chemotaxis, cell structure, and molecular biosynthesis, among others (Salmon et 
al., 2003; Kang et al., 2004). 
In the case of the pyrimidine starved mutant, 41 of FNR’s targets (visualized on our upstream 
network) are down-regulated significantly while 10 are upregulated. FNR itself was only 
modestly upregulated (log2 fold change 0.73). The transcription patterns of some of the genes 
that are directly regulated by FNR, suggest that the response to oxygen limitation (which one 
would expect in our petri-dish setup, and according to Van Puyvelde might be a trigger for the 
switch between phenotypes) is not induced. For example, yfiD should be highly induced under 
anaerobic conditions (Scott et al., 2003). Incidentally, yfiD is known to be upregulated in 
biofilms. However, in the carA mutant yfiD is down regulated (log2 fold change -2.95). A very 
interesting observation is that arcA is downregulated as well. As can be expected, the genes 
under the control of ArcA are down-regulated too. The above observations indicate that the 
switch from aerobic metabolism to micro-aerobic/anaerobic metabolism is not taking place. A 
possible explanation is that O2 is not limiting in the growth medium of the ΔcarA strain, which 
is unlikely however since the mutant did not have a growth defect under the tested conditions 
that would have accounted for lower oxygen consumption. A second possibility is that the 
wild type cells have a pre-emptive response in anticipation of oxygen limitation that would 
occur in a biofilm, and that this pre-emptive response is not taking place in the mutant. A third 
possibility is that iron-sulphur cluster biogenesis or transport is affected, which would have an 
effect on FNS activity. This possibility will be elaborated on in later paragraphs when the suf 
system is discussed.  
The nucleoid associated protein FIS (factor for inversion stimulation) is also a highly 
connected hub with 24 connections in our upstream network(Figure 35). The fis gene shows 
an upregulation of transcription in the carA mutant (log2 fold change 1.87). Our subnetwork 
extraction of genes that are directly controlled by FIS showed that out of 10 genes that are 
known to be activated by FIS, 3 were upregulated. Out of 11 genes that are known to be 
repressed by FIS, 7 were down-regulated. The above results indicate that pyridine starvation 
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affects transcription regulatory networks on the highest hierarchical levels. Some of the 
downstream processes that are affected will be discussed in the following sections. In 
particular, we seek to explain the increase in c-di-GMP and the inhibition of biofilm 
production.  
 
Table 8. Sigma factors and the anti-sigma factors and adaptor proteins that control their activity. The 
expression patters of the anti-sigma factors resemble those of the sigma factors, because anti-sigma 
factors are regulated by their own sigma factors, creating a negative feedback circuit. A notable 
exception is rsd whose transcription is regulated by both RpoD and RpoS. RpoN does not have a 
cognate anti-sigma factor; instead, activity depends on ATP-dependent bacterial enhancer binding 
proteins. 
Sigma factor log2 fold change anti-sigma factor/ 
adaptor protein 
log2 fold change 
 
rpoD 
-1.27 
rsd  -1.06 
hscC 0.13 
rpoS -1.45 rssB (hnr) -0.56 
rpoE 
-0.93 
rseB -0.81 
rseA -1.45 
rpoN -0.90   
rpoH 0.35 dnaK -1.40 
fliA -1.42 flgM -1.45 
 
 
 
 
Figure 34 Sub-network extraction from our upstream-regulatory network, showing genes regulated 
by FNR(STM1660) and ArcA. Most of the genes are down-regulated. The TCA cycle genes are up-
regulated. Genes that are down-regulated are shown in blue and genes that are upregulated are shown 
in yellow.  
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Figure 35 Subnetwork extraction of genes regulated by FIS. The colour of nodes indicate whether the 
gens are up or down regulated under our experimental conditions (yellow and blue respectively). The 
colour of the circles surrounding the nodes indicate whether the genes are activated or repressed by 
Fis, according to RegulonDB and other sources. Genes that are down-regulated are shown in blue and 
genes that are upregulated are shown in yellow.  
 
 Pyrimidine starvation leads to an increase in c-di-GMP by influencing 
gene expression levels in key pathways 
In the next paragraphs, we aim to unravel the cause for increased c-di-GMP levels during 
pyrimidine starvation. We will explore two possibilities: (i) That the increase in c-di-GMP 
might be caused by imbalances in the nucleotide pools which leads to an in increase in GTP, 
the substrate for c-di-GMP synthesis. (ii) That the increase in c-di-GMP may be driven by a 
combination of increased levels of DGCs and decreased levels of PDEs.  
 The effect of pyrimidine starvation on the nucleotide biosynthesis pathways 
The transcriptomics results indicate that the pyrimidine starved ΔcarA mutant exhibits changes 
in the regulation of genes involved in nucleotide metabolism (Table 9). CytoKegg was used 
to import the metabolic pathways into Cytoscape; expression data were mapped onto the 
nodes. Genes involved in de novo pyrimidine metabolism, pyrimidine salvage and pyrimidine 
uptake are highly up-regulated. Genes for de novo purine biosynthesis, salvage and 
interconversion are also up-regulated. Genes involved in deoxyribonucleotide metabolism are 
down-regulated. The pur genes are all under control of the repressor PurR, however the 
pyrimidine genes are not regulated by a single repressor and have regulatory mechanisms that 
differ between the genes, as discussed in Chapter 1. 
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The up-regulation of the de novo pyrimidine biosynthesis genes can be interpreted as a futile 
attempt to make more UMP (Figure 36). However, since the first enzymatic step of this 
pathway that starts with the conversion of glutamine is not functioning, not enough UMP can 
be made via this pathway. The expression results also seem to indicate that a pathway to 
convert cytidine to CMP (via the enzyme encoded by udk) is upregulated, perhaps in an 
attempt to maintain CXP nucleotide levels. The same enzyme will also enable the conversion 
of uridine to UMP. The downregulation of cdd could lower conversion of cytidine to uridine 
and so also contribute to the maintenance of CXP nucleotide levels. The expression of cdd is 
induced by cytidine and inhibited by CytR (Pedersen et al., 1991; Gerlach et al., 1991). The 
expression of udk is activated by RbsR and D-Ribose (Shimada et al., 2013). To clarify the 
effect that fluctuations in nucleotide pools have on the regulation of pyrimidine pathway 
genes, further studies are needed.  
 
Figure 36 Pyrimidine biosynthesis pathway indicating changes in gene regulation. Gene names are 
written in rectangles, yellow indicates up regulation and blue indicates down regulation. Metabolites 
are indicated in circles. The levels of the nucleotides were measured by LC-MS/MS (see previous 
chapter). Dark blue means a compound has a significant decrease in levels in the carA mutant, yellow 
means levels are significantly increased. Light blue means that there is a slight, but non-significant 
decrease.  
 
The purine de novo synthesis genes are up-regulated, while the salvage genes are down- 
regulated. The genes encoding purine salvage enzymes are down-regulated, which can be 
interpreted as an indication that there is an ample supply of purines produced by the de novo 
pathway. Another gene that shows increased expression is prsA (encodes the 5-
Phosphoribosyl-1-α-diphosphate synthase, log2 fold change of 1.15), which plays an important 
role in nucleotide biosynthesis by supplying 5-Phosphoribosyl-1-α-diphosphate (PRPP). We 
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were able to verify the expression results for some nucleotide biosynthesis genes by using our 
own in-house collection of promotor-GFP fusions (Supp. Figure 12 and Figure 39).  
Table 9.Gene expression results of enzymes of purine and pyrimidine metabolism. Genes with 
significant changes in their regulation are underlined and shown in bold.  
Pathway Gene Locus in 
LT2 
Product q-val log2 FC 
De novo synthesis of 
IMP 
purF STM2362 amidophosphoribosyltransferase 1 0.27 
 purD STM4175 phosphoribosylamine--glycine ligase 0.00 1.09 
 purN STM2500 phosphoribosylglycinamide formyltransferase 0.00 1.02 
 purT STM1883 phosphoribosylglycinamide formyltransferase 
2 
0.00 1.00 
 purG STM2565 phosphoribosylformylglycinamidine synthase 0.000 2.02 
 purM STM2499.S phosphoribosylformylglycinamidine cyclo-
ligase 
0.00 1.48 
 purK STM0533 N5-carboxyaminoimidazole ribonucleotide 
synthase 
0.002 0.95 
 purE STM0534 N5-carboxyaminoimidazole ribonucleotide 
mutase 
0.001 1.01 
 purC STM2487 phosphoribosylaminoimidazole-
succinocarboxamide synthase 
0.066 0.69 
 purB STM1232 adenylosuccinate lyase 0.000 0.99 
 purH STM4176 bifunctional 
phosphoribosylaminoimidazolecarboxamide 
formyltransferase/IMP cyclohydrolase 
0.00 1.77 
Biosynthesis of AMP purA STM4366 adenylosuccinate synthetase 0.000 1.46 
 purB STM1232 adenylosuccinate lyase 0.000 0.99 
 adk STM0488 adenylate kinase 0.000 1.14 
Biosynthesis of GMP guaB STM2511 inosine 5'-monophosphate dehydrogenase 0.00 2.16 
 guaA STM2510 GMP synthase 0.05 0.12 
 gmk STM3740 guanylate kinase 0.000 0.90 
Purine interconversion/ 
salvage 
guaC STM0141 GMP reductase 0.000 1.98 
 gsk STM0491 inosine-guanosine kinase 0.000 1.69 
 deoD STM4570 purine nucleoside phosphorylase 0.000 -0.92 
 rihC STM0051 ribonucleoside hydrolase RihC 1.000 0.52 
 hpt STM0170 hypoxanthine phosphoribosyltransferase 0.269 0.73 
 gpt STM0317 xanthine phosphoribosyltransferase 0.004 0.83 
 add STM1463 adenosine deaminase 0.646 0.34 
 apt STM0483 adenine phosphoribosyltransferase 0.000 -1.16 
 amn STM2009 AMP nucleosidase 0.000 -0.31 
 mtn 
(pfs) 
STM0207 5'-methylthioadenosine/S-
adenosylhomocysteine nucleosidase 
0.000 1.21 
 hisG STM2071 ATP phosphoribosyltransferase 1.000 -0.18 
Purine repressor purR STM1430 HTH-type transcriptional repressor PurR 0.000 0.92 
De novo pyrimidine 
biosynthesis 
carB STM0067 carbamoyl phosphate synthase large subunit 0.000 4.87 
 
 pyrI STM4459 aspartate carbamoyltransferase regulatory 
subunit 
0.000 4.74 
 pyrB STM4460 aspartate carbamoyltransferase catalytic 
subunit 
0.000 4.83 
 pyrL STM4461 pyrBI operon leader peptide 0.000 4.20 
 pyrC STM1163 Dihydroorotase 0.000 2.71 
 pyrD STM1058 dihydroorotate dehydrogenase 2 0.000 3.52 
 pyrE STM3733 orotate phosphoribosyltransferase 0.000 2.18 
 pyrF STM1707 orotidine 5'-phosphate decarboxylase 0.000 2.64 
 pyrH STM0218 uridylate kinase 0.000 -0.18 
Pyrimidine salvage ndk STM2526 nucleoside diphosphate kinase 0.000 2.75 
 pyrG STM2953 CTP synthetase 0.011 -0.53 
 upp STM2498 uracil phosphoribosyltransferase 0.00 1.87 
 udk STM2122 uridine kinase 0.000 1.42 
 cmk STM0980 cytidylate kinase 0.046 -0.20 
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Pathway Gene Locus in 
LT2 
Product q-val log2 FC 
Deaminases cdd STM2183 cytidine deaminase 0.000 -1.34 
 codA STM3334 cytosine deaminase 0.000 2.36 
Enzymes splitting 
glycosyl bond of 
nucleotides 
udp STM3968 uridine phosphorylase 0.234 0.01 
 rihA STM0661 pyrimidine-specific ribonucleoside hydrolase 
RihA 
1.000 0.33 
 rihC STM0051 ribonucleoside hydrolase RihC 1.000 0.52 
Pyrimidine regulator rutR 
(ycdC) 
STM1122 transcriptional repressor 0.000 -0.81 
Genes and enzymes of 
deoxyribonucleotide 
metabolism 
nrdA STM2277 ribonucleotide-diphosphate reductase subunit 
alpha 
0.000 -1.15 
 nrdB STM2278 ribonucleotide-diphosphate reductase subunit 
beta 
0.000 -1.30 
 nrdH STM2805 glutaredoxin-like protein 1.000 -2.17 
 nrdI STM2806 ribonucleotide reductase stimulatory protein 1.000 -2.00 
 nrdE STM2807 ribonucleotide-diphosphate reductase subunit 
alpha 
1.000 -0.94 
 nrdF STM2808 ribonucleotide-diphosphate reductase subunit 
beta 
1.000 0.70 
 nrdG STM4451 anaerobic ribonucleotide-triphosphate 
reductase-activating protein 
1.000 -0.53 
 nrdD STM4452 anaerobic ribonucleoside-triphosphate 
reductase 
0.000 -2.37 
 nrdR STM0415 transcriptional repressor NrdR 0.032 0.85 
 dut STM3731 deoxyuridine 5'-triphosphate 
nucleotidohydrolase 
1.000 0.60 
 dcd STM2121 deoxycytidine triphosphate deaminase 1.000 0.50 
 thyA STM3001 thymidylate synthase 0.000 -0.25 
 tdk STM1750 thymidine kinase 1.000 0.49 
 tmk STM1200 thymidylate kinase 0.000 -0.62 
 deoA STM4568 thymidine phosphorylase 0.000 -0.65 
 ybjR STM0931 aminidase 0.021 0.03 
 yjjG STM4559.S nucleotidase 0.000 1.26 
“SILENT GENES” ushA STM0494 silent protein UshA 0.002 0.85 
Pyrimidine base 
transporters 
codB STM3333 cytosine permease 0.000 3.35 
 uraA STM2497 uracil transporter 0.03 0.86 
 dctA STM3614 C4-dicarboxylate transporter 0.012 0.69 
Purine base 
transporters 
purP 
(yieG) 
STM3851.S xanthine/uracil permease 0.000 1.72 
 yicE STM3747 NCS2 family purine/xanthine transport protein 1.000 -1.05 
Nucleoside 
transporters 
nupC STM2409 NUP family nucleoside transport protein 0.003 -0.60 
 nupG STM3113 nucleoside transport 1.000 0.42 
 yegT STM2142 MFS family transport protein 1.000 -0.51 
 xapB STM2421 MFS superfamily xanthosine permease 1.000 0.00 
 nepI STM3776 purine ribonucleoside efflux pump NepI 1.000 1.14 
Outer membrane 
protein, porin 
tsx STM0413 nucleoside-specific channel-forming protein 0.000 1.47 
Proteins regulating 
Nucleoside transport 
and catabolism 
deoR STM0864 DeoR family transcriptional repressor 0.322 0.66 
 cytR STM4094 GalR/LacI family transcriptional repressor 1.000 0.42 
 crp STM3466 cAMP-activated global transcriptional 
regulator 
0.029 -0.36 
 xapR STM2420 DNA-binding transcriptional activator XapR 1.000 -0.26 
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The transcriptome results clearly suggest that the nucleotide levels in the carA mutant are 
perturbed. Thus we determined the intracellular pyrimidine nucleotide levels of planktonic 
ΔcarA cells grown in petri-dishes under the conditions of impaired biofilm formation by 
performing LC-MS/MS. Metabolites were extracted from planktonic cells at the time point 
where early biofilm formation of the wild type is initiated (~10 hours after inoculation). It was 
found that the pyrimidine nucleotide pools (CDP, CTP, UMP, UDP and UTP) in the ΔcarA 
mutant were reduced to less than three quarters of the wild type control levels (Figure 37 and 
Supp. Table 6), suggesting a possible role in the biofilm inhibition. CMP levels were found 
to be increased, which is consistent with the observation that udk transcription is upregulated. 
This could possibly be explained by the fact that CMP is not an intermediate in the de novo 
production of CTP and can be formed by metabolizing lipopolysaccharides and phospholipids, 
as well as RNA turnover (Jensen et al., 2008). However, this suggestion needs to be verified.  
Chapter 5: Mechanisms behind biofilm inhibition 
117 
 
 
Figure 37 Intracellular levels of pyrimidine and purine nucleotides of S. Typhimurium 14028 wild 
type (dark grey bars) and the pyrimidine starved ΔcarA mutant (light grey bars). The p-values of 
statistically significant differences (using an unpaired t-test with a 95% confidence interval) are 
indicated on the relevant graphs. Bars represent the means of three independent experiments and the 
error bars represent the standard deviations. 
 
In the case of the purines all nucleotide levels were markedly increased (Figure 37). More 
specifically, IMP, AMP, ADP, GMP and GDP showed a significant increase in concentration 
in ΔcarA compared to the wild type strain. ATP and GTP levels were also enhanced in the 
ΔcarA strain, but not in a statistically significant manner. Similar findings were published in 
1991 by Vogel and colleagues (Vogel et al., 1991), who observed increased ATP and GTP 
levels in the pyrimidine requiring E. coli B AS19 leu pyrB5 rel+ strain, under conditions of 
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partial pyrimidine starvation, which were induced by slow growth on orotate. This increase in 
purine nucleotides could thus be responsible for driving the increased production of c-di-GMP. 
Of note is that it was previously shown that the triphosphates, rather than the di- or 
monophosphates, are the primary nucleotides in Salmonella cells (Bochner; Ames, 1982). 
Although we reported the same here for the wild type strain, the pyrimidine starved ΔcarA 
mutant exhibits a deviation in which [AMP]>[ATP]>[ADP] and [GMP]>[GDP]>[GTP]. The 
possibility that the higher concentrations of AMP and GMP might be cause by a shortage of 
Pi in the medium is worthy of further investigation. 
Based on our observations we propose a hypothesis for the up-regulation of the pur genes (and 
the subsequent increase in purine nucleotides). It is already well established that expression of 
the pur genes (including purR itself) is negatively regulated by the transcriptional repressor 
PurR in combination with the co-repressor guanine. However, since the concentrations of 
guanine and hypoxanthine were found to be increased in the pyrimidine starved mutant (Supp. 
Table 6), reduced activation of PurR is unlikely. Also reduced transcription of purR is 
certainly not the cause since our transcriptome results do not indicate a down-regulation of 
purR (in fact there is a modest up-regulation with log2 fold change of 0.92 and a q-value 
smaller than 0.05). Other genes that would normally be repressed by PurR are also upregulated 
(Figure 38). For example, the gene cvpA (encoding an enzyme for colicin production) is up 
regulated (log2 fold change 1.56). The fact that these genes are also up regulated indicates that 
that an unidentified factor may prevent PurR and its co-repressors from binding to the 
upstream DNA and inhibiting pur gene transcription. This possibility that an unknown factor 
interferes with regulation by PurR was not pursued as part of this thesis due to time- 
constraints; however we are of the opinion that this is a very exciting topic for further research.  
In addition to the upregulation of the pur genes, the observed increase in purine nucleotides 
could be explained by elevated levels of PRPP which could drive purine nucleotide 
production. The first enzymatic step in purine biosynthesis (catalysed by Glutamine PRPP 
amidotransferase/ PurF) is subject to synergistic inhibition by AMP and GMP and feed 
forward regulation by PRPP (Jensen et al., 2008). PRPP and AMP compete for the same 
binding site and both exhibit positive cooperativity with GMP (Messenger; Zalkin, 1979; 
Muchmore et al., 1998). Thus when PRPP concentrations are high, inhibition by AMP can be 
overridden. Furthermore, increased levels of PRPP synthase (encoded by prsA) have been 
observed in a pyrimidine requiring mutant. Although the exact mechanism remains unsolved, 
it seems to involve a uridine nucleotide other than UMP (White et al., 1971; Olszowy; Switzer, 
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1972; Jensen et al., 2008). Pyrimidine mediated prsA gene regulation occurs by an increase of 
transcription from the P2 promotor (Post et al., 1993). Based on the available information we 
postulated that an increase in PRPP production, induced by a low uridine nucleotide pool in 
the pyrimidine starved ΔcarA mutant (vide supra), could be responsible for driving purine 
biosynthesis, leading to an unchecked inflation of the purine nucleotide pools. This hypothesis 
is supported by our observation that the transcription of a prsA P2 promoter GFP fusion is 
increased in the pyrimidine starved ΔcarA mutant as compared to the wild type, and that 
complementation with 70 µM uracil restores the mutant’s expression levels to the wild type 
norm (Figure 39). The RNAseq results also show an increase of prsA transcription (log2 fold 
change of 1.16, q-value < 0.05). Due to the resolution of RNAseq it is not possible to see if 
transcripts originate from the P1 or P2 promotor. Interestingly, the prsA P2 promoter is 
regulated by PurR (Choi; Zalkin, 1992). Thus if the psrA induction under pyrimidine starvation 
is caused by a reduced activity of PurR, the same mechanism would likely also affect pur gene 
transcription because they are also regulated by PurR, providing a potential link between the 
observed induction of all the genes involved. Given the above results we were curious to see  
whether exogenously applied purine pathway intermediates might have an  inhibitory effect 
on biofilm formation, however this was not the case (Supp. Figure 13).  
To summarize, our RNAseq results indicate that pyrimidine starvation causes an increase in 
purine nucleotides, including GTP, which is a substrate for c-di-GMP production. In the next 
section we will focus on the role of c-di-GMP metabolizing proteins and their gene expression 
levels.  
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Figure 38 Genes regulated by PurR are all up-regulated 
 
 
Figure 39 Normalized fluorescence of the prsA promoter in the S. Typhimurium 14028 wild type 
(grey lines) and the ΔcarA mutant (black lines). Under conditions of pyrimidine starvation there is an 
increase in prsA promotor activity in the ΔcarA mutant (left). When the concentration of extracellular 
uracil is increased to 70µM (right) prsA promotor activity in the ΔcarA mutant returns to wild type 
levels.  Stars indicate a significant difference in the slope of the two conditions between two time points 
(as determined by an unpaired t-test with a confidence interval of 95%) indicating that there is a 
significant difference in transcription from the promoters. The error bars represent the standard 
deviations between 3 technical repeats (corresponding to three wells in a multi-well plate). The 
experiment was repeated for a second time on a different day and similar profiles were obtained. 
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 Transcription of genes encoding c-di-GMP metabolizing enzymes 
When considering the individual differential expression patters of 21 c-di-GMP metabolizing 
enzymes, only 3 had notable changes in their expression (Supp. Table 6) based on the RNA 
sequencing results. The DGC adrA was downregulated, while the DCG STM1987 (gcpA) and 
the PDE STM1697 were up-regulated in the carA mutant. qRT-PCR results did not indicated 
noteworthy changes in regulation in any of the DGC or PDE encoding genes that we analysed 
(Supp. Table 7). These results are clearly not conductive to explaining the observed increase 
in the global intracellular c-di-GMP pool.  
Studies on the contribution of individual PDEs or DGCs on the global c-di-GMP pool in 
Salmonella are lacking. Indeed, very often c-di-GMP levels are not even measured, but 
changes to the global c-di-GMP pool are assumed based on phenotypic changes. 
We can only assume that the increase in c-di-GMP is not driven by changes in the number of 
DGC or PDE proteins in the cell, but rather by a change in their activity. The high levels of 
the substrate GTP available in the carA mutant, may drive the production of c-di-GMP by 
DGCs, or perhaps inhibit c-di-GMP breakdown by PDEs. The inhibition of biofilm formation 
despite high levels of c-di-GMP is an indication that other regulatory mechanisms have a 
higher priority in determining this particular phenotypic outcome. 
In the next section, we seek to clarify how biofilm inhibition is achieved, despite high levels 
of c-di-GMP.  
 Pyrimidine starvation impacts the transcription of key biofilm 
determinant csgD 
In the following paragraphs we explore the mechanisms by which pyrimidine starvation 
impairs biofilm formation. To this end we consult the upstream and downstream networks 
produced by PheNetic to find the biofilm related pathways that are affectced and identify the 
regulator mechanisms behind the effects. RNAseq results were verified with GFP-promoter 
fusions, and in some case RT-qPCR. Knockout and complementation mutants were also used 
t for further confirmation that specific genes are involved.  
 Transcription of csgD and downstream pathways are affected 
The transcriptome analysis indicated that genes involved in curli-production were strongly 
down-regulated in the carA mutant (log2 fold changes ranging between -7.0 to -3.7). Genes 
further downstream in the biofilm regulatory pathway, that are regulated by CsgD were also 
affected. These genes include the csgBAC and csgDEF operons (involved in curli production), 
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adrA (c-di-GMP synthesis for activation cellulose production by BcsA), wraB (oxidation-
reduction process) and yccJ (unknown function). The cellulose producing gene bcsA itself, 
which is not part of the CsgD transcription regulon, was not differentially regulated. Given 
that the expression of adrA and csgBAC is under direct control of CsgD (Ogasawara et al., 
2011), their down-regulation can likely be attributed to reduced transcription of csgD. The 
bcsABZC operon, on the other hand, is constitutively transcribed and does not require CsgD 
(Gualdi et al., 2008) or AdrA for transcription. BcsA-BcsB is however post-translationally 
activated by c-di-GMP produced by AdrA (Simm et al., 2004; García et al., 2004). 
Based on “the “upstream” network produced by PheNetic (Figure 40) we see that various 
regulators are implicated in changes in csgD transcription. These regulators include fliZ, crp, 
rpoS, cpxR, ompR, ihfA, fis, hilA OMRA, OMRB. Based on their log2fold values it is clear that 
the majority of regulators involved in regulating the expression patterns of csgD are not 
significantly differentially transcribed themselves. However, the gene encoding positive 
regulator RpoS is down regulated with a log2 fold value of -1.5. The fis gene, encoding a global 
regulator that represses rpoS transcription, is upregulated (log2 fold change = 1.87). Thus they 
may provide a possible mechanism explaining the down regulation of csgD proceeding via fis 
and rpoS (including effect on rsd that impacts interplay between RpoD and RpoS). 
Nevertheless, it should be kept in mind that transcriptional activators and repressors of csgD 
function in parallel to control its induction. Small non-significant effects on the transcription 
levels of the regulators coupled with post-transcriptional and post-translational effects can 
induce highly amplified effects downstream in their cascade, as is visible in the expression 
levels of csgD, the other curli genes and adrA. 
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Figure 40 Sub-network extraction from our “upstream” network showing the curli genes and adrA as 
well as their regulators. PheNetic does not indicate whether interactions are repressive or activating; 
this information was added in Cytoscape (triangular arrowhead means activation, blunt arrow indicates 
repression, round arrowhead indicates a dual function). Information on nature of interactions came 
from EcoCyc and literature (Cabeza et al., 2007). Regulators with hick black borders are those with 
log2 fold values < -1.0 or > 1. Grey arrows indicate protein DNA interactions, yellow arrows indicate 
sigma factor regulation, and green arrows indicate sRNA regulation that occurs on a post 
transcriptional level.  
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Figure 41 Pannels A to D depict the normalized fluorescence of csgD, csgB, adrA and bcsA promoter 
fusions in the S. Typhimurium 14028 wild type control (WT) (light grey line) and the S. Typhimurium 
14028 ΔcarA mutant complemented with 17.5 µM uracil (black line), showing a clear down-regulation 
in the mutant. Expression was measured over 24 hours at 25˚C. Stars indicate a significant difference 
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in gene expression (slope of the curve). Panels E to G: Addition of 70 µM uracil to the mutant (grey 
line) enhanced the expression of genes to levels similar to that of the wild type (grey dotted line), in 
the case of csgB transcription is upregulated in the mutant. The error bars represent the standard 
deviations of the technical repeats (n=3). The experiments were repeated two to four times on different 
days and showed similar patterns. 
 
Results from GFP promoter fusion studies verified the RNAseq results. When the ΔcarA 
mutant was complemented with sufficient uracil (17.5 µM) to restore planktonic growth but 
not biofilm formation, the expression of adrA, csgBAC and csgDEFG was found to be 
significantly lower than in the wild type, while bcsABZC transcription was not notably affected 
(Figure 41).  
Since a ΔcsgD mutant shows a similarly decreased level of biofilm formation as the pyrimidine 
starved ΔcarA mutant (Figure 42), these results suggest that pyrimidine limitation reduces 
biofilm formation by downregulating csgD and its regulon members. Consistently, the 
expression from the csgD fusion was restored to wild type levels when 70 µM uracil (enough 
to also restore biofilm formation) was added to the growth medium, while adrA expression 
was partially reinstated (Figure 41) and csgB expression was slightly upregulated compared 
to the wild type (Figure 41). Plasmid based expression of csgD could partially restore biofilm 
formation of a carA mutant complemented with 17.5 µM uracil. Furthermore deletion of csgD 
in the ΔcarA background caused severe inhibition of biofilm formation (Figure 42), despite 
the addition of 70µM uracil, indicating that uracil can only restore biofilm formation if 
chromosomally encoded CsgD is present, highlighting its important role. 
Adding extra uracil (17.5 and 70 µM) to the wild type strain did not affect transcription from 
the csgD, csgB, adrA or bcsA promoters (Supp. Figure 14). These results are consistent with 
the observation that exogenous uracil did not cause any changes in biofilm formation of the 
wild type strains as determined by crystal violet staining.  
It should be noted that the above time-lapse experiments were performed in multi-well plates. 
Measurements are the sum of the fluorescence originating from free-living cells in the growth 
medium and cells adherent to the surface. To make sure that the observed changes in gene 
expression were the cause of reduced biofilm formation rather than the consequence we aimed 
at measuring gene expression in the separate growth phases. Hereto, biofilm and planktonic 
samples were taken in the petri-dish setup (described above) at the 10 hour time point and 
transcription levels of the genes of interest were determined by RT-qPCR (Supp. Figure 15 
and Supp. Table 7). Although csgD, csgB and adrA were expressed in the wild type when 
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grown in the planktonic phase, their expression was, as expected, at least two times higher in 
the biofilm phase. BcsA mRNA levels on the other hand were similar in both phases. In the 
pyrimidine starved ΔcarA mutant (17.5 µM uracil), the csgD and csgB mRNA levels were 
significantly lower than in the wild type, both in the planktonic cells and the “biofilm” cells 
that were loosely associated with the surface (RQ values of 0.2 for csgD and 0.02 for csgB). 
Also, transcription of adrA was moderately reduced, with RQ values of 0.77 and 0.55 for the 
free-living and attached samples respectively, while bcsA transcription was only slightly 
affected (RQ values of 0.85 and 0.73 for free living and attached respectively). Again 
complementation with the higher, biofilm-restoring concentration of uracil (70 µM) resulted 
in a partial or complete restoration (or even induction) of csgD, csgB and adrA expression, in 
both the planktonic and biofilm phase. These results are in agreement with the results obtained 
from RNAseq and the GFP-reporter assay and indicate that pyrimidine starvation represses 
the expression patterns of genes involved in matrix production already in the planktonic phase 
and as such impairs adhesion and the switch from free-living to biofilm mode of growth. 
Moreover, this repression persists after the pyrimidine-starved bacteria encounter the surface. 
In the next sections of this chapter we will elaborate on the link between pyridine starvation, 
csgD down-regulation and biofilm inhibition. 
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Figure 42 The effects of uracil on the planktonic phase (top image) and biofilm formation (bottom 
image) of S. Typhimurium ATCC14028 wild type, ΔcarA, ΔcarAΔcsgD and ΔcsgD strains after 24 
hours, using the Calgary setup. Plasmid based expression (on pFAJ1708) of csgD in the ΔcarA 
background increases biofilm formation in the presence of 17.5 µM uracil from 15% to almost 40%. 
Furthermore, the restoration of biofilm formation (bottom image) of a ΔcarA,by 70µM uracil requires 
the presence of CsgD as deduced from the observation that a double mutant cannot make adequate 
biofilm despite uracil addition. In strains that have a sufficient supply of pyrimidines (either due to de 
novo synthesis or complementation with 70 µM uracil) and that are able to express chromosomaly 
encoded csgD, the presence of csgD on a plasmid has a negative effect on biofilm formation.  3 to 10 
biological repeats were used and were divided into 3 technical repeats each. Experiments were 
conducted on 2 different days. Error bars represent the standard deviations.  
 
 Attempt to link perturbations in intracellular nucleotide levels to changes in 
csgD expression and biofilm formation via fis and rpoS  
Based on the RNAseq results, combined with measurements of intracellular nucleotides we 
propose that a regulatory mechanism involving PRPP, PrsA and PurR is responsible for the 
increase in purine nucleotides, as described earlier in this chapter. The increase in GTP, which 
is the substrate for c-di-GMP production, may be a possible cause for the increase in 
intracellular concentration of this signaling molecule. However, the mechanisms by which 
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csgD transcription is repressed despite high c-di-GMP concentrations were not yet revealed, 
and we aim to do so in this section. 
Various regulatory pathways act on the regulation of csgD expression. Although many known 
regulators did not display significant changes in their expression levels, some possible 
pathways by which they could impact curli-production were identified by PheNetic. One 
pathway that did show changes in the expression levels of the regulators proceeded via Fis and 
RpoS. The mRNA levels of Fis are known to be under the control of nucleotide availability. 
This could provide a link between the nucleotide starvation that the carA mutant is subjected 
to, and the subsequent defect in curli production. The gene encoding positive regulator RpoS 
is down regulated with a log2 fold value of -1.5. The fis gene encoding a global regulator that 
represses rpoS transcription is upregulated (log2 fold change = 1.87).  
Expression of fis in E. coli is controlled at the transcriptional level in accordance with nutrient 
availability. Normally it is highly expressed during early logarithmic phase (when cells are 
grown in rich medium it is the most abundant protein in the cell) but it is poorly expressed in 
late logarithmic phase and stationary phase (Ball et al., 1992; Walker; Osuna, 2002). A single 
promotor (conserved between E. coli and Salmonella) is responsible for the expression of the 
dusB-fis operon and expression regulation Salmonella is similar to that in E. coli (Osuna et al., 
1995). As is typical for a gene involved in the modulation of many cellular processes, Fis is 
regulated at different levels and by several systems. At the transcription level, Fis is 
negatively-autoregulated, positively controlled by IHF and also regulated by both growth rate-
dependent (only indirect evidence) and stringent control systems (negative regulation by 
ppGpp(p)). A very interesting mechanism of growth-phase dependent transcriptional 
regulation relies upon the availability of the nucleotide triphosphate CTP, which is the 
nucleotide with which transcription of fis is initiated and whose largest concentration is seen 
during log phase, a fact that correlates with the pattern of fis expression. Walker and colleagues 
made the following very interesting observation: in a E. coli strain that has a mutation in its 
pyrimidine biosynthesis pathway, which leads to an excess of purines and  a lack of CTP and 
UTP (similar to what we see in the carA mutant) transcription is not initiated by CTP at 
position +1C anymore ( in other literature indicated as 8C, based on its position, 8bp relative 
to the -10 box). Instead, GTP is used at an otherwise unfavourable position -2G (also 
sometimes referred to as 6G). In such abnormal conditions, transcription of fis is upregulated 
despite a reduced growth rate (Walker, Osuna 2002, Walker, Mallik et al. 2004). Walker and 
colleagues postulated that the switch from +1C to -2G can be attributed to the following 
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combined effects: (a) An increment in the GTP/CTP ratio which favors the kinetics of 
initiation at -2G over + 1C and (b) a decrease in UTP pools which tends to hinder the kinetics 
of the first phosphodiester bond formation with +1C and possibly lower the efficiency with 
which initiation form +1C results in productive transcripts. A similar mechanism has been 
suggested for rrnB P1, see review (Turnbough 2008). Another mechanism of fis upregulation, 
that was not predicted by PheNetic, could involve DksA. DksA, which is a protein that is 
associated with RNA polymerase in regulating transcription, inhibits transcription of fis by 
increasing the inhibitory effects of ppGpp, decreasing the lifetime of the RNA polymerase-fis 
promoter complex, and increasing the sensitivity to the CTP nucleotide concentration (Mallik, 
Paul et al. 2006). In the carA mutant dksA is downregulated (log2 fold change -1.25). Given 
that our carA mutant has an increase in purine nucleotides and a lack of pyrimidine 
nucleotides, it might be the case that the transcription start site differs between the carA and 
the wild type strain.  
Thus we propose the following: Fis levels in the cytoplasm are increased, because high purine 
levels combined with low pyrimidine levels favours transcription form -2G. Fis represses 
transcription of rpoS.  Due to lower intracellular RpoS levels, csgD transcription is reduced. 
In an attempt to verify this hypothesis we collaborated with the group of professor N. Buys 
where they performed primer extension analysis to determine the fragment sizes of the 5’-
UTR region of the dusB-fis operon. We expected to see a larger fragment for the pyrimidine 
starved ΔcarA strain (2bp longer than the wild-type fragment or the fragment from ΔcarA with 
70µM uracil). Initial results were promising and the fragments did indeed differ with ~2 bp in 
length when comparing pyrimidine starved with pyrimidine sufficient conditions (wild type 
or mutant with 70uM uracil). Peak locations were: wild type (124.36bp), ΔcarA + 17.5 µM 
uracil (122.98 bp), ΔcarA + 70 µM uracil (123.65 bp). However, it appeared that the dusB 
gene and promotor region contained a deletion of about 40bp, because the fragments were 
shorter than expected by this number of nucleotides. However, during a second attempt (using 
the same primer), longer fragments were detected. Peaks were found at: wild type (163.63 bp), 
ΔcarA + 17.5 µM uracil (160.74 bp), ΔcarA + 70 µM uracil (no peak, however the negative 
control  sample had a peak at 162.42 bp indicating that they might have been swapped) We 
performed a PCR on genomic DNA from  the wild type and mutant strains, and loaded the 
samples on a gel. We found two fragments in each strain, which differed about 50bp from each 
other (Supp. Figure 16). BLAST searches against the ATCC14028 reference genome 
(NC_016856) revealed that both fragment sets matched the same region in the genome and no 
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other region, suggesting that a this section of the genome was duplicated (which is not present 
in the reference genome assembly). Due to this complication and time-constraints we did not 
pursue the primer extension analysis any further, however we believe that it is worthy of 
further investigation . In the next subsections we discuss other processes that are also affected 
by pyrimidine starvation and their possible links to biofilm formation. 
 Other processes that are affected by pyrimidine starvation and their 
possible links to biofilm formation 
Aside from effect on nucleotide biosynthesis and curli production, multiple other processes 
were also differentially regulated in response to pyrimidine starvation, as can be expected 
given that various global regulators were affected. Some of these processes are discussed 
below: 
 Motility genes are affected in the pyrimidine starved state 
Motility and biofilm formation are often inversely regulated (Pesavento et al., 2008), however 
motility has also been shown to be a requirement for surface attachment. (Guttenplan; Kearns, 
2013). The chemotactic sensory machinery, together with the motor complex and flagellum 
endows bacteria with the capacity to move up and down chemical gradients. The absence of 
different che genes has been shown to affect the rotational bias of the flagella locking it either 
in a mode that favors “smooth swimming” or “tumbling”(Kuo; Koshland, 1989; Conley et al., 
1989).  
Our transcriptome results show that chemotactic genes cheM, cheR, cheY, cheB, cheA, cheW, 
cheV are down regulated in the ΔcarA strain. Their log2 fold changes are between -2.43 and -
1.45. The motor complex gene motA, flagellar genes flgK and fliC have log2fold changes of -
2.5, -1.94 and -3.28 respectively. The transcription results suggest that the pyrimidine starved 
mutant has defective chemotaxis sensory transduction which would impact its capability to 
recognize and respond to concentration gradients of attractants or repellents in its extracellular 
environment. In addition, some of the structural components of the motor and flagellum are 
inhibited as well, suggesting impaired motility. However, the results from our swimming 
assays showed that the mutant is able to swim (Supp. Figure 17); in fact, its diameter on the 
swimming plate is larger than that of the wild type, so the exact way in which motility is 
affected is not clear. It is possible that factors such as adaptation time and tumbling frequency 
are affected in a manner that still allows the bacteria to swim, but this has to be confirmed with 
three-dimensional tracking. 
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 Translation machinery is affected during pyrimidine starvation 
A comprehensive study on global gene expression in E. coli biofilms conducted by Schembi 
and colleagues (2003) found a significant increase in the transcription of ribosomal protein 
genes when comparing biofilm cells to free living cells in the stationary phase (Schembri et 
al., 2003). Increases in ribosomal proteins in biofilms produced by other bacteria have also 
been identified, suggesting that it is a conserved response of bacterial cells to biofilm 
formation (Whiteley, 2001; Southey-Pillig et al., 2005).  
In our dataset a cluster of ribosomal subunit protein(r-protein) genes are downregulated (log2 
fold changes between -2.8 to – 1.7) in the pyrimidine starved mutant. The majority of the 
downregulated r-protein genes belong to the same operon (rspJ, rplC, rplD, rplW, rplB, rpsS, 
rplV,rpsC, rplP, rpmC and rpsQ), which is predicted to be transcriptionally activated by FNR 
and inhibited by DksA-ppGpp and ArcA-pasp54. The downregulation of r-protein genes can be 
interpreted in the following ways. (i) There is a reduction in the growth rate. (ii) There is a 
reduction in protein synthesis. (iii) Ribosome synthesis is halted due to limiting aminoacyl 
tRNA (amino acid starvation). Since the growth medium contains amino acids and since 
planktonic growth was not affected, the first and third explanations are unlikely under our 
experimental conditions. Thus, the downregulation of translation machinery is possibly due to 
reduced protein synthesis in the carA mutant, compared to the wild type, which is synthesizing 
extra proteins that are required for making biofilms.  
 Iron-sulfur metabolism 
Iron/sulfur centers are key cofactors of proteins intervening in multiple conserved cellular 
processes, such as gene expression, DNA repair, RNA modification, central metabolism and 
respiration (Py; Barras, 2010). The expression of the suf operon has been shown to be induced 
by oxidative stress (Yeo et al., 2006; Lee et al., 2008). In bacteria such as E. coli, where both 
Isc and Suf systems are present, it is thought that Isc system plays a primary role to assemble 
Fe-S cluster whereas the Suf system serves as a back-up and/or a specified system adapted to 
pro-oxidative and iron-depleted conditions. 
It has been reported that changes in Fe/S homeostasis influenced mucoidity, motility  and 
biofilm formation in E. coli and Thermotoga maritima (Beloin et al., 2004; Pysz et al., 2004; 
Giel et al., 2006; Trotter et al., 2009; Wu; Outten, 2009), however the link between Fe/S 
homeostasis and cell surface properties is yet to be unraveled. 
Chapter 5: Mechanisms behind biofilm inhibition 
132 
 
Genes sufA, sufB, sufC,sufD, sufS and ynhA(sufE) from the iron-sulfur cluster assembly group 
(GO:0016266) are all downregulated in the pyrimidine starved strain (log2 fold values of -1.5 
to -2.00).This cluster is positively regulated by OxyR, IHF and IscR (YfhP) and is negatively 
regulated by NsrR and Fur. It is unclear whether these changes are a cause or a consequence 
of impaired biofilm capabilities. 
 Arginine metabolic genes 
Our gene expression results indicate that a gene (artJ) with a role in L-argenine uptake is 
upregulated (Table 10). Furthermore out of the 8 genes involved in argenine biosynthesis, 3 
(argI, argC and argA) are significantly upregulated and 1 (argE) is significantly 
downregulated (ArgR and the co-repressor arginine regulate all of these genes). 
The gene artJ encodes the periplasmic binding protein of an L-argenine ABC transporter. 
Previous work by others showed that overexpression of artJ from a plasmid stimulated 
arginine uptake (Wissenbach et al., 1995). The observation that this gene is upregulated in the 
carA mutant, is not unexpected, because the mutant has an increased reliance on extracellular 
arginine compared to the wild type. Nevertheless, it is unlikely that the requirement for 
exogenous arginine affects biofilm formation, which we verified later (Supp. Figure 18). The 
addition of various concentrations of arginine did not improve the ΔcarA mutant’s ability to 
make biofilm indicating that its ability to make biofilm depends mostly on uracil and not so 
much on arginine. Although changes in the expression of some of the arginine biosynthesis 
genes is a clear indication that the mutant cells are attempting to replenish their arginine 
supplies it appears that this does not affect biofilm formation because addition of arginine to 
the carA mutant does not increase its ability to form biofilm, however addition of uracil does. 
Furthermore, a pyrB deletion mutant (which is only impaired in pyrimidine biosynthesis but 
not arginine biosynthesis) also has a biofilm defect and csgD, csgB and adrA down-regulation 
(Supp. Figure 19).  
 Other processes 
From the downstream network it was possible to see that genes involved lipid-A biosynthesis 
(lpxB and lpxA) and lipopolysaccharide biosynthesis (rfbG, rfbJ, rfbI, rfbJ) were down 
regulated (log2 fold changes  -2.56 and -1/35). Lipopolysaccharides make up an important 
component of the outer membrane and the biofilm matrix and the downregulation of these 
genes may thus also contribute to lower biofilm formation, or it could be an effect of less 
biofilm formation. 
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Table 10 Genes involved in arginine biosynthesis and uptake 
Role Gene Locus q-val log2 fold change 
Biosynthesis of arginine argD STM1303 0.05 0.32 
 argA STM2992 0.00 1.55 
 argR STM3360 0.66 0.60 
 argE STM4120 0.00 -1.36 
 argC STM4121 0.00 1.53 
 argB STM4122 1.00 0.31 
 argH STM4123 0.00 -0.54 
 argI STM4469 0.00 2.70 
Arginine uptake artJ STM0887 0.00 1.82 
 artM STM0888 0.00 -0.96 
 artQ STM0889 0.00 -0.50 
 artI STM0890 0.52 0.06 
 artP STM0891 0.00 -0.02 
 
 The PhoBR two-component pathway 
We see that PhoB is upregulated (log2 fold change of 1.93) in the pyrimidine starved mutant. 
Studies on E. coli, P. fluorescens, Pseudomonas aureofaciens, and V. cholera reported that 
PhoB activation inhibits biofilm formation (Pratt et al., 2009; Grillo-Puertas et al., 2016).  
The two-component system PhoBR regulates the response to extracellular Pi concentrations. 
Furthermore the Pho regulon also plays an important adaptive role in bacterial stress response 
and virulence (Lamarche et al., 2008; Marzan; Shimizu, 2011). A recent publication Grillo-
Puertas and colleagues (2016) showed that PhoB activation by inorganic polyphosphate 
(polyP) in non-limiting phosphate conditions inhibits E. coli biofilm formation. Their key 
findings were: (i) The wild type strain makes biofilm under conditions where extracellular Pi 
was low or sufficient, but not under high extracellular Pi conditions (high Pi inhibits biofilm 
formation). (ii) PhoB suppresses biofilm formation under high Pi conditions, but not under Pi 
sufficient or low Pi conditions. (iii) When polyP degradation is inhibited, biofilm formation is 
also inhibited under all extracellular Pi conditions (in other words, polyP degradation is a 
requirement form biofilm formation). (iv) In the absence of PhoB, polyP degradation is no 
longer a requirement for biofilm formation and biofilm can be made even under high 
extracellular Pi concentrations. Based on these findings they concluded that activation of PhoB 
(and biofilm inhibition) is linked to the maintenance of polyP levels under conditions where 
extracellular Pi is high. Although they did not report a mechanism they hypothesized that polyP 
level fluctuations control the intracellular Pi levels. And also that an intracellular Pi deficiency 
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could be generated when polyP was maintained or not degraded during the stationary phase, 
with consequent PhoB activation (Grillo-Puertas et al., 2016). Our transcription results 
indicated an upregulation of PhoB (log2 fold change 1.92). It would be interesting to further 
investigate the possible role of PhoB in regulating Salmonella biofilm formation. 
 Genes with unknown roles in biofilm formation 
Among the genes that are the most highly up/down regulated in the pyrimidine starved mutant 
are a few genes for wich very little is known about their functions.Two such genes are yciE 
and yciF which are members of the RpoS regulon (Ibanez-Ruiz et al., 2000). Their 
transcription is activated by YncC (Beraud et al., 2010). In E. coli they are induced under 
osmotic stress imposed by NaCl in both anaerobic and aerobic comditions (reference webber). 
In Salmonella, yciF is induced by bile in a manner independent of RpoS (Prouty et al., 2004). 
Transcription is repressed by H-NS (Yoshida et al., 1993). The amino acid sequences of these 
genes are conserved between Salmonella and E. coli (86% identity for both genes). According 
to our transcriptome results, expression of yciE and yciF is repressed in the ΔcarA strain (log2 
fold changes -5.38 and -4.62). The gene yncC is downregulated (log2 fold change -1.13). This 
gene encodes a putative regulator that is part of the RpoS sigmulon (Beraud et al., 2010).The 
gene ymdF is also a target of YncC regulation and is also not well characterized. It has been 
shown to have a role in resistance to oxidative stress in Klebsielle pneumoniae (Tu et al., 
2009). In our mutant strain ymdF is down-regulated (log2 fold change -3) 
 Anti-sense transcription 
Among the most highly differentially expressed regions are anti-sense to coding sequences. 
The prevalence of antisense transcription has been noted by others, and it is believed that this 
provides another layer in regulatory networks by controlling gene expression (Sallet et al., 
2013; Brophy & Voigt, 2016). The interaction network that we used as input for PheNetic did 
not contain any antisense interactions. However, as more information on this phenomena 
becomes available, it can also be included into the interaction network.  
5.4 Conclusion 
In the previous chapter, we showed that pyrimidine starvation is associated with reduced 
biofilm formation in spite of increased levels of c-di-GMP. Here we used a network based 
approach to analyse transcriptome data in order  to gain more insight into how c-di-GMP levels 
are upregulated, biofilm formation is down-regulated and what the other effects of pyrimidine 
starvation are on homeostasis. 
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We found that pyrimidine starvation affects various global regulators, and processes under 
their control including: nucleotide metabolism, curli biosynthesis, iron-sulfer metabolism, 
translation and motility. 
We provided evidence that the increase in c-di-GMP pool size might in part be explained by 
an inflation of the purine nucleotide pools brought about by the upregulated transcription of 
genes involved in the de novo synthesis of purines as well as a possible increase in the PRPP 
pool due to upregulated transcription of prsA. Both of the latter effects might potentially be 
mediated by a repression of the PurR activity under conditions of low uridine nucleotide levels 
by a yet unknown mechanism (Figure 43). Finally, we proposed a mechanism for linking 
changes in the intracellular nucleotide pools to transcriptional effects on fis which in turn 
affects rpoS and csgD expression ultimately impacting the initiation of biofilm formation 
(Figure 43). The verification of these mechanisms, specifically the part involving fis 
transcription, was beyond the scope of this PhD and we hope that it can be pursued in a follow-
up project.  
 
Figure 43.Scheme showing the effect of pyrimidine starvation on the various components involved 
in nucleotide metabolism, biofilm formation and virulence. Components which are downregulated are 
indicated in green while those that are upregulated are shown in red. Genes are indicated in italic with 
colored arrows under the gene names. Proteins are indicated in grey circles. Intermediates and/ or 
derivatives of the pyrimidine pathway are enclosed by a green square, and those of the purine pathway 
are enclosed by a red square. Lines with arrows indicate an activation, while lines with round ends 
indicate inhibition. Solid lines indicate links with a known mechanism. Dashed lines indicate links 
with unknown regulatory mechanisms (yellow dashed lines are of particular interest). Dotted lines 
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indicate putative links. The global pool of c-di-GMP (red ovals) is increased under conditions of 
pyrimidine starvation. The lightning bolt indicates that the effect of high intracellular levels of c-di-
GMP on CsgD expression under pyrimidine starved conditions is unclear. Relevant literature: (Vogel 
et al., 1991)a, (Olszowy; Switzer, 1972)b and (Jensen et al., 2008)c. 
 
5.5 Materials and Methods 
 Bacterial strains and growth conditions 
Bacterial strains and plasmids used in this study are listed Chapter 4. Prior to experiments 
strains were stored at -80˚C and inoculated onto Lysogeny broth (LB) agar plates, containing 
the relevant antibiotics if needed. Once inoculated, LB agar plates were incubated at 37˚C 
overnight, and subsequently stored at 4˚C. Single colonies were used to inoculate liquid LB 
cultures (containing antibiotics if needed), and were incubated overnight at 37˚C with shaking. 
Antibiotics used were ampicillin (100 µg/ml) and kanamycin (50 µg/ml). Antibiotics and uracil 
were obtained from Sigma. Biofilm formation and reporter fusion assays were performed 
using 1:20 diluted tryptic soy broth (TSB) from Becton Dikinson.  
 Construction of deletion and complementation mutants 
Plasmids used are listed in Chapter 4. A complementation plasmid was constructed by cloning 
the PCR amplified csgD coding sequence, as XbaI/BamHI fragment downstream of the 
constitutive nptII promoter into the RK2-based plasmid pFAJ1708 (Dombrecht et al., 2001). 
This plasmid is stably inherited even in the absence of antibiotic selection due to the presence 
of a toxin anti-toxin system. For each complementation construct ~50 nt upstream and 
downstream the ORF were included. Cloning steps were performed using E. coli TOP10F’. 
All plasmids were verified by PCR and sequencing analysis. 
 Temporal quantification of gene transcription with plasmid based 
GFP fusions 
To obtain a comprehensive picture of the gene expression dynamics, caused by an excess or a 
shortage of uracil, we made use of an in-house collection of GFP fusions to promoters of genes 
that are important in biofilm formation (Robijns et al., 2014). Three sets of comparisons were 
done: (i) S. Typhimurium 14028 wild type without added uracil vs wild type with 70 µM uracil 
(excess uracil), (ii) wild type without uracil vs ΔcarA with 17.5 µM uracil (enough to restore 
planktonic growth but not biofilm formation) and  (iii) wild type without uracil vs ΔcarA with 
70 µM uracil (enough to restore biofilm formation).  
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Overnight cultures of the S. Typhimurium 1402m8 wild type and ΔcarA strains, containing 
reporter fusion plasmids, were grown in LB medium with ampicillin100 at 37˚C whilst shaking. 
2 µl overnight culture of each reporter fusion was transferred in triplicate (i.e. 3 wells per 
reporter fusion) to black polystyrene 96-well plates (Greiner bio-one 655096) containing 200 
µl TSB 1/20 per well (with uracil if needed). Ampicillin was omitted to minimize effects on 
gene transcription; the omission of antibiotics did not negatively impact plasmid maintenance 
during the timeframe of the experiments (the expression of GFP from a constitutive promotor 
was assayed in the presence and absence of ampicillin, see Supplemental Figure 20). The 
multi-well plates were incubated at 25˚C with shaking. A Synergy MX multimode reader was 
used to measure absorbance and fluorescence at regular intervals over a course of 18, 24 or 48 
hours. Absorbance was measured using a wavelength of 600 nm, followed directly by 
fluorescence measurement with excitation at 488 nm and emission at 511 nm. 
Time-dependent changes in transcription profiles were obtained from the OD and fluorescence 
values as described (Robijns et al., 2014) using a custom Microsoft Office Excel template and 
GraphPad Prism. In short, the effects of growth rate on the accumulation of fluorescence were 
normalized and first derivatives were determined in order to give a measure of gene expression 
at each time point. Significant differences in the first derivative of the control vs the test 
condition were calculated using a two-tailed heteroscedastic t-test with a significance level of 
0.05. 
 Metabolite extraction and mass spectrometry analysis 
Prior to metabolite extraction, the optical densities of overnight cultures were determined as 
described above and normalized to an OD595 of 1.5 by suspension of pelleted cells in the 
appropriate volume of TSB1/20. Petri-dishes containing 20 ml TSB1/20 (with the appropriate 
amounts of uracil added) were inoculated with 200 µl overnight culture. Petri-dishes were 
incubated statically at 25˚C for 8 to 10 hours before cells were harvested by pouring off the 
liquid growth medium (containing the free-living planktonic cells). This time point was 
selected because it corresponds to the time when S. Typhimurium enters late exponential phase 
and switches from a planktonic lifestyle to early biofilm formation. A 15 ml fraction of the 
harvested planktonic cells was used for metabolite extraction. The remaining 5 ml fraction 
was used for determining culture optical density, colony forming units and protein content by 
bicinchoninic acid (BCA) assay. When applicable, cells attached to the bottom of the plate 
(biofilm cells) were harvested by adding 10 ml TSB 1/20 to the petri-dish, scraping the biofilm 
off the plate and dispersing the clumps by passing them through a needle as described before. 
Chapter 5: Mechanisms behind biofilm inhibition 
138 
 
The harvested biofilm cells were divided into two aliquots of 5 ml, which were subsequently 
used for metabolite extraction, colony forming unit determination and protein quantification 
by BCA assay.  
The extraction solution contained HPLC grade acetonitrile, methanol and water in a 2:2:1 
volume ratio as well as 0.1 M formic acid. Final extracts were evaporated with Speed-Vac. 
Prior to mass spectrometric analysis, residues were dissolved in 200 µL H2O. 
The concentrations of nucleotides were determined with LC-MS/MS. Briefly, a Hypercarb 30 
x 4.6 mm 5 µm column (ThermoFisher) protected by a 2 µm column saver (Supelco 
Analytical) and a C18 security guard (Phenomenex) was applied. Eluent A was 10 mM 
ammonium acetate in HPLC-gradient grade water adjusted to pH 10.0 with ammonium 
hydroxide. Eluent B was acetonitrile. A linear gradient from 4% B (v,v) up to 60% B (v,v) 
over 8 min was applied, followed by an equilibration phase of further 4 min at 4% B (v,v). 
The injection volume was 20 µl per sample and the flow rate was constantly held at 0.6 ml/min. 
Specific mass transitions (UDP and UTP in negative ionization mode, all other analytes in 
positive ionization mode) were recorded by a tandem mass spectrometer (5500QTRAP, 
ABSCIEX). All experiments were conducted in triplicate starting from biologically 
independent overnight cultures. Data were processed with Microsoft Office Excel 2013 and 
GraphPad Prism 6. 
Concentrations of metabolites were normalized according to optical density.  
 Experimental setup for RNA extraction 
Overnight cultures of S. Typhimurium ATCC14028 wild type and ΔcarA were normalized to 
similar optical densities (OD600  of 1.5) and re-suspended in TSB 1/20. Petri-dishes, containing 
20 ml TSB 1/20, were inoculated with bacteria to a final dilution of 1/200. Inoculated petri-
dishes were put into a 25ºC incubator for approximately 10 hours. After incubation the 
planktonic fractions were poured off, their optical densities (OD600) were recorded and the 
samples were prepared for RNA extraction. The amount of biofilm at the bottom of the plates 
was coloured with Crystal Voilet, carefully rinsed with water to remove unattached bacteria, 
and de-stained with 30% acetic acid. The optical densities (OD570) of the liquid was measured 
to get an indication of the amount of biofilm at the bottom of each plate. Four biological repeats 
were used for each strain. 
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 RNA extraction 
In the petri-dish biofilm assay, bacteria were harvested from both the planktonic 10h 
incubation. Samples of 20 ml were taken from the liquid, planktonic fraction, added to 2.5 ml 
icecold phenol/EtOH (5%/95%) solution and flash frozen in liquid N2.  
Prior to RNA purification, samples were thawed on ice and centrifuged. Cell pellets were 
treated with 5 mg lysozyme (from chicken egg white, 40000 u/mg, Sigma Aldrich). RNA was 
purified with a Promega SV Total RNA Isolation kit according to the manufacturer’s 
instructions, except for the on-column DNase treatment, which was omitted. DNA remainders 
were removed using the Ambion Turbo DNA-freeTM kit. The absence of DNA was verified 
with PCR amplification, where RNA is unable to amplify, with taq polymerase (NEB). RNA 
was concentrated and purified by adding 1/10 volume NaOAc (3M, pH 5.2) and 2.5 volume 
isopropanol. After 20 minutes precipitation at -80°C and centrifugation, pellets were washed 
with one volume of EtOH, centrifugated and air-dried. The quality and concentration of RNA 
samples were verified with a NanodropTM 1000 Spectrometer (Thermo Scientific) and via 
capillary gel electrophoreses (Experion Automated Electrophoresis station & Experion 
RNAStdSens Analysis chips, both from Bio-Rad). 
 RNA sequencing 
Total RNA samples were sent to BGI (Hong Kong) for sequencing. According to the BGI 
project report, rRNA was removed with a kit (manufacturer information was not provided by 
the sequencing facility). Fragmentation buffer was added for interrupting mRNA to short 
fragments. Taking these short fragments as templates, random hexamer-primer were used to 
synthesize the first-strand cDNA. The second-strand cDNA was synthesized using buffer, 
dATPs, dGTPs, dCTPs, dUTPs, RNase H and DNA polymerase I respectively after removing 
dNTPs. Short fragments were purified with a QiaQuick PCR extraction kit and resolved with 
EB buffer for end reparation and adding poly (A). After that, the short fragments were 
connected with sequencing adapters. Then, the UNG enzyme was used to degrade the second-
strand cDNA, and the product was purified by MiniElute PCR Purification Kit before PCR 
amplification. The TruSeq RNA-seq libraries, of about 160 bp short-inserts were sequenced 
in 101bp paired-end fashion, on the same lane, using an Illumina HiSeq4000 platform. The 
sequencing images were translated into text-based sequencing data via base calling software 
as FASTQ documents. Data processing performed by BGI included removing adaptor 
contamination and low-quality reads from raw read.  
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 Transcriptome assembly and analysis 
The Rockhopper package was used to assemble clean reads and quantify gene expression. The 
algorithms used by Rockhopper (McClure et al., 2013) have been developed specifically for 
analysis of bacterial transcriptome data and support various stages of bacterial RNA-seq data 
analysis, including aligning sequencing reads to a genome, constructing transcriptome maps, 
quantifying transcript abundance, testing for differential gene expression, determining operon 
structures and visualizing results. 
The log2 fold changes in gene expression of the test condition versus the control condition 
were calculated with the formula log2(
1+𝑡𝑒𝑠𝑡
1+𝑐𝑜𝑛𝑡𝑟𝑜𝑙
). A list of gene names, the q-values calculated 
by Rockhopper and the log fold changes were used as input for PheNetic. The predicted genes 
were removed from the list and kept separately for future analysis (might be useful for gene 
prediction in unannotated regions of the genome).  
 Network based- analysis 
A physical interaction network for Salmonella enterica LT2, compiled from publicly available 
interaction data, was downloaded from the PheNetic website.  
Protein-protein interactions from E. coli were obtained from Peregrin-Alvarez and colleagues 
(Peregrín-Alvarez et al., 2009), whereas regulatory interactions came from RegulonDB 
(Salgado et al., 2012). E. coli data was converted to Salmonella using orthology mapping 
(Altenhoff et al., 2011). Also included in the network are Salmonella metabolic interactions 
described by the KEGG interaction database (Kanehisa; Goto, 2000).  Furthermore, 
information on interactions obtained with text mining, as identified by EVEX, (Hakala et al., 
2015) and small molecule interactions derived from the literature, reviewed by Robijns (2013), 
are also included in the network. The complete network consists of 2699 genes/gene products 
linked by 15709 interactions. This interaction network, as well as the list containing gene 
expression data were used as input for PheNetic’s “upstream” and “downstream” analysis 
algorithms. PheNetic extracts the sub-network that best explains genes prioritized through a 
molecular profiling experiment. Depending on its run mode, PheNetic searches either for the 
pathways (in)activated in the molecular phenotype (downstream analysis) or for a regulatory 
mechanism that explains the observed molecular phenotype (upstream analysis)(DeMaeyer et 
al., 2013; DeMaeyer et al., 2015). Phenetic can be accessed at http://bioinformatics.intec.uge
nt.be/phenetic2/#/home. 
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The parameter settings were as follows: q-value cut-off: 0.05 (default setting) ,log2 fold cut-
off of 1.5. The number of genes in list (determined by q-value and log2fold cut-offs) was 427. 
Path length: 4 (default setting based on results from original PheNetic publication). k-best 
paths: 50 (maximum search space allowed by PheNetic). Resulting network size: 220. 
Resulting networks were downloaded and viewed in Cytoscape (Shannon et al., 2003). 
 Primer extension analysis 
In order to determine the transcription start site of fis in the wild type and ΔcarA mutant under 
various conditions, RNA was extracted as described before. cDNA was synthesized using a 
kit as described before, however a fluorescenty labelled primer that specifically binds near the 
5’ end of the dusB-fis operon was used to amplify the 5’-UTR. The resulting fragments were 
analysed with an ABI 3001 sequencer. The regulatory region in front of the operon was 
verified with Sanger sequencing. 
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Chapter 6 
6 Prevention of Salmonella biofilm formation by 5-FU 
6.1 Abstract 
In this chapter we demonstrate that 5-FU can inhibit Salmonella biofilm formation at 
concentrations that are low enough not to impact planktonic growth. The production of curli 
fimbriae is strongly inhibited by 5-FU, which is a very likely explanation for the observed 
biofilm inhibition. Higher concentrations of 5-FU can dramatically inhibit planktonic growth 
as well. Biofilm inhibition appears to occur via down-regulation of curli production.  
6.2 Introduction 
As exemplified in the previous two chapters and by others, intact nucleotide biosynthesis plays 
an important role in biofilm formation (Attila et al., 2009; Ueda et al., 2009; Garavaglia et al., 
2012), and therefore drugs that disrupt nucleotide metabolic processes can potentially be 
useful as biofilm inhibitors.  
Nucleoside and nucleotide analog (pro-)drugs can enter the cell by way of similar mechanisms 
used for the salvage of their natural counterparts. One of the ways in which nucleotide analog 
drugs interfere with normal cellular processes is by causing imbalances in the NTP pools 
(Ingraham et al., 1982; Weigel et al., 1999; Wyatt; Wilson, 2009).  
As mentioned in Chapter 3 the potential of using these drugs to inhibit bacterial growth, 
biofilm formation and virulence has been the subject of recent review (Soo et al., 2016; Yssel 
et al., 2017). Out of the various available FDA approved nucleoside and nucleobase analog 
drugs, the antibiofilm properties of 5-FU has been the subject of the most thorough 
investigation. Nevertheless, the mechanism by which 5-FU inhibits biofilm formation is not 
well understood, and the only detailed investigation into its mode of action comes from whole 
transcriptome analysis in E. coli (Attila, Ueda et al. 2009). In E. coli 5-FU acts on biofilm 
formation through AriR as demonstrated by the observation that a ΔariR mutant is not 
sensitive to the inhibitory effects 5-FU. To our knowledge the effects of 5-FU on Salmonella 
biofilm formation have, however,  not been tested before. AriR is not present in the S. 
Typhimurium genome, it is not known whether and how this affect the activity of 5-FU on 
Salmonella biofilm formation. In the following sections we hope to shed more light onto the 
effects of 5-FU against Salmonella biofilms. 
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6.3 Results 
 5-FU inhibits Salmonella biofilm formation  
5-FU uracil inhibits Salmonella planktonic growth and biofilm formation in a concentration 
dependent manner (Figure 44). The IC50 and BIC50 values were respectively 2.00 and 0.75 
µM. We found that the addition of 1.25 µM 5-FU to the TSB 1/20 growth medium reduced 
biofilm formation to 7% of untreated levels while planktonic growth remained at 81% of wild 
type untreated levels. 
 Differential gene expression in Salmonella in response to 5-FU 
treatment 
To explore the mechanism by which 5-FU represses Salmonella’s ability to form biofilm, a 
GFP-promotor fusion library was used to analyze changes in the transcriptional profiles of 131 
genes over a period of 18 hours. 12 genes showed differential regulation between treated and 
untreated samples at 3 or more time-points over the 18 hour period (Figure 45). 
Genes involved in putrescine transport (potF) and cellular response to DNA damage (asnA) 
were downregulated in the first 9 hours and upregulated thereafter. Genes that were repressed 
by 5-FU are: csgD and csgB (curli formation), adrA (c-di-GMP production for activation of 
cellulose synthesis), yciG (flagellum-dependent swarming), nark (nitrate transport), virK 
(virulence), aroQ (amino acid biosynthesis) and ybeL (unknown functions).  
Genes that were induced by 5-FU are: carA (pyrimidine biosynthesis), hisG (histidine 
biosynthesis), tig (protein folding) and cysJ (sulfite reduction). Although the CysJ protein has 
been identified as the NADPH:flavin oxidoreductase component of the CysJI sulfite reductase 
complex, it has been shown that CysJ functions together with YcbX to detoxify mutagenic 
base analogs (Kozmin et al., 2010), also by reduction. Our GFP library also included 
promotors from cysB and cysD, which showed no change in promoter activity between the 
treated and untreated conditions suggesting that other parts of the sulfate assimilation pathway 
are not affected by 5-FU. Thus it is an open question whether the upregulation of cysJ is related 
to its role in detoxification of modified base analogs rather than sulfate metabolism. Although 
CysJ and YcbX would not actually be able to detoxify 5-FU (it detoxifies N-hydroxylated base 
analogs which cause double strand breaks), their transcription could be upregulated by DNA 
damage. The downregulation of csgB by 5-FU may explain the reduction in adhesion as curli 
fibers are major constituents of the exopolysaccharide matrix (Steenackers et al., 2012). 
Chapter 6: Biofilm inhibition by 5-FU 
145 
 
6.4 Conclusion 
Given recent successful demonstrations of the anti-biofilm properties of 5-FU against E.coli 
and Pseudomonas we were interested in determining if it also works against Salmonella. 
Although 5-FU was already demonstrated to be effective in the clinical setting with regards to 
preventing biofilm formation on catheters, not much is known about how it affects biofilm 
regulatory pathways. The proposed mechanism of action in E.coli that depends on the presence 
of AriR is not possible in Salmonella, because there is no AriR homolog in this species. We 
found that 5-FU is a very strong inhibitor of S. Typhimurium biofilm formation, and that it 
can effectively abolish biofilm formation without affecting planktonic growth at low 
concentrations. The production of curli is strongly inhibited by 5-FU, which is a very likely 
explanation for biofilm inhibition. Chronic carriage of Salmonella by individuals or even pets 
is an important source of gastroenteritis outbreaks and is often associated with biofilms 
(Buchwald; Blaser, 1984; Costerton et al., 1999; Gonzalez-Escobedo et al., 2011; Gunn et al., 
2014). Removal of the gallbladder (cholecystectomy) is the most common treatment for 
chronic typhoid carriers; however, this treatment is both costly and invasive (Gonzalez-
Escobedo et al., 2011). Thus there is incentive for further research into-, and development of 
anti-Salmonella biofilm strategies using 5-FU. For example, 5-FU treatment could be 
combined with antibiotic treatment in cases where a person is infected with a strain that is 
associated with chronic carriage. However, this would also require knowledge on factors that 
are associated with chronic carriage as well as strain identification techniques. Aside from the 
anti-biofilm properties of 5-FU, at higher concentrations it is very effective at inhibiting 
planktonic growth as well, and thus may be a viable option for treating antibiotic resistant 
Salmonella infections. Fluoroquinolone resistant Salmonella spp were recently listed by the 
WHO organization as a high-priority pathogen, requiring urgent new R&D strategies for 
antibiotic development (WHO, 2017). 
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Figure 44 (Top left) 5-FU inhibits Salmonella biofilm formation and planktonic growth in a 
concentration dependent manner. (Bottom left and right) IC50 and BIC50 values were also calculated 
(bottom left and right respectively). Error bars represent standard deviations from 15 samples (3 
biological repeats from 5 different days).(Top right) Biofilms were grown on the bottom of petri dishes 
for 24 hours at 25ºC in TSB1/20 (treated and untreated). The wild type strain ATCC14028 was 
fluorescently labelled with a constitutively expressed GFP on plasmid pFPV25.1. The untreated 
biofilm shows heterogeneously distributed biofilm structures while the treated sample contains 
scattered cells that are not connected to each other. The figures show one layer from a Z-stack through 
the biofilm. 
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Figure 45 Promotor activity of various genes involved in biofilm formation. Measurements were made 
every 3 hours over a period of 18 hours. Stars indicate a significant change in promotor activity between 
two time points when comparing the untreated and treated samples. 
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6.5 Materials and methods 
 Assaying biofilm formation  
Biofilm formation in the presence of various concentrations of 5-FU (obtained from Sigma) 
were done using the Calgary setup described in previous chapters. 
 High throughput biofilm assay 
Single colonies of S. Typhimurium 14028 containing promotor-GFP fusions for various genes 
associated with biofilm formation (Robijns et al., 2014) were used to inoculate liquid LB 
cultures, and were incubated overnight at 37˚C with shaking. The optical densities (OD) of 
overnight cultures (ONCs) were determined at 595 nm and normalized to an OD of 1.5 before 
centrifugation at 3000 × g for 5 minutes and resuspension in 1:20 diluted tryptic soy broth 
(TSB) from Becton Dikinson. High-throughput biofilm assays were performed using the 
Calgary biofilm device, which consists of a standard 96-well plate and a lid that has 
polystyrene pegs which fit into the wells (Ceri et al., 199). All experiments were performed 
using TSB 1/20 as growth medium to which 5-FU was added in a dilution series. Wells were 
filled with 200 µl medium and inoculated with 1 µl bacteria from the normalized overnight 
cultures.  Plates were incubated statically at 25˚C. After 24 hours, the lids were removed and 
the biofilms that formed on the pegs at the surface-liquid interface were stained with a solution 
consisting of 0.1% crystal violet dissolved in isopropanol, methanol and phosphate buffered 
saline (PBS) in a (1:1:18) ratio (modified protocol (Fletcher, 1977). The pegs were de-stained 
with 30% acetic acid and biofilm formation was quantified by measuring the optical density 
of the resolubized stain at 575 nm using a Synergy Multimode reader. The optical density of 
the planktonic phase was determined at 600 nm. Experiments were repeated 3 to 15 times 
using biologically independent overnight cultures, with two to three technical repeats per 96-
well plate, as indicated in the relevant results section. Data processing was done using 
Microsoft Office Excel 2013 and GraphPad Prism 6. 
The average values of biofilm formation and planktonic growth of the control conditions were 
calculated per biologically independent experiment after subtraction of the blank. The control 
values of each 96-well plate were then used to calculate the percentage of planktonic growth 
and biofilm formation at a given concentration for each strain from the same plate. The mean 
growth percentages and standard deviations were calculated from the values of the biologically 
independent experiments. IC50 and BIC50 values were also calculated.  
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 Microscopy 
Overnight cultures of S. Typhimurium 14028 containing a constitutively expressed gfpmut3 
gene (encoded on plasmid pFPV25.1) were inoculated, incubated and normalized as described 
in the previous section. Ampicillin100 was added to the LB medium before overnight 
incubation. Petri-dishes containing 10ml TSB 1/20 and Amp100 were inoculated in duplicate 
with 100µL bacteria from the ONCs. No additional compounds were added to the control 
samples, while 1.5 µM 5-FU was applied to the treated samples.  Samples were incubated for 
24 hours at 25 ºC. After incubation the liquid planktonic phase was poured off, and the 
remaining liquid was removed with a pipette. Samples were rinsed with TSB 1/20 to remove 
non-attached cells from the bottom of the petri-dish. The washing liquid was removed by 
careful pouring and pipetting. 
Images were taken with a Zeiss confocal laser scanning microscope (LSM 700), with digital 
camera (AxioCam MRm), and the associated Zen 2011 software. 
 Temporal quantification of gene transcription 
To obtain a comprehensive picture of the gene expression dynamics, caused by treatment with 
5-FU at a concentration that inhibits biofilm formation, we made use of an in-house collection 
of GFP fusions to promoters of genes that are important in biofilm formation (Robijns et al., 
2014). Overnight cultures of the S. Typhimurium 14028 wild type containing reporter fusion 
plasmids, were grown in LB medium with Amp100 at 37˚C whilst shaking. 2 µl overnight 
culture of each reporter fusion was to black polystyrene 96-well plates (Greiner bio-one 
655096) containing 200 µl TSB 1/20 per well. Untreated and treated (1.5 µM 5-FU) samples 
were inoculated in triplicate. Antibiotics were omitted to minimize effects on gene 
transcription; the omission of antibiotics does not negatively impact plasmid maintenance 
during the timeframe of the experiments. The multi-well plates were incubated at 25˚C with 
shaking. A Synergy MX multimode reader was used to measure absorbance and fluorescence 
at regular intervals of 3 hours over a course of 18 hours. Absorbance was measured using a 
wavelength of 600 nm, followed directly by fluorescence measurement with excitation at 488 
nm and emission at 511 nm. 
Time-dependent changes in transcription profiles were obtained from the OD and fluorescence 
values as described (Robijns et al., 2014). In short, the effects of growth rate on the 
accumulation of fluorescence were normalized and first derivatives were determined in order 
to give a measure of gene expression at each timepoint. Significant differences in the first 
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derivative of the control vs the treated condition were calculated using a two-tailed 
heteroscedastic t-test with a significance level of 0.05. 
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Chapter 7 
7 Concluding remarks 
7.1 General remarks 
Revealing the underlying molecular mechanisms that control a given complex phenotype is 
challenging, as changes in a specific phenotype may result from perturbations of many 
pathways, any of which may contribute very little to the observed phenotype on its own. We 
have used a network-based approach to search for mechanistic insights into how pyrimidine 
metabolism affects biofilm formation. This approach combined the vast amount of 
interactomics knowledge available for Salmonella, represented as an interactions network, 
with gene lists containing data of gene-expression experiments. Such an approach has various 
benefits. First, the interaction network aids in filtering noise from the gene expression studies. 
Second, the interaction networks compensate for missing information; genes relevant to the 
process under study that are not contained in the gene list can be recovered through their 
connectedness with the differentially expressed genes. Finally, integrating multiple molecular 
levels into an interaction network (for example protein-DNA interactions, protein-protein 
interactions and phosphorylation, and so forth), provides a holistic insight into the process of 
interest. 
 Nucleotides and biofilm formation 
In this work, the regulation of Salmonella biofilm formation was studied, with particular focus 
on the role of nucleotide biosynthesis pathways. Bacteria exhibit multicellular behavior by 
forming biofilms. These structures provide them with protection against environmental 
stresses. Biofilms are problematic in industry and medicine related environments. A better 
understanding of the molecular processes that control biofilm formation might lead to more 
directed prevention and removal approaches. We reviewed the potential of repurposing 
nucleoside-based drugs as antibacterial agents. Many of the anti-neoplastic and antiviral drugs 
that are in clinical use are derived from nucleotides. Because nucleotides play such an 
important role in bacterial homeostasis, these drugs can impact diverse processes such as 
survival, growth, biofilm formation and quorum sensing, and thus would be useful weapons 
in our fight against pathogenic bacteria. The advantages of repurposing drugs that are already 
approved were discussed. In conclusion our results complement and expand observations that 
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advocate the therapeutic potential of interfering with pyrimidine biosynthesis to prevent the 
transition from free-living growth to growth as part of matrix-embedded communities.  
A deeper understanding of the regulatory cascades controlling biofilm formation can aid in 
the identification of actors that might be candidate-targets for anti-biofilm drugs. Prior 
research, by other researchers, on E. coli and Pseudomonas has revealed the important role of 
pyrimidine biosynthesis, and here we further explored that role. Our work contributes to the 
current understanding of the role that nucleotides play in the regulation of biofilm formation  
To gain more insight into how pyrimidine availability influences the switch to a biofilm mode 
of life, various techniques and assays were performed including time-lapse studies with GFP-
promotor fusions, intracellular metabolite quantification and RNA-sequencing. The PheNetic 
algorithm was used to analyze the data. This approach enabled us to extract a core regulatory 
network, explaining how pyrimidine starvation affects gene transcription in Salmonella. The 
obtained regulatory network summarizes until today the most complete view on the global 
impact of pyrimidine starvation on enteric bacteria. Furthermore, it contributes to a better 
understanding of the link between metabolic processes and biofilms formation. Additionally, 
more general, a proof-of-principle for extracting the active regulatory network from 
transcriptome data was hereby delivered. 
We showed that pyrimidine deficiency results in biofilm inhibition via inhibition of csgD 
transcription. Furthermore, this inhibition occurs despite an increase in intracellular c-di-GMP 
concentrations. We argue that the increase in c-di-GMP concentration is driven by an increase 
in purine nucleotide production. The downregulation of csgD promotor activity, despite that 
high levels of c-di-GMP remains unclear. An interesting link for further exploration is how 
changes in nucleotide levels affect the expression of the global regulator Fis, which regulates 
more than 20% of the genes present in the Salmonella genome. 
 Possible polar effects on carB due to carA deletion 
Here we discuss two possible scenarios that may result from deleting carA. The first possibility 
is that transcription of carB is affected. The second possibility is that translation of carB is 
affected.  
The ΔcarA mutant was constructed by replacing the carA coding sequence with an antibiotic 
resistance cassette, and then removing the cassette according to the protocol by Datsenko and 
List of references 
153 
 
Wanner (2000). The replaced region also include 7bp in front (partially overlapping with the 
Shine-Delgarno sequence) and 6bp after the coding sequence.  
The genes carA and carB encode the smaller and larger subunits of the enzyme carbamoyl 
phosphate synthase and are transcribed from tandem promoters, P1 and P2, downstream of the 
carA coding sequence (Bouvier et al., 1984). Carbamoyl phosphate synthase catalyses the 
synthesis of carbamoyl phosphate from bicarbonate and glutamine. The glutaminase subunit 
encoded by carA release ammonia from glutamine. The synthase subunit then uses the released 
ammonia and bicarbonate for the formation of carbamoyl phosphate, at the expense of one 
ATP. The synthase subunit can also function on its own using free ammonia as substrate 
(instead of glutamine). 
The ΔcarA mutant we constructed, retain the P1 and P2 promotors. Thus, it is possible for 
carB transcription to occur from the P1 and P2 promotors (Jensen et al., 2000). Our RNA 
sequencing results indeed show that this occurs, because carB is upregulated in the mutant 
strain (log2 fold change 4.9). Transcription from P1 is negatively regulated by pyrimidines and 
to a lesser extent by purines, with the latter occurring by PurR-mediated repression. While 
transcription from P2 is negatively regulated by arginine bound to ArgR. Based on our 
nucleotide measurements, which show reduced levels of pyrimidine nucleotides, and the 
observations that we made regarding upregulation of other genes that are under PurR control, 
it is not a surprise to see high levels of transcription for carB  
Nevertheless, just because transcription continues, does not mean that translation actually 
takes place. If the way in which the carA mutant was constructed, had a negative impact on 
the translation of carB mRNA, then the entire enzyme complex, instead of just one subunit 
would be affected and no carbamoyl phosphate, instead of very little, would be produced. This 
would lead to complete inhibition of de novo pyrimidine synthesis, as opposed to severe 
inhibition. The ΔcarA mutant grown in TSB1/20 without added uracil does have some limited 
growth. This can either be due exogenously supplied pyrimidines in the medium, or due to 
some activity from the de novo pathway using free ammonia as a substrate for the first 
enzymatic step. However, based on the experiments that we conducted we cannot accurately 
say which option is true. Nonetheless, we can construct a hypothesis to explain our 
observations: 
If the following are all true: (i) carB transcription is up-regulated, (ii) translation occurs, (iii) 
the synthase subunit can make sufficient amounts of carbamoyl phosphate from free ammonia, 
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(iv) and the other de novo pathway enzyme levels are also increased. Then it is reasonable to 
expect an increase in pyrimidine nucleotides via the de novo pathway. However, our 
nucleotide measurements show that pyrimidine nucleotide production is impaired. Which 
(given that options i and iv are true, and options ii and iii are not known) is an indication that 
not enough carbamoyl phosphate is produced to keep pyrimidine pools at a wild type levels.  
Overexpression of carB per se probably does not impair biofilm formation. Rather, it is 
pyrimidine starvation which causes this effect, because we also observe biofilm inhibition 
when the other de novo enzymes in the pathway are deleted or replaced by kanamycin 
resistance cassettes. The main aim of the work presented in this thesis was to evaluate the 
potential of inhibiting biofilm formation by interfering with de novo pyrimidine biosynthesis. 
We feel that our results are compelling enough to confirm that this is indeed a viable strategy, 
regardless of which enzymatic step is targeted. 
Nevertheless, there are a number of controls that one can use to determine whether knocking 
one gene in a operon out causes disruptions in the other genes of that operon. To test if this is 
the case, one can use a plasmid complementation system. If plasmid based expression of the 
chromosomally deleted gene does not (partially)restore the wild type phenotype, one has to 
consider the possibility that neighbouring genes were affected. One can use RT-PCR to check 
if the other genes in the operon are transcribed, or Western blotting to check if translation of 
the encoded proteins occurs. To prevent polar effects one can use scarless gene editing 
techniques to make in-frame deletions (Cox et al., 2007; Blank et al., 2011; Yang et al., 2014; 
Kim et al., 2014). 
7.2 Future perspectives 
 Linking fis expression and nucleotide levels to global transcriptome 
changes that may impact biofilm formation 
In wild type cells, transcription of the dusB-fis operon is predominantly initiated from +1C. 
The growth-phase dependent transcription form this site correlates with intracellular CTP 
concentration, which is high during early exponential phase and low during entry into 
stationary phase. Under conditions of pyrimidine starvation (where purine levels are high) 
transcription is initiated from -2G in a growth-phase independent manner (Walker; Osuna, 
2002; Walker et al., 2004). Fis regulates the transcriptional induction of RpoS by binding to a 
region upstream of its promotor to repress it during exponential growth (Hirsch; Elliott, 2005). 
In turn, RpoS is a sigma factor that is responsible for csgD transcription during biofilm 
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formation. In Chapter 5 we hypothesize that continued transcription of fis from -2G in the 
pyrimidine starved mutant is responsible for reduced transcription of rpoS and subsequently 
csgD. To verify the link between nucleotide dependent regulation of fis and transcription of 
rpoS and csgD, we propose to do the following experiments and hope to see the listed 
outcomes: 
I. Abolish growth phase regulation of fis transcription in the wild type and determine if 
biofilm formation is inhibited. This would involve replacing +1C with an A or a G. 
Transcription of fis should continue at a high level even during stationary phase. If our 
hypothesis is correct, rpoS and csgD should be down-regulated and the mutant should 
have reduced biofilm formation. Transcription of rpoS, csgD and fis can be measured 
with qRT-PCR and compared between the wild type and the relevant Pfis mutant.  
II. Reduce fis expression from -2G in the carA mutant to see if transcription of rpoS and 
csgD is increased and if biofilm formation is increased as well. This would involve 
replacing -2G with a C or a T in the ΔcarA mutant. The transcription of fis would then 
depend on the availability of pyrimidine nucleotides and ought to be reduced during 
all growth phases. We expect to see increased expression of rpoS and csgD. However, 
increased levels of RpoS during early exponential phase might have other detrimental 
effects due to competition with RpoD and lead to unexpected phenotypic outputs or 
problems with growth. 
III. Interfere with Fis dependent repression of rpoS transcription in the ΔcarA background 
by deleting the Fis-binding site in PrpoS. Here we would expect that the continued high 
levels of Fis in the pyrimidine-starved mutant would no longer inhibit rpoS 
transcription (and subsequent csgD transcription). We would also expect that such a 
mutant would form more biofilm that the ΔcarA mutant. However, as mention in point 
II some detrimental effects can be expected.  
 Regulatory interplay between the purine and pyrimidine pathways 
The observation that pyrimidine starvation causes a “runaway” effect in purine biosynthesis 
is very interesting. This was something that was already observed in the 1980’s, and so far 
there is no complete explanation for how this happens. Based on the transcription profiles of 
genes in the PurR regulon, the hypothesis is that there is an unknown factor at play. It could 
be a protein or ligand that directly interacts with PurR to alter its activity, or it could be a 
transcription factor that binds the DNA in the vicinity of the Pur-box and interferes with PurR 
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regulation. It would also be useful to measure intracellular PRPP levels in the carA mutant 
under pyrimidine starved and pyrimidine sufficient conditions, as well as in the wild type.  
 Partitioning of nucleotide resources during biofilm formation 
At any point in a metabolic pathway where a single, inevitably limiting resource (in this case 
UMP or a later derivative) is partitioned into two or more components (for example UTP and 
a UDP-sugar), there must necessarily be some decision-making mechanism in order to allow 
cells to match changes in substrate availability with cellular demands. It can be speculated that 
when the availability of pyrimidines is low, this resource would rather be partitioned towards 
DNA/RNA synthesis instead of matrix production. Such a partitioning of pyrimidine resources 
has been shown to play a role in capsulation of Pseudomonas (Gallie et al., 2015). To further 
investigate how such a partitioning of pyrimidine resources could be achieved, we propose 
that different concentrations of isotopically labelled uracil should be added to the growth 
medium and that its fate be determined by measuring its incorporation into UTP, CTP and 
othe nucleotide-derived molecules. 
 Screening NNADs 
NNADs can be screened against the 12 families of bacteria that were identified by the WHO 
as antibiotic-resistant “priority pathogens”. The list includes Acinetobacter, Pseudomonas, 
Klebsiella, E.coli, Serratia and Proteus.The activities of the NNADs should be tested for their 
bactericidal effects, biofilm inhibitory effects, anti-virulence activities and also as adjuvants 
for standard antibiotic therapies. 
 Effect on virulence 
Given the link between biofilm formation, virulence and regulation by c-di-GMP, it would be 
interesting to see whether interfering with nucleotide biosynthesis, or treatment with NNADs 
impacts Salmonella pathogenicity. For this we propose cell culture assays using intestinal 
epithelial cells and eventually studies using animal models. 
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7.3 Final remarks 
Recent advances in high-throughput metabolomics have enabled the detection and 
quantification of thousands of intracellular metabolite ions. In a recently published landmark 
study Fuhrer and colleagues (2017) explored the relationships between >3800 single-gene 
deletions and >7000 metabolite ions in E. coli. Their map revealed a largely unknown 
landscape of gene-metabolite interactions (Fuhrer et al., 2017). The model that the constructed 
for linking genes to metabolites, and the methods which they used might be useful to predict 
the effects of targeting an enzyme in a particular metabolic pathway. For example, when 
deciding which enzymatic steps in the nucleotide biosynthesis patwahys to target as a means 
to interferre with biofilm formation; The best candidate enzymes, to target with drugs that are 
designed to bind to them, can be selected based on the effects that their inhibition would have 
on the synthesis of biofilm matrix components 
Appendix 
159 
 
Appendix 
 
 
Supp. Figure 1 Diagram providing an overview of the de novo pyrimidine biosynthesis pathway:  
intermediates as well as the genes encoding enzymes responsible for catalyzing the reactions are 
shown. The bifurcation point where UTP is partitioned towards either CTP or UDP-glucose production 
is also indicated. Uracil from the growth medium can be salvaged and converted to UMP (black dotted 
line). Feedback inhibition of reactions by pathway end products are indicated in grey lines. 
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Supp. Figure 2 (Panel A) Concentration dependent induction of biofilm formation of E. coli 
BW25113 by uracil. The results are represented as percentages of the E. coli BW25113 control. (Panel 
B) Relative biofilm formation and planktonic growth of E. coli BW25113 (with and without added 
uracil) after 24 hours, compared to S. Typhimurium 14028. BW25113 biofilm levels are 10% of that 
of S. Typhimurium 14028. Biofilm formation of BW25113 was stimulated by 27.5 µM uracil to 30% 
of that of S. Typhimurium 14028. The planktonic phase was not affected by exogenous uracil. The de 
novo supply of pyrimidines in the parental BW25113 strain is sufficient to meet the requirements for 
free-living growth, but not for maximal biofilm production. (Panels C and D) Concentration-dependent 
restoration of planktonic growth and biofilm formation of E. coli BW25113 mutants that contain single 
gene deletions of enzymes for pyrimidine biosynthesis. The results are represented as percentages of 
the E. coli BW25113 parental control (red dotted lines). With the exception of pyrI::Km, all mutant 
strains are defective in growth and biofilm formation. Restoration of planktonic growth to the normal 
parental level, requires the addition of ≥ 17.5µM uracil to the medium (black box, panel C). Addition 
of ≥ 35 µM uracil induces biofilm formation to levels that are 200 - 600% of that of the parental control 
(black box, panel D). The pyrI::Km mutant, in which the regulatory subunit of ATCase is deleted, 
exhibits enhanced biofilm formation together with reduced planktonic growth, irrespective of the 
addition of uracil to the medium. Such a mutant can still synthesize UMP via the de novo pathway but 
is insensitive to feedback inhibition by CTP and UTP leading to an unchecked production of 
pyrimidines. This suggests that it does not matter whether the required pyrimidine compounds are 
supplied via the environment or intracellularly. Experiments were performed using 3 independent 
overnight cultures which were used to inoculate separate multi-well plates with 2 to 3 technical repeats 
per condition. Error bars represent the standard deviations of the independent experiments.  
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Supp. Table 1 Strains from the E. coli BW25113 single-gene deletion Keio-collection that were used 
in this study (Baba et al., 2006). 
Designation  Ecogene accession numbers 
BW25113  
carA::Km Eck0033 
pyrE:: Km Eck3632 
pyrI:: Km Eck4239 
pyrB::Km Eck4240 
pyrC::Km Eck1047 
pyrD::Km Eck0936 
pyrF::Km Eck1276 
upp::Km Eck2494 
 
 
 
Supp. Figure 3 Relative biofilm formation of the E. coli BW25113 parental strain and the upp::Km 
mutant in the absence and presence of exogenous 30 µM uracil. The level of the parental control’s 
biofilm in the absence of uracil was set to 100%. The addition of uracil significantly enhanced the 
parental strain’s biofilm production (p value = 0.022). An insignificant increase was observed for the 
upp::Km mutant, indicating that it is less sensitive to the stimulatory effect that uracil has on biofilm 
formation. Data are represented as the means of independent experiments (n =3 to 4) and the error bars 
represent standard deviations. An unpaired t-test with a 95% confidence interval was used. 
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Supp. Figure 4 Panel A: Relative UDP-glucose levels from planktonic cultures under varying 
conditions of pyrimidine-availability were determined by mass spectrometry. For each sample, the 
peak area in the chromatogram was divided by the respective optical density (OD600) to obtain a 
normalized quantity. Samples were taken after 10 hours of incubation. There are no significant 
differences in intracellular UDP-glucose concentrations between the wild type control and any of the 
other conditions. Three biologically independent samples were used per condition. Data are 
represented as means ± standard deviations. Panel B: The amount of biofilm formed on the bottom of 
petri-dishes after 10 hours of growth was determined with crystal violet staining From left to right are: 
wild type, mutant with 17.5 µM uracil and mutant with 70 µM uracil. Photographs of only one replicate 
from each condition is shown.  
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Supp. Figure 5 The biofilm phenotypes of mutants defective in curli and/ or cellulose production (see 
main text for details). These results indicate that curli production is more important for biofilm foration 
under our experimental conditions. Data are represented as the means and standard deviations of at 
least 3 biological replicates. 
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Supp. Figure 6 Concentration of c-di-GMP from cellular extracts of S. Typhimurium 14028 wild type 
and the ΔcarA mutant as determined by LC-MS/MS. Metabolites were extracted from biologically 
independent cultures and normalized according to sample protein content. The error bars represent 
standard deviations of the three independent experiments. Significant differences between samples are 
indicated above the bars (unpaired t-test, 95% confidence interval, p value = 0.0010). Note that 
normalization by protein content leads to an underestimation of c-di-GMP levels in the pyrimidine 
starved ΔcarA mutant, when compared to normalization by optical density. This could mean that the 
actual protein content in the pyrimidine starved ΔcarA mutant is overestimated. The BCA method is 
sensitive to the presence of tryptophan, tryptophan might be increased in the pyrimidine starved ΔcarA 
mutant due to increased levels of PRPP (See the results section for details). 
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Supp. Table 2 Results from c-di-GMP concentration determination. The amount of c-di-GMP 
extracted from each sample was normalized according to the sample optical density or protein content. 
Condition Replica  Un-normalized 
Mass Spec data 
Sample characteristics Normalized [c-di-GMP] 
c-di-
GMP 
[nM] 
c-di-
GMP 
per 
sample 
(ng) 
Total 
protein 
content 
(µg) 
 
Optical 
density 
(OD600)** 
ng/mg 
protein 
Average 
fold 
change 
pmol/sample/ 
OD600 
Average 
fold 
change 
Salmonella Typhimurium 14028  
Wild type: 
Planktonic  
1 1.57 0.217 453.333 0.076 0.48 1.00 
 
4.132 1.00 
 2 4.7 0.649 1776 0.138 0.37 6.812 
3 6.53 0.901 1114.667 0.147 0.81 8.884 
Wild type: 
Biofilm 
1 6.34 0.875 597.334 - 1.46 3.25 
 
- - 
2 9.19 1.268 864 1.47 
3 19 2.622 1065.778 2.46 
ΔcarA +17.5 
µM uracil:  
Planktonic 
1 56.6 7.812 3210.667 0.104 2.43 5.64 
 
108.846 21.29 
 2 84.2 11.621 3608 0.106 3.22 158.868 
3 81.1 11.193 3010.667 0.105 3.72 154.476 
ΔcarA +70 
µM uracil:  
Planktonic 
1 2.9 0.400 781.333 0.167 0.51 1.07 
 
3.473 0.67 
 2 1.77 0.245 1698.667 0.100 0.14 3.54 
3 5.16 0.712 632 0.162 1.13 6.37 
ΔcarA +70 
µM uracil:  
Biofilm 
1 24.9 3.437 420.444 - 8.17 8.57 - - 
2 4.67 0.645 413.333 1.56 
3 44.4 6.128 1364.444* 4.49 
E. coli BW25113 
Wild type: 
Planktonic  
1 10.5 1.449 1095.200 0.08 1.32 1 26.25 1 
2 5.64 0.778 827.200 0.072 0.94 15.67 
3 7.67 1.059 1063.200 0.088 1.00 17.43 
Wild type: 
Biofilm 
1 2.72 0.375 1047.73 - 2.82 1.11 - - 
2 4.78 0.660 1522.400 0.43 
3 3.36 0.464 1293.067 0.36 
ΔcarA +17.5 
µM uracil:  
Planktonic 
1 24.4 3.368 1279.200 0.104 2.63 2.09 46.92 2.19 
2 22.1 3.050 1131.200 0.095 2.70 46.53 
3 18.6 2.567 1727.200 0.102 1.49 36.47 
ΔcarA +140 
µM uracil:  
Planktonic 
1 11.5 1.587 1495.200 0.207 1.06 1.14 11.11 1.07 
2 26.9 3.713 2971.200 0.213 1.25 25.26 
3 30.3 4.182 2975.200 0.224 1.41 27.05 
ΔcarA +140 
µM uracil:  
Biofilm 
1 
2 
3 
3.53 
3.67 
4.18 
0.487 
0.507 
0.577 
175.733 
290.400 
321.956 
- 2.77 
1.74 
1.79 
1.93 - - 
Fold changes are defined directly in terms of ratio: = (strain of interest)/(wild type) *Outlier detected 
with Grubbs test. **OD600 was only measured for planktonic samples. 
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Supp. Table 3 Summary of Rockhopper output when the LT2 genome was used as reference for 
alignment 
Strain Experimental 
repeat 
Total 
reads 
Successfully 
aligned reads 
Aligning 
sense to 
protein 
coding 
genes 
Aligning 
antisense to 
protein 
coding 
genes 
Aligning to 
unannotated 
regions 
Wild 
type 
1 5600139 5419326 (97%) 43% 43% 10% 
 2 5615813 5440361(97%) 40% 41% 13% 
 3 5599389 5415217 (97%) 39% 40% 15% 
 4 5601998 5412869 (97%) 39% 40% 15% 
ΔcarA 1 3683063 5387418 (96%) 33% 34% 16% 
 2 5595815 5387418 (96%) 35% 36% 17% 
 3 5083473 4869480 (96%) 32% 33% 21% 
 4 5608974 5392786 (96%) 30% 30% 19% 
 
Supp. Table 4 Summary of Rockhopper output when the LT2 plasmid was used as reference for 
alignment 
Strain Experimental 
repeat 
Total 
reads 
Successfully 
aligned reads 
Aligning 
sense to 
protein 
coding 
genes 
Aligning 
antisense 
to protein 
coding 
genes 
Aligning to 
unannotated 
regions 
Wild type 1 5600139 32926 (1%) 44% 41% 15% 
 2 5615813 30046 (1%) 43% 42% 15% 
 3 5599389 33903 (1%) 44% 40% 15% 
 4 5601998 30017 (1%) 44% 41% 14% 
ΔcarA 1 3683063 26472 (1%) 42% 38% 20% 
 2 5595815 39157 (1%) 42% 39% 19% 
 3 5083473 33035 (1%) 42% 39% 19% 
 4 5608974 35347 (1%) 41% 40% 20% 
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Supp. Table 5 Genes with large differential expression profiles 
Gene Synonym Product Transcripti
on Start 
Transcripti
on Stop 
RPKM 
WT 
RPKM 
carA 
qValue WT 
vs carA 
log2 fold 
change 
csgB STM1143 minor curlin subunit 1231077 1231588 15131 98 0.00 -7.02 
- predicted 
RNA 
antisense: csgC csgA 
csgB 
1232391 1231057 14755 116 0.00 -6.75 
- predicted 
RNA 
- 1231057 1231076 2735 22 0.00 -6.69 
csgA STM1144 major curlin subunit 1231589 1232092 23668 209 0.00 -6.60 
- predicted 
RNA 
- 1232093 1232146 852 7 0.00 -6.52 
- predicted 
RNA 
antisense: rrsG 2800146 2801555 13 495 0.00 5.39 
yciE STM1730 cytoplasmic protein 1826390 1826932 1093 24 0.00 -5.37 
- predicted 
RNA 
antisense: rrsE 4396189 4394697 16 551 0.00 5.30 
- predicted 
RNA 
antisense: rrsC 4101646 4100154 19 640 0.00 5.25 
- predicted 
RNA 
antisense: rrsA 4197573 4196081 19 640 0.00 5.25 
- predicted 
RNA 
antisense: rrsB 4352644 4351152 19 640 0.00 5.25 
- predicted 
RNA 
antisense: rrsD 3570493 3571985 18 607 0.00 5.22 
rrsE STM4177 16S ribosomal RNA 4394675 4396219 16 517 0.00 5.20 
rrsB STM4132 16S ribosomal RNA 4351130 4352673 19 607 0.00 5.17 
- predicted 
RNA 
antisense: rrsH 290693 289201 16 512 0.00 5.13 
rrsA STM3988 16S ribosomal RNA 4196059 4197600 19 608 0.00 5.13 
rrsC STM3889 16S ribosomal RNA 4100132 4101675 20 607 0.00 5.13 
rrsG STM2659 16S ribosomal RNA 2801660 2800118 15 444 0.00 5.10 
rfbU STM2086 O-antigen biosynthesis 
protein RfbU 
  
67 1 0.00 -5.09 
rrsD STM3398 16S ribosomal RNA 3572006 3570463 19 572 0.00 5.09 
rrsH STM0249 16S ribosomal RNA 289189 290732 17 481 0.00 5.04 
- predicted 
RNA 
- 1826334 1826389 1074 29 0.00 -5.02 
csgF STM1140 curli production 
assembly/transport 
protein CsgF 
1229307 1228859 1110 30 0.00 -4.98 
- predicted 
RNA 
antisense: carB carA 80254 76997 35 988 0.00 4.92 
carB STM0067 carbamoyl phosphate 
synthase large subunit 
77045 80280 35 947 0.00 4.86 
rfbM STM2084 mannose-1-phosphate 
guanylyltransferase 
  
76 1 0.00 -4.86 
pyrB STM4460 aspartate 
carbamoyltransferase 
catalytic subunit 
4704910 4703970 34 896 0.00 4.82 
- predicted 
RNA 
antisense: codB 3502208 3501985 10 272 0.00 4.82 
- STM1513 cytoplasmic protein 1592040 1592256 1952 63 0.00 -4.82 
- predicted 
RNA 
- 1592028 1592039 525 17 0.00 -4.77 
csgG STM1139 curli production 
assembly/transport 
protein CsgG 
1228858 1228025 1058 34 0.00 -4.76 
- predicted 
RNA 
antisense: STM1513 1592281 1592027 1827 60 0.00 -4.75 
- predicted 
RNA 
antisense: prgH 3017362 3017419 8 222 0.00 4.75 
pyrI STM4459 aspartate 
carbamoyltransferase 
regulatory subunit 
4703969 4703426 31 759 0.00 4.73 
csgC STM1145 curli assembly protein 
CsgC 
1232147 1232473 299 9 0.00 -4.73 
- predicted 
RNA 
antisense: rrlG 2796891 2798402 26 600 0.00 4.73 
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Gene Synonym Product Transcripti
on Start 
Transcripti
on Stop 
RPKM 
WT 
RPKM 
carA 
qValue WT 
vs carA 
log2 fold 
change 
- predicted 
RNA 
- 1232474 1232603 242 7 0.00 -4.70 
- predicted 
RNA 
antisense: rrlD 3567093 3568799 37 821 0.00 4.64 
- predicted 
RNA 
antisense: rrlH 294312 292606 37 811 0.00 4.63 
- predicted 
RNA 
antisense: rrlB 4356166 4354460 37 811 0.00 4.63 
- predicted 
RNA 
antisense: rrlE 4399590 4397884 37 811 0.00 4.63 
yciF STM1729 cytoplasmic protein 1825763 1826333 1289 47 0.00 -4.62 
- predicted 
RNA 
antisense: rrlC 4105007 4103301 37 807 0.00 4.62 
- predicted 
RNA 
antisense: rrlA 4201095 4199389 37 807 0.00 4.62 
- predicted 
RNA 
- 1229327 1229308 1029 36 0.00 -4.62 
- predicted 
RNA 
- 75794 75845 26 584 0.00 4.59 
- predicted 
RNA 
- 1592257 1592292 217 8 0.00 -4.55 
csgE STM1141 curli production 
assembly/transport 
protein CsgE 
1229723 1229328 1160 43 0.00 -4.54 
rfbV STM2087 abequosyltransferase 
RfbV 
  
90 3 0.00 -4.51 
rfbN STM2085 O antigen biosynthesis 
rhamnosyltransferase 
RfbN 
  
73 2 0.00 -4.47 
- predicted 
RNA 
- 77029 77044 34 698 0.00 4.45 
- predicted 
RNA 
antisense: yciG 
STM1731 yciE yciF 
1827833 1825513 1279 55 0.00 -4.41 
- STM1731 catalase 1826933 1827835 1089 46 0.00 -4.40 
- STM1243 cold shock-like protein 
CspH 
1331050 1330826 4 86 0.00 4.39 
rfbK STM2083 phosphomannomutase 
  
54 1 0.00 -4.38 
rfbX STM2088 O-antigen transferase 
 
2168625 67 2 0.00 -4.35 
- predicted 
RNA 
antisense: csgE csgF 
csgD csgG 
1228015 1230502 1110 47 0.00 -4.33 
- predicted 
RNA 
- 1230503 1230483 483 23 0.00 -4.26 
- predicted 
RNA 
- 1228024 1228015 361 16 0.00 -4.23 
pyrL STM4461 pyrBI operon leader 
peptide 
4705048 4704919 15 252 0.00 4.22 
rfbP STM2082 undecaprenyl-
phosphate galactose 
phosphotransferase 
2162361 
 
56 2 0.00 -4.10 
- predicted 
RNA 
antisense: carA 75915 75794 39 614 0.00 4.07 
- predicted 
RNA 
antisense: pyrD 1147318 1147004 15 225 0.00 4.05 
gatY STM3253 D-tagatose-1,6-
bisphosphate aldolase 
subunit GatY 
  
64 3 0.00 -4.03 
- predicted 
RNA 
- 1799796 1799828 363 21 0.00 -3.96 
- predicted 
RNA 
- 4351031 4350964 16 227 0.00 3.95 
- predicted 
RNA 
antisense: rrlB 4353786 4353212 44 595 0.00 3.95 
- predicted 
RNA 
- 4100096 4099855 29 407 0.00 3.93 
- predicted 
RNA 
antisense: STM05625 3024249 3024364 19 264 0.00 3.88 
yjiG STM4513 inner membrane 
protein 
  
106 6 0.00 -3.87 
rrlA STM3991 23S ribosomal RNA 4198116 4201110 61 781 0.00 3.87 
yjiH STM4514
.S 
inner membrane 
protein 
  
85 4 0.00 -3.85 
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rrlB STM4135 23S ribosomal RNA 4353187 4356180 59 736 0.00 3.85 
- predicted 
RNA 
antisense: rrlG 2799226 2799732 38 481 0.00 3.84 
rrlC STM3891 23S ribosomal RNA 4102028 4105021 58 725 0.00 3.84 
rrlD STM3396 23S ribosomal RNA 3570071 3567078 58 717 0.00 3.83 
rrlE STM4179 23S ribosomal RNA 4396611 4399604 58 713 0.00 3.82 
- predicted 
RNA 
antisense: rrlD 3569473 3570049 38 466 0.00 3.80 
- predicted 
RNA 
antisense: rrlE 4397210 4396634 38 466 0.00 3.80 
- predicted 
RNA 
antisense: livJ 3734706 3734855 255 16 0.00 -3.78 
- predicted 
RNA 
antisense: rrlH 291772 291256 57 679 0.00 3.78 
csgD STM1142 DNA-binding 
transcriptional 
regulator CsgD 
1230482 1229724 1148 74 0.00 -3.74 
rrlH STM0252 23S ribosomal RNA 291244 294336 66 745 0.00 3.71 
- predicted 
RNA 
antisense: livJ 3735499 3735515 222 16 0.00 -3.69 
livJ STM3567 high-affinity branched-
chain amino acid 
transporter substrate-
binding protein LivJ 
3735599 
 
184 13 0.00 -3.66 
- STM0562
5 
hypothetical protein 3024357 3024093 15 179 0.00 3.66 
yciG STM1728 cytoplasmic protein 1825513 1825756 2313 170 0.00 -3.65 
- STM1146 hypothetical protein 
 
1232924 139 9 0.00 -3.63 
rrlG STM2657 23S ribosomal RNA 2799764 2796755 55 570 0.00 3.57 
creD STM4590 inner membrane 
protein 
4846401 4847901 11 128 0.00 3.54 
pyrD STM1058 dihydroorotate 
dehydrogenase 2 
1146942 1147978 15 158 0.00 3.54 
- predicted 
RNA 
antisense: narV 1667144 1666906 252 20 0.00 -3.53 
- predicted 
RNA 
antisense: metW metZ 3141209 3141080 28 290 0.00 3.50 
- predicted 
RNA 
antisense: pyrI pyrL 
yjgF pyrB STM4457 
4702871 4705027 86 856 0.00 3.45 
- predicted 
RNA 
- 2596997 2596843 413 33 0.00 -3.43 
lysA STM3013 diaminopimelate 
decarboxylase 
3173967 3172469 5 50 0.00 3.41 
metZ STM2989 Met tRNA 3141064 3141140 23 222 0.00 3.41 
melA STM4298 alpha-galactosidase 
  
125 10 0.00 -3.39 
sicP STM2879 chaperone protein SicP 3024092 
 
5 48 0.00 3.36 
- predicted 
RNA 
antisense: sdaA 1924330 1923352 50 469 0.00 3.33 
- predicted 
RNA 
antisense: fliC 2047633 2049196 1985 182 0.00 -3.33 
melB STM4299 melibiose:sodium 
symporter 
  
52 4 0.00 -3.32 
codB STM3333 cytosine permease 3501826 
 
18 173 0.00 3.32 
fliC STM1959 flagellin 2049195 2047580 2083 196 0.00 -3.29 
ygbJ STM2918 3-hydroxyisobutyrate 
dehydrogenase 
3061630 
 
7 69 0.00 3.26 
- STM1939 glucose-6-phosphate 
dehydrogenase 
2033021 2032538 7 61 0.00 3.25 
asnT STM2004 Asn tRNA 2084219 2084294 6 57 0.00 3.25 
narW STM1579 nitrate reductase 2 
subunit delta 
  
200 19 0.00 -3.24 
prgH STM2874 secretion system 
protein PrgH 
3017580 3016318 4 39 0.00 3.24 
- predicted 
RNA 
antisense: STM2786 2935411 2934578 35 316 0.00 3.24 
- predicted 
RNA 
antisense: aceK 4405772 4405740 267 26 0.00 -3.23 
- predicted 
RNA 
- 2596843 2596997 446 42 0.00 -3.22 
- predicted 
RNA 
antisense: hilD 3017941 3017928 26 218 0.00 3.20 
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sdhC STM0732 succinate 
dehydrogenase 
cytochrome b556 
subunit 
797783 
 
290 2396 0.00 3.19 
- predicted 
RNA 
antisense: narY narW 1666018 1665855 295 29 0.00 -3.19 
- STM2786 tricarboxylic transport 
protein 
2934536 2935567 34 288 0.00 3.19 
sdaA STM1826 L-serine deaminase 
I/L-threonine 
deaminase I 
1923353 1924746 44 362 0.00 3.17 
- predicted 
RNA 
antisense: rrlC 4103200 4102050 104 808 0.00 3.16 
- predicted 
RNA 
antisense: sdhD sdhC 
sdhA 
798734 797783 251 2034 0.00 3.15 
- predicted 
RNA 
antisense: narW 1666399 1666304 211 21 0.00 -3.15 
yibK STM3695 tRNA (cytidine(34)-2'-
O)-methyltransferase 
3889589 3890064 7 69 0.00 3.15 
- predicted 
RNA 
antisense: narZ 1663630 1663265 278 28 0.00 -3.14 
sseI STM1051 secreted effector 
protein SseI 
1139971 1140939 5 47 0.00 3.13 
- STM2800 L-alanine exporter 
AlaE 
2948289 2948935 41 336 0.00 3.13 
metW STM2990 Met tRNA 3141170 3141246 23 193 0.00 3.12 
narV STM1580 nitrate reductase 2 
subunit gamma 
 
1667341 223 23 0.00 -3.12 
- predicted 
RNA 
antisense: yfiA 2808028 2807651 2467 263 0.00 -3.10 
chaB STM1770 cation transport 
regulator 
1868991 1868750 520 54 0.00 -3.09 
- predicted 
RNA 
antisense: ymdF 1206426 1206120 1925 211 0.00 -3.09 
yfiA STM2665 translation inhibitor 
protein RaiA 
2807652 2808028 2254 240 0.00 -3.08 
- predicted 
RNA 
- 2014755 2014667 182 19 0.00 -3.07 
iadA STM4512 isoaspartyl dipeptidase 4767272 4766093 171 18 0.00 -3.07 
- predicted 
RNA 
antisense: yfiD 2786013 2786240 271 27 0.00 -3.06 
- STM4510 aspartate racemase 
  
65 7 0.00 -3.06 
narY STM1578 nitrate reductase 2 
subunit beta 
  
242 26 0.00 -3.06 
dppD STM3627 dipeptide ABC 
transporter ATP-
binding subunit DppD 
3812333 
 
120 13 0.00 -3.06 
- predicted 
RNA 
antisense: narZ narY 1664825 1664398 283 30 0.00 -3.04 
aceK STM4185 bifunctional isocitrate 
dehydrogenase 
kinase/phosphatase 
4405066 4408045 401 44 0.00 -3.03 
ymdF STM1121 cytoplasmic protein 1206120 1206372 2058 233 0.00 -3.03 
- predicted 
RNA 
antisense: gcvT 3216491 3216593 26 194 0.00 3.01 
hilD STM2875 transcriptional 
regulator HilD 
3017704 3018765 14 109 0.00 3.00 
rpmE2 STM0469 50S ribosomal protein 
L31 
526352 526612 78 8 0.00 -2.99 
- STM0759 hypothetical protein 823590 823044 2653 309 0.00 -2.97 
- predicted 
RNA 
antisense: narY 1665731 1665159 264 30 0.00 -2.97 
- predicted 
RNA 
- 4404982 4405065 1245 147 0.00 -2.97 
- predicted 
RNA 
- 4195964 4195815 44 304 0.00 2.95 
- predicted 
RNA 
antisense: STM0759 823043 823583 2264 272 0.00 -2.94 
yfiD STM2646 autonomous glycyl 
radical cofactor 
2786289 2785906 217 24 0.00 -2.94 
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- predicted 
RNA 
antisense: mutT 162015 161539 65 451 0.00 2.91 
- predicted 
RNA 
antisense: yfcB 2496114 2496594 46 313 0.00 2.90 
- predicted 
RNA 
antisense: rrlD 3568900 3569399 189 1203 0.00 2.87 
- predicted 
RNA 
antisense: rrlB 4354359 4353860 189 1203 0.00 2.87 
- predicted 
RNA 
antisense: rrlE 4397783 4397284 189 1203 0.00 2.87 
yecF STM1949 cytoplasmic protein 2039344 2039767 50 333 0.00 2.85 
rpsQ STM3431 30S ribosomal protein 
S17 
 
3591574 584 73 0.00 -2.85 
aceA STM4184 isocitrate lyase 4403659 4404981 2300 299 0.00 -2.82 
rtT STM1758 - 1852683 1852825 60 384 0.00 2.82 
glyX STM4353 Gly tRNA 4596652 4596727 582 3695 0.00 2.81 
- predicted 
RNA 
antisense: pyrC 1248592 1249557 56 357 0.00 2.79 
- predicted 
RNA 
- 1206373 1206425 605 82 0.00 -2.79 
- predicted 
RNA 
antisense: tyrT rtT 
tyrV 
1852872 1852617 54 338 0.00 2.78 
selC STM3751 Sec tRNA 3948576 3948670 6 41 0.00 2.77 
ompC STM2267 outer membrane porin 
protein C 
2366641 2365443 1469 198 0.00 -2.75 
- predicted 
RNA 
antisense: rrlG 2798495 2799102 183 1081 0.00 2.75 
ais STM2296 ipopolysaccharide core 
heptose(II)-phosphate 
phosphatase 
2403760 2402658 82 498 0.00 2.75 
ndk STM2526 nucleoside 
diphosphate kinase 
2660519 2660024 227 1379 0.00 2.74 
- predicted 
RNA 
antisense: rrlH 292505 291895 197 1156 0.00 2.74 
- predicted 
RNA 
antisense: ompC 2365468 2366641 1379 188 0.00 -2.73 
- predicted 
RNA 
antisense: yaiY 432864 432968 154 22 0.00 -2.73 
narZ STM1577 nitrate reductase 2 
subunit alpha 
1660681 
 
209 28 0.00 -2.72 
argI STM4469 ornithine 
carbamoyltransferase 
4712767 4711709 23 146 0.00 2.72 
tyrV STM1759 Tyr tRNA 1852858 1852942 28 170 0.00 2.71 
yfhL STM2576 ferredoxin 2721682 2721986 18 113 0.00 2.71 
- predicted 
RNA 
antisense: narY 1665060 1664957 241 33 0.00 -2.70 
- predicted 
RNA 
antisense: sitD 3009488 3009448 210 30 0.00 -2.70 
pyrC STM1163 dihydroorotase 1249575 1248515 59 350 0.00 2.70 
lysT STM0751 Lys tRNA 818778 818853 404 2358 0.00 2.69 
- predicted 
RNA 
antisense: aceB aceA 
aceK 
4405418 4401982 1806 256 0.00 -2.69 
mutT STM0137 7,8-dihydro-8-
oxoguanine-
triphosphatase 
161496 162156 77 454 0.00 2.67 
rpsS STM3436 30S ribosomal protein 
S19 
3593802 3593494 447 61 0.00 -2.66 
yfcB STM2385 50S ribosomal protein 
L3 glutamine 
methyltransferase 
2496595 2495662 41 236 0.00 2.66 
- STM0361 cytochrome BD2 
subunit II 
 
411192 309 44 0.00 -2.66 
lldD STM3694 L-lactate 
dehydrogenase 
 
3889529 11 64 0.00 2.64 
- predicted 
RNA 
antisense: motA 2020209 2020336 188 27 0.00 -2.64 
- predicted 
RNA 
antisense: motA 2020475 2020754 235 35 0.00 -2.63 
- predicted 
RNA 
antisense: guaB 2625415 2625894 58 326 0.00 2.62 
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yhdG STM3384 tRNA-dihydrouridine 
synthase B 
3555256 3556236 135 752 0.00 2.61 
dppF STM3626 dipeptide ABC 
transporter ATP-
binding subunit DppF 
 
3810216 104 15 0.00 -2.61 
pyrF STM1707 orotidine 5'-phosphate 
decarboxylase 
1801340 
 
18 105 0.00 2.60 
sdhD STM0733 succinate 
dehydrogenase 
cytochrome b556 
small membrane 
subunit 
  
154 852 0.00 2.60 
rplV STM3435 50S ribosomal protein 
L22 
3593493 3593161 605 88 0.00 -2.60 
- predicted 
RNA 
antisense: yecF 2039544 2039344 67 370 0.00 2.59 
- predicted 
RNA 
antisense: acrB 529356 529553 306 46 0.00 -2.58 
serW STM0949 Ser tRNA 1027530 1027443 16 88 0.00 2.58 
- predicted 
RNA 
antisense: sitC sitD 3009274 3008722 216 33 0.00 -2.57 
- predicted 
RNA 
antisense: ndk 2659956 2660516 235 1262 0.00 2.57 
- predicted 
RNA 
antisense: narU narZ 1660786 1660557 290 45 0.00 -2.57 
- predicted 
RNA 
antisense: argI 4711839 4712744 26 154 0.00 2.57 
- STM1025 hypothetical protein 1113574 1112956 8 45 0.00 2.57 
gltW STM2658 Glu tRNA 2800033 2799958 28 151 0.00 2.56 
- predicted 
RNA 
antisense: cheM 2014662 2016419 335 52 0.00 -2.55 
glnU STM0677 Gln tRNA 738523 738449 533 2837 0.00 2.55 
- predicted 
RNA 
antisense: lysY lysW 
valT lysT 
819295 818744 265 1394 0.00 2.54 
- predicted 
RNA 
- 4703028 4703013 128 670 0.00 2.54 
rfbJ STM2089 CDP-abequose 
synthase 
2170904 2169999 109 16 0.00 -2.52 
gcvT STM3055 glycine cleavage 
system 
aminomethyltransferas
e T 
3216703 3215563 28 146 0.00 2.52 
ybgT STM0742 outer membrane 
lipoprotein 
812253 812380 347 55 0.00 -2.52 
motA STM1923 motility protein protein 
A 
2021011 
 
226 36 0.00 -2.52 
- predicted 
RNA 
antisense: glgP 3698969 3699186 334 53 0.00 -2.50 
- predicted 
RNA 
antisense: cydB ybgT 812372 811910 329 52 0.00 -2.50 
dinP STM0313 DNA polymerase IV 357794 358855 15 80 0.00 2.49 
- predicted 
RNA 
antisense: suhB 2684722 2684432 81 419 0.00 2.49 
rbsD STM3881 D-ribose pyranase 4091653 4092085 16 88 0.00 2.49 
glyV STM4352 Gly tRNA 4596420 4596495 528 2672 0.00 2.49 
- STM4457 transposase 4703012 4702512 27 136 0.00 2.49 
valT STM0752 Val tRNA 818985 819060 264 1334 0.00 2.48 
aceB STM4183 malate synthase 4401979 4403658 1478 242 0.00 -2.48 
- STM1269 chorismate mutase 1349851 1350398 45 229 0.00 2.48 
rfaQ STM3723 lipopolysaccharide 
core biosynthesis 
protein 
  
51 8 0.00 -2.48 
- predicted 
RNA 
antisense: ydgA 1539790 1540029 274 45 0.00 -2.47 
yifB STM3899 ATP-dependent 
protease 
4108383 4106478 8 43 0.00 2.47 
- STM1284 hypothetical protein 1361827 1360406 745 123 0.00 -2.47 
- predicted 
RNA 
- 1868749 1868722 267 44 0.00 -2.45 
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suhB STM2546 inositol 
monophosphatase 
2684426 2685250 51 256 0.00 2.45 
rpmC STM3432 50S ribosomal protein 
L29 
  
645 107 0.00 -2.44 
- predicted 
RNA 
antisense: glyV glyX 
glyY 
4596954 4596240 538 2657 0.00 2.44 
- STM2011
.1n 
hypothetical protein 2093957 2094232 26 134 0.00 2.44 
- STM2787 tricarboxylic transport 2935573 2936023 28 144 0.00 2.44 
- predicted 
RNA 
antisense: yfbQ 2442242 2442025 50 244 0.00 2.44 
- predicted 
RNA 
- 694521 694542 104 505 0.00 2.43 
- predicted 
RNA 
antisense: sdaA 1924499 1924382 45 221 0.00 2.43 
- predicted 
RNA 
antisense: fis yhdG 3556544 3555256 148 725 0.00 2.43 
- predicted 
RNA 
antisense: purG 2711816 2711922 45 220 0.00 2.43 
cheM STM1919 methyl accepting 
chemotaxis protein II 
2016427 2014756 328 55 0.00 -2.42 
sitD STM2864 Fur regulated iron 
ABC transporter 
permease SitD 
 
3009806 196 33 0.00 -2.41 
speE STM0166 spermidine synthase 195901 195009 34 169 0.00 2.41 
tyrT STM1757 Tyr tRNA 1852569 1852653 52 253 0.00 2.41 
ileT STM3989 Ile tRNA 4197670 4197746 352 1694 0.00 2.40 
ileU STM4133 Ile tRNA 4352741 4352817 352 1694 0.00 2.40 
- predicted 
RNA 
antisense: STM1269 1350181 1349930 59 285 0.00 2.40 
rplD STM3439 50S ribosomal protein 
L4 
3595555 
 
631 105 0.00 -2.40 
- predicted 
RNA 
antisense: narZ 1661790 1661725 243 41 0.00 -2.39 
- predicted 
RNA 
antisense: ydgA 1540230 1540543 274 47 0.00 -2.39 
nrdD STM4452 anaerobic 
ribonucleoside-
triphosphate reductase 
  
44 7 0.00 -2.39 
- predicted 
RNA 
antisense: cydA 811105 810913 282 47 0.00 -2.38 
- predicted 
RNA 
antisense: acrB 530689 530846 278 47 0.00 -2.37 
- predicted 
RNA 
antisense: mnmA 1322466 1322672 63 297 0.00 2.37 
- predicted 
RNA 
antisense: codB 
STM3334 
3503090 3503039 45 212 0.00 2.37 
yohL STM3023 transcriptional 
repressor RcnR 
3184055 3183783 7 36 0.00 2.37 
- predicted 
RNA 
antisense: ilet alaT 4197941 4197647 361 1690 0.00 2.36 
- predicted 
RNA 
antisense: ileU 
STM4134 
4353012 4352718 361 1690 0.00 2.36 
- STM0360 cytochrome BD2 
subunit I 
408661 
 
399 72 0.00 -2.36 
priA STM4095 primosomal protein N' 4305565 4303355 17 80 0.00 2.35 
rfbA STM2095 glucose-1-phosphate 
thymidylyltransferase 
  
67 11 0.00 -2.35 
cadA STM2559 lysine decarboxylase 1 2699876 2702095 110 19 0.00 -2.35 
- STM3334 cytosine deaminase 
 
3505021 23 112 0.00 2.35 
glnW STM0676 Gln tRNA 738413 738339 478 2207 0.00 2.34 
- predicted 
RNA 
antisense: STM0362 
STM0361 STM0360 
STM0359 
411231 408438 468 84 0.00 -2.34 
- STM3156 cytoplasmic protein 
 
3318575 11 55 0.00 2.34 
- STM3617 endoglucanase 3798530 
 
170 30 0.00 -2.33 
dppB STM3629 dipeptide ABC 
transporter permease 
DppB 
3814407 3813243 126 22 0.00 -2.33 
rplW STM3438 50S ribosomal protein 
L23 
 
3594637 707 124 0.00 -2.32 
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- predicted 
RNA 
antisense: narZ 1662881 1662803 240 43 0.00 -2.32 
- predicted 
RNA 
antisense: guaB 2625124 2625189 45 202 0.00 2.31 
- predicted 
RNA 
antisense: guaC 164390 164052 68 306 0.00 2.31 
rplC STM3440 50S ribosomal protein 
L3 
3596203 3595556 860 154 0.00 -2.31 
rpsC STM3434 30S ribosomal protein 
S3 
3593160 3592442 535 95 0.00 -2.31 
- predicted 
RNA 
antisense: cheR 2014306 2014351 162 30 0.00 -2.31 
msgA STM1241 virulence protein 
MsgA 
1329716 1329446 38 173 0.00 2.31 
rplB STM3437 50S ribosomal protein 
L2 
3594625 3593803 467 84 0.00 -2.31 
glyY STM4354 Gly tRNA 4596884 4596959 181 814 0.00 2.30 
rplP STM3433 50S ribosomal protein 
L16 
3592441 
 
614 111 0.00 -2.30 
sdhA STM0734 succinate 
dehydrogenase 
flavoprotein subunit 
 
800488 94 422 0.00 2.30 
lexA STM4237 LexA repressor 4459249 4459857 97 434 0.00 2.30 
- predicted 
RNA 
- 3814421 3814408 788 145 0.00 -2.29 
tusA STM3578 tRNA 2-thiouridine 
synthesizing protein 
TusA 
3746759 3744830 52 241 0.00 2.29 
- predicted 
RNA 
antisense: yfbE 2404801 2403916 93 416 0.00 2.29 
ygdQ STM3006 integral membrane 
transport protein 
 
3164971 74 13 0.00 -2.28 
- predicted 
RNA 
antisense: rplC rpsJ 
rpmC rplB rplD rplP 
rpsQ rpsC rpsS rplW 
rplV 
3591604 3596679 655 119 0.00 -2.28 
- predicted 
RNA 
antisense: STM2901 3045655 3045510 57 256 0.00 2.27 
yaiY STM0378 inner membrane 
protein 
433067 432680 119 21 0.00 -2.27 
- predicted 
RNA 
antisense: acrB 529892 529905 275 52 0.00 -2.27 
yfbE STM2297 UDP-4-amino-4-
deoxy-L-arabinose--
oxoglutarate 
aminotransferase 
2403907 2405110 77 343 0.00 2.27 
lldP STM3692 L-lactate permease 3885815 
 
16 75 0.00 2.27 
adrA STM0385 diguanylate cyclase 
AdrA 
438038 440087 248 46 0.00 -2.27 
rfbB STM2097 dTDP-glucose-4,6-
dehydratase 
  
98 18 0.00 -2.26 
alaT STM3990 Ala tRNA 4197858 4197933 232 1020 0.00 2.26 
- STM4134 Ala tRNA 4352929 4353004 232 1020 0.00 2.26 
gltU STM3890 Glu tRNA 4101759 4101834 43 189 0.00 2.26 
orgA STM2870 oxygen-regulated 
invasion protein OrgA 
  
18 79 0.00 2.26 
ybfE STM0695 LexA regulated protein 758141 757785 26 116 0.00 2.25 
ydgA STM1466 periplasmic protein 1540709 1539199 242 45 0.00 -2.25 
- predicted 
RNA 
antisense: ftnB 2027770 2027497 71 313 0.00 2.25 
sitC STM2863 Fur regulated iron 
ABC transporter 
permease SitC 
  
181 35 0.00 -2.25 
ydiY STM1327 outer membrane 
protein 
1406281 1407109 17 77 0.00 2.25 
deaD STM3280
.S 
ATP-dependent RNA 
helicase DeaD 
3448145 3446182 119 22 0.00 -2.24 
cheR STM1918 chemotaxis protein 
methyltransferase 
2014647 
 
118 22 0.00 -2.24 
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yhfL STM3480 outer membrane 
lipoprotein 
3635924 3636119 27 117 0.00 2.24 
- STM3898 hypothetical protein 4106478 4107324 193 833 0.00 2.24 
- STM2449
.S 
acetyltransferase 2560120 
 
112 21 0.00 -2.24 
- predicted 
RNA 
- 3594636 3594626 519 98 0.00 -2.23 
stpA STM2799 DNA binding protein 
StpA 
2947638 2946352 21 92 0.00 2.23 
rsmC STM4556 rRNA small subunit 
methyltransferase C 
4812173 4811135 19 80 0.00 2.21 
asnW STM2012 Asn tRNA 2094236 2094161 33 140 0.00 2.21 
- predicted 
RNA 
- 128743 128594 76 327 0.00 2.21 
yjgF STM4458 enamine/imine 
deaminase 
4703419 4703029 299 1250 0.00 2.21 
- predicted 
RNA 
antisense: purG 2711568 2711632 52 215 0.00 2.20 
rimK STM0875 ribosomal protein S6--
L-glutamate ligase 
946561 947463 27 113 0.00 2.20 
metU STM0675 Met tRNA 738323 738247 242 1012 0.00 2.20 
- STM0359 cytoplasmic protein 408443 408652 1551 315 0.00 -2.19 
- STM2901 cytoplasmic protein 3045229 
 
58 244 0.00 2.19 
yfeZ STM2448 inner membrane 
protein 
  
50 9 0.00 -2.18 
nanA STM3339 N-acetylneuraminate 
lyase 
3509012 
 
56 11 0.00 -2.18 
rph STM3734 ribonuclease PH 3927407 3926679 19 77 0.00 2.18 
dppA STM3630 dipeptide ABC 
transporter substrate-
binding protein DppA 
3816182 3814422 1508 306 0.00 -2.17 
glgP STM3534 glycogen 
phosphorylase 
3701369 3698902 164 32 0.00 -2.17 
pyrE STM3733 orotate 
phosphoribosyltransfer
ase 
3926665 3925585 24 103 0.00 2.17 
lamB STM4231 maltoporin 4451991 4453437 11 48 0.00 2.17 
gcvH STM3054 glycine cleavage 
system protein H 
3215562 3215173 35 141 0.00 2.17 
- predicted 
RNA 
- 3596218 3596204 815 161 0.00 -2.16 
yfgE STM2496 DnaA regulatory 
inactivator Hda 
2610585 2609220 31 128 0.00 2.16 
ribH STM0417 6,7-dimethyl-8-
ribityllumazine 
synthase 
471024 471526 22 88 0.00 2.16 
- predicted 
RNA 
antisense: leuW metU 
metT glnU glnV glnW 
738196 738778 478 1951 0.00 2.16 
guaB STM2511 inosine 5'-
monophosphate 
dehydrogenase 
2625925 2624452 48 194 0.00 2.15 
cydB STM0741 cytochrome d terminal 
oxidase polypeptide 
subunit II 
811106 812252 235 47 0.00 -2.15 
yiaJ STM3667 IclR family 
transcriptional 
repressor 
3855417 3854552 28 115 0.00 2.15 
dppC STM3628 dipeptide ABC 
transporter permease 
DppC 
3813236 3812334 99 20 0.00 -2.15 
- STM2754 hypothetical protein 2892409 2893611 9 36 0.00 2.15 
leuW STM0678 Leu tRNA 738631 738547 616 2476 0.00 2.14 
acrB STM0475 RND family acridine 
efflux pump 
532406 529247 236 48 0.00 -2.14 
envE STM1242 lipoprotein EnvE 1330422 1329896 9 38 0.00 2.14 
- predicted 
RNA 
antisense: sdhB sdhA 801217 799195 120 482 0.00 2.13 
- predicted 
RNA 
antisense: STM2901 3045458 3045305 71 286 0.00 2.12 
- predicted 
RNA 
antisense: rpoC 4374073 4373723 315 65 0.00 -2.12 
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Gene Synonym Product Transcripti
on Start 
Transcripti
on Stop 
RPKM 
WT 
RPKM 
carA 
qValue WT 
vs carA 
log2 fold 
change 
rpsJ STM3441 30S ribosomal protein 
S10 
3596685 3596219 836 170 0.00 -2.12 
- predicted 
RNA 
antisense: dppA 3814268 3816179 1500 314 0.00 -2.12 
- STM1023 hypothetical protein 1112373 
 
50 10 0.00 -2.10 
- predicted 
RNA 
antisense: tatE 694799 694512 186 702 0.00 2.08 
flgL STM1184 flagellar hook-
associated protein 
FlgL 
1267144 1268101 219 47 0.00 -2.08 
- STM2902 cytoplasmic protein 
 
3046044 17 68 0.00 2.08 
rfbF STM2092 glucose-1-phosphate 
cytidylyltransferase 
 
2173350 125 26 0.00 -2.08 
- predicted 
RNA 
antisense: qor 4465554 4466492 351 77 0.00 -2.06 
sufS STM1373 bifunctional cysteine 
desulfurase/selenocyst
eine lyase 
 
1457405 82 17 0.00 -2.06 
- predicted 
RNA 
antisense: phoB 451138 451016 71 277 0.00 2.06 
znuA STM1891 zinc ABC transporter 
substrate-binding 
protein ZnuA 
1987359 1986400 140 30 0.00 -2.06 
qor STM4245 quinone 
oxidoreductase 
4466536 4465535 332 73 0.00 -2.05 
- predicted 
RNA 
antisense: acrB 531105 531333 302 66 0.00 -2.05 
yfbQ STM2331 aminotransferase AlaT 2441969 2443211 39 149 0.00 2.05 
- predicted 
RNA 
antisense: STM0842 910687 910534 76 287 0.00 2.05 
caiF STM0068 DNA-binding 
transcriptional 
activator CaiF 
  
43 9 0.00 -2.04 
- STM1638 SAM-dependent 
methyltransferase 
1729044 1729893 22 84 0.00 2.04 
leuV STM4553 Leu tRNA 4810715 4810629 86 325 0.00 2.04 
holD STM4557 DNA polymerase III 
subunit psi 
4812263 
 
24 89 0.00 2.03 
hutH STM0791 histidine ammonia-
lyase 
854896 858737 434 98 0.00 -2.03 
sulA STM1071 cell division inhibitor 
SulA 
1162888 1162340 27 101 0.00 2.03 
- STM2610 periplasmic lysozyme 
inhibitor 
2758320 2758781 158 34 0.00 -2.02 
- predicted 
RNA 
antisense: fhuA 224006 223802 79 300 0.00 2.02 
ynhA STM1374 cysteine desufuration 
protein SufE 
1457418 
 
48 11 0.00 -2.02 
- predicted 
RNA 
- 2660023 2659974 180 661 0.00 2.02 
- predicted 
RNA 
antisense: flgK flgL 1268091 1265476 244 55 0.00 -2.02 
ftnB STM1932 ferritin-like protein 2027167 2027885 91 340 0.00 2.01 
osmC STM1563 peroxiredoxin OsmC 1644673 1644177 733 168 0.00 -2.01 
- predicted 
RNA 
antisense: ydgA 1539406 1539683 273 60 0.00 -2.01 
ileV STM0250 Ile tRNA 290790 290866 106 387 0.00 2.01 
- STM4239 cytoplasmic protein 
 
4461470 1647 377 0.00 -2.01 
purG STM2565 phosphoribosylformyl
glycinamidine 
synthase 
2712150 2708254 30 112 0.00 2.00 
- STM2788 tricarboxylic transport 
protein 
2936024 2937554 25 96 0.00 2.00 
nanT STM3338 sialic acid transporter 3508047 3506467 79 17 0.00 -2.00 
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Supp. Figure 7 Sub-network extraction from our regulatory network, showing the RpoS sigmulon. 
Four clusters are visible: (Top left) those including genes that are transcribed by RNAP in association 
with RpoS or RpoD. (Top right) Those transcribed by RNAP in association with RpoS only. (Bottom 
left). Those transcribed by RNAP paired with any of three or more different sigma factors. (Bottom 
right) RNAP paired with RpoS or an unspecified sigma factor. Genes that are only transcribed by RpoS 
are all down regulated. BioCyc was consulted to determine which sigma factors associate with RNAP 
for the transcription of the various genes.  
 
 
Supp. Figure 8 Sub-network extraction from our regulatory network, showing the RpoH sigmulon. 
Two clusters are visible :(Left). Genes that are transcribed by RNAP in association with either RpoS 
or RpoD. (Right) Genes transcribed by RNAP in association with RpoH. BioCyc was consulted to 
determine which sigma factors associate with RNAP for the transcription of the various genes. 
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Supp. Figure 9 Sub-network extraction from our upstream-regulatory network showing the RpoE 
sigmulon. Genes were divided into four clusters based on the sigma factors, which associate with the 
core RNAP to allow their transcription. All but one gene is downregulated in the carA mutant. BioCyc 
was consulted to determine which sigma factors associate with RNAP for the transcription of the 
various genes. 
 
 
Supp. Figure 10 (previous page) Sub-network extraction from our upstream-regulatory network 
showing the RpoN sigmulon. Genes were divided into four clusters based on the sigma factors which 
associate with the core RNAP to allow their transcription. All but two genes are downregulated in the 
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ΔcarA mutant. BioCyc was consulted to determine which sigma factors associate with RNAP for the 
transcription of the various genes.  
 
Supp. Figure 11 Sub-network extraction from our upstream-regulatory network, showing the FliA and 
its first-neighbours that are under its direct control. Only one gene is transcribed by RNAP in complex 
with either FliA or RpoD, the rest are all transcribed between RNAP in complex with FliA. BioCyc 
was consulted to determine which sigma factors associate with RNAP for the transcription of the 
various genes. 
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Supp. Figure 12 Normalized fluorescence of the purF promoter (left) and the purA promoter (right) 
in the S. Typhimurium 14028 wild type (grey lines) and the ΔcarA mutant complemented with 17.5 
µM uracil (black lines), with both promoters showing a clear upregulation in the mutant. Stars 
indicate a significant difference in the slope of the two conditions between two time points (as 
determined by an unpaired t-test with a confidence interval of 95%) indicating that there is a 
significant difference in transcription from the promoters. The error bars represent the standard 
deviations between 3 technical repeats (corresponding to three wells in a multi-well plate). The 
experiments were repeated for a second time on a different day and similar profiles were obtained. 
 
Supp. Table 6 Intracellular metabolite concentrations from S. Typhimurium 14028 wild type and 
ΔcarA mutant in TSB1/20. The ΔcarA mutant was grown in the presence of 17.5 µM uracil to 
complement its growth defect. Metabolite concentrations were normalized to the optical density of 
each sample. The experiment was conducted in triplicate. 
 Normalized metabolite concentrations [pmol/sample/OD600] 
ATP ADP AMP GTP GDP GM
P 
CTP CDP CM
P 
UTP UDP UM
P 
IMP Gua
nine 
Hypox
anthin
e 
Wild type 
 1 608.
9 
285.5 687.5 186 64.3 63.1 172.
1 
258.
1 
236.
9 
48.6 61.5 359.
8 
114 17.2 63.7 
2 754.
5 
286.2 424.6 134.
7 
44.2 37.5 234.
1 
577.
8 
203.
6 
55 61.7 168.
3 
45 8.3 18.2 
3 460.
7 
236.8 656.4 106.
8 
37.7 49.3 144.
8 
433.
7 
267.
5 
36.7 41.2 284.
1 
74.2 11.7 127 
ΔcarA 
 1 1925
.9 
1425.
9 
7268.
5 
283.
3 
346.
3 
435.
2 
126.
9 
379.
6 
510.
2 
8.9 24.7 143.
5 
675.
9 
296.
3 
6342.6 
2 1121 788.7 5322.
6 
137.
9 
161.
3 
229 82.3 302.
4 
313.
7 
4.8 16.5 130.
7 
338.
7 
151.
6 
5201.6 
3 1027
.8 
930.6 9166.
7 
142.
4 
193.
1 
318.
1 
87.5 285.
4 
456.
3 
5.8 18.3 138.
2 
506.
9 
314 6701.4 
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Supp. Table 6 Expression patters of genes encoding-di-GMP metabolising enzymes. Underlined 
genes had significant changes in their expression levels. Class I GGDEF domain proteins contain all 
residues that are required for catalytic activity, while Class II GGDEF domain proteins are catalytically 
inactive. In Class I EAL domains all resides required for c-di-GMP dependent phosphodiesterase 
activity are conserved. Class 2 EAL domain proteins lack the conserved loop 6, nevertheless some of 
these proteins have been demonstrated to possess PDE activity. Class 3 EAL domain proteins are 
predicted to be catalytically inactive 
Name Synonym Product Enzyme activity class Effect on csgD 
expression  
q-
value 
log fold 
change 
adrA STM0385 diguanylate cyclase 
AdrA 
DGC 
(I) 
 0.00 -2.26 
- STM1697 diguanylate 
cyclase/phosphodies
terase domain-
containing protein 
No PDE 
(III) 
 0.00 1.35 
gcpA STM1987 inner membrane 
protein 
DGC 
(I) 
Positive 0.00 1.30 
yfiN STM2672 diguanylate 
cyclase/phosphodies
terase 
DGC 
(I) 
 1 1.24 
- STM0343 diguanylate 
cyclase/phosphodies
terase domain-
containing protein 
PDE 
(I) 
 1 -1.04 
yfeA STM2410 diguanylate 
cyclase/phosphodies
terase domain-
containing protein 
No DGC activity, 
putative PDE 
(I, II) 
 1 1.04 
- STM1827.S diguanylate 
cyclase/phosphodies
terase 
PDE 
(I) 
Negative 0.00 -0.68 
- STM3388 signal transduction 
protein 
DGC 
(I) 
Positive 1 0.58 
yhdA STM3375 regulatory protein 
CsrD 
No PDE or DGC 
activity (in E. coli) 
(III, II) 
 1 -0.50 
yeaJ STM1283 methyl-accepting 
chemotaxis protein 
DGC 
(I) 
 1 -0.51 
rtn STM2215 lambda/N4 phages 
resistance 
membrane protein 
PDE 
(II) 
 1 0.49 
yciR STM1703 RNase II stability 
modulator 
PDE, DGE 
(I, I) 
Negative 1 0.43 
- STM2503 diguanylate cyclase Probably PDE-like 
(I) 
 1 -0.42 
- STM4551 diguanylate 
cyclase/phosphodies
terase domain-
containing protein 
DGC 
(I) 
Positive 1 0.42 
yegE STM2123 diguanylate 
cyclase/phosphodies
terase 
DGC 
(I) 
Positive  0.53 0.36 
yjcC STM4264 diguanylate 
cyclase/phosphodies
terase 
PDE 
(I) 
Negative 1 -0.35 
ylaB STM0468 diguanylate 
cyclase/phosphodies
terase domain-
containing protein 
No PDE activity 
(III) 
 1 0.34 
yhjH STM3611 diguanylate 
cyclase/phosphodies
PDE 
(II) 
Negative 
 
0.05 -0.17 
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Name Synonym Product Enzyme activity class Effect on csgD 
expression  
q-
value 
log fold 
change 
terase domain-
containing protein 
yhjK STM3615 diguanylate 
cyclase/phosphodies
terase 
Probable PDE 
(I) 
 1 0.11 
ydiV STM1344 anti-FlhC(2)FlhD(4) 
factor 
No PDE 
(III) 
 0.03 0.04 
 PSLT032 Plasmid encoded 
putative PDE/DGC 
Unknown  0.00 -0.70 
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Supp. Table 7 Fold change in mRNA levels (RQ) of genes involved in adhesion and c-di-GMP 
metabolism 
Assay BF: ΔcarA 
+ 70 µM 
uracil 
PL: ΔcarA + 70 
µM uracil 
BF: ΔcarA + 17.5 
µM uracil 
PL: ΔcarA + 17.5 
µM uracil 
BF: 
Wild 
type 
PL: 
Wild 
type 
       
adrA 3.4099 ↑ 0.6347 0.5548 0.7664 1.9588 1 
bcsA 1.4247 0.6798 0.7285 0.8463 1.0248 1 
csgB 5.5317 ↑ 0.2143 ↓ 0.0232 ↓ 0.0116 ↓ 3.0256 ↑ 1 
csgD 3.366   ↑ 0.5153 0.2158 ↓ 0.1986 ↓ 1.8792 1 
purR 0.6297 0.7557 0.683 0.709 0.5786 1 
gcpA  0.9895 
 
0.8973 
 
1 
STM1697 
 
0.9685 
 
0.9832 
 
1 
STM1827 
 
0.8034 
 
0.7378 
 
1 
STM2503 
 
0.8317 
 
1.0319 
 
1 
STM3388 
 
0.8368 
 
0.6268 
 
1 
yciR 
 
0.7896 
 
0.8438 
 
1 
ydiV 
 
0.7489 
 
0.7498 
 
1 
yeaJ 
 
1.1564 
 
1.2989 
 
1 
yegE 
 
1.0515 
 
1.047 
 
1 
yfiN 
 
0.8836 
 
1.1456 
 
1 
yhdA 
 
0.8479 
 
1.0521 
 
1 
yhjH 
 
0.8701 
 
1.0788 
 
1 
yjcC 
 
0.8023 
 
0.9136 
 
1 
yjiE 
 
0.9355 
 
1.3431 
 
1 
       
Directions of arrows indicate up or down regulation. PL and BF indicates planktonic and biofilm 
samples respectively.  
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Supp. Figure 13. Externally applied purine pathway intermediates does not have noteworthy effects 
on biofilm formation or planktonic growth of the wild type strain S. Typhimurium ATCC14028 
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Supp. Figure 14 Normalized fluorescence of csgD, csgB, adrA and bcsA promoter fusions in the S. 
Typhimurium 14028 wild type control (light grey line) and in the presence of 17.5 and 70 µM added 
uracil (black line and blue line respectively), showing no noteworthy difference in transcription 
between the conditions. The error bars represent the standard deviations of the technical repeats (n=3). 
Blue starts represent significant differences between the control and 17.5µM uracil treated condition. 
Black starts represent significant differences between the control and the 70 µM uracil treated 
condition. Experiments conducted on different occasions show similar trends. 
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Supp. Figure 15 Relative gene expression of csgD, csgB, adrA and bcsA from free-living (planktonic) 
bacteria as well as surface-associated (biofilm) bacteria were determined with RT-qPCR. Panel A 
shows the changes in gene expression (RQ) compared to the wild type planktonic bacteria. The dotted 
lines indicate thresholds for fold changes. Arrows indicate that the expression of csgB in the pyrimidine 
starved ΔcarA mutant was too low to be visible on the graph. The error bars in panel A represent the 
RQ min and max values (predicted with 95% confidence). 
 
 
Supp. Figure 16 Fragment analysis results, obtained by amplifying the dusB-fis promotor region, two 
biological repeats were used per strain. 
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Supp. Figure 17 Swimming plates showing the effect of added uracil on the ΔcarA mutant. Without 
added uracil there is very little growth and no visible swimming. When 17.5 µM was added the 
diameter of the colony exceeded that of the wild type control. However, the white band on the outer 
perimeter that is visible on the wild type colony was absent from the mutant. When 70µM uracil was 
added the diameter of the colony increased even further, however, the outer white band became visible 
again. Medium consisting of 2% agar and TSB 1/20 were inoculated with 1µL of normalized ONC and 
incubated for 24 hours at 25ºC.  
 
 
Supp. Figure 18 The addition of arginine to the wild type and the ΔcarA strain does not change their 
biofilm phenotypes, which is a further indication that the carA mutants phenotype is largely determined 
by uracil and not by arginine. Three biological repeats for each strain were divided into three technical 
repeats each. 
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Supp. Figure 19 Normalized fluorescence of csgD, csgB, adrA and bcsA promoter fusions in the S. 
Typhimurium 14028 wild type control (WT) (light grey line) and the S. Typhimurium 14028 ΔpyrB 
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mutant complemented with 17.5 µM uracil and 70 µM uracil to the mutant (black lines). These 
expression patterns resemble those of the carA mutant indicating that pyrimidine limitation affects both 
mutants similarly. The error bars represent the standard deviations of the technical repeats (n=3). The 
experiments were repeated two to four times on different days and showed similar patterns. 
 
 
 
Supp. Figure 20 GFP was expressed constitutively from pFPV25.1. The results from the two 
independent experiments that are shown here indicate that the absence of ampicillin does not change 
the expression profile indicating that the absence of ampicillin does not negatively impact plasmid 
maintenance during the course of the experiment. 
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